{"matching_results": 20102, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "icrowdnewswire.com", "matching_results": 1858, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1648}, {"key": "negative", "matching_results": 206}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "americanbankingnews.com", "matching_results": 1095, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 856}, {"key": "negative", "matching_results": 232}, {"key": "neutral", "matching_results": 7}]}]}, {"key": "freelancer.com.co", "matching_results": 722, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 665}, {"key": "negative", "matching_results": 55}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "wkrb13.com", "matching_results": 469, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 379}, {"key": "negative", "matching_results": 90}]}]}, {"key": "tickerreport.com", "matching_results": 458, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 398}, {"key": "negative", "matching_results": 60}]}]}, {"key": "zolmax.com", "matching_results": 458, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 365}, {"key": "negative", "matching_results": 93}]}]}, {"key": "dailypolitical.com", "matching_results": 437, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 359}, {"key": "negative", "matching_results": 78}]}]}, {"key": "watchlistnews.com", "matching_results": 436, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 349}, {"key": "negative", "matching_results": 87}]}]}, {"key": "thelincolnianonline.com", "matching_results": 394, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 321}, {"key": "negative", "matching_results": 73}]}]}, {"key": "openpr.com", "matching_results": 385, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 345}, {"key": "negative", "matching_results": 39}, {"key": "neutral", "matching_results": 1}]}]}]}], "results": [{"id": "oz_VJ_1tqm9LdqUwjBzP2YzCgjRqUJOwtfhSwl_paaXTsR4j-XQmc7IzWPyjkwO7", "result_metadata": {"score": 36.336155}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. David Kerstein", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New Chief Medical Officer", "relevance": 0.33, "type": "JobTitle"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.909247, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Physician", "relevance": 0.615714, "dbpedia_resource": "http://dbpedia.org/resource/Physician"}], "categories": [{"score": 0.772817, "label": "/science/medicine/pharmacology"}, {"score": 0.692055, "label": "/science/medicine/oncology"}, {"score": 0.570508, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "managerOf", "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer | MarketScreener", "score": 0.573875, "arguments": [{"text": "Chief Medical Officer", "location": [73, 94], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "New", "location": [69, 72], "entities": [{"type": "Organization", "text": "New", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Anchiano Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.979866, "count": 1}, {"text": "Appointment of Dr. David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.689599, "count": 1}, {"text": "New Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.249553, "count": 1}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.02706, "count": 1}]}, "crawl_date": "2018-11-26T13:48:14Z", "url": "https://www.marketscreener.com/ANCHIANO-THERAPEUTICS-LTD-20568859/news/Anchiano-Therapeutics-Announces-Appointment-of-Dr-David-Kerstein-as-New-Chief-Medical-Officer-27661783/", "host": "marketscreener.com", "text": "Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T00:00:00Z", "enriched_text": {"entities": [{"count": 14, "sentiment": {"score": 0, "label": "neutral"}, "text": "David Kerstein", "relevance": 0.898821, "type": "Person"}, {"count": 7, "sentiment": {"score": -0.295754, "label": "negative"}, "text": "Anchiano Therapeutics Ltd.", "relevance": 0.566813, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Medical Director of Oncology Clinical Research", "relevance": 0.397126, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer", "relevance": 0.328898, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Medical Director of Clinical Research", "relevance": 0.327905, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Medical Officer", "relevance": 0.320519, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics", "relevance": 0.306527, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Frank Haluska", "relevance": 0.293738, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Clinical Research Associate", "relevance": 0.278867, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano", "relevance": 0.257696, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Director", "relevance": 0.244424, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "CAMBRIDGE", "relevance": 0.244194, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dainippon Sumitomo Pharma Global Oncology", "relevance": 0.240402, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "Tufts University School of Medicine", "relevance": 0.230511, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity"], "name": "Tufts University School of Medicine", "dbpedia_resource": "http://dbpedia.org/resource/Tufts_University_School_of_Medicine"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Managing Director", "relevance": 0.224322, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.416504, "label": "positive"}, "text": "urinary bladder", "relevance": 0.222644, "type": "Anatomy"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.217272, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tufts University", "relevance": 0.214864, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "Tufts University", "dbpedia_resource": "http://dbpedia.org/resource/Tufts_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "bladder cancer.", "relevance": 0.214721, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mass.", "relevance": 0.213876, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LifeSci Advisors", "relevance": 0.202864, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.494432, "label": "negative"}, "text": "Takeda Pharmaceuticals International Co.", "relevance": 0.202214, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "ARIAD Pharmaceuticals, Inc.", "relevance": 0.198326, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "Boston Biomedical", "relevance": 0.188658, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jerusalem", "relevance": 0.187862, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Jerusalem", "dbpedia_resource": "http://dbpedia.org/resource/Jerusalem"}}, {"count": 1, "sentiment": {"score": 0.433481, "label": "positive"}, "text": "Ashley R. Robinson", "relevance": 0.185971, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Israel", "relevance": 0.177167, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MA", "relevance": 0.1691, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "arr@lifesciadvisors.com", "relevance": 0.1691, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "info@anchiano.com", "relevance": 0.1691, "type": "EmailAddress"}], "sentiment": {"document": {"score": 0.393281, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "the Company", "keywords": [{"text": "Company"}]}, "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company\u2019s new Chief Medical Officer.", "object": {"text": "new Chief Medical Officer", "keywords": [{"text": "Chief Medical Officer"}], "entities": [{"type": "JobTitle", "text": "Chief Medical Officer"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "object": {"text": "an accomplished physician experienced in leading clinical drug development programs for oncology therapies", "keywords": [{"text": "oncology therapies"}, {"text": "clinical drug development"}, {"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an accomplished physician", "keywords": [{"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "action": {"verb": {"text": "experience", "tense": "past"}, "text": "experienced", "normalized": "experience"}}, {"subject": {"text": "an accomplished physician", "keywords": [{"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "object": {"text": "clinical drug development programs", "keywords": [{"text": "clinical drug development"}, {"text": "programs"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\u201d said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "object": {"text": "David, a skilled medical lead and accomplished clinical drug strategist,", "keywords": [{"text": "clinical drug strategist"}, {"text": "skilled medical lead"}, {"text": "David"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "are thrilled to have", "normalized": "be thrill to have"}}, {"subject": {"text": "Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics", "keywords": [{"text": "Chief Executive Officer"}, {"text": "Frank Haluska"}, {"text": "Anchiano Therapeutics"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Frank Haluska"}, {"type": "JobTitle", "text": "President and Chief Executive Officer"}, {"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "sentence": " \u201cWe are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\u201d said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "object": {"text": "We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano", "keywords": [{"text": "clinical drug strategist"}, {"text": "skilled medical lead"}, {"text": "David"}, {"text": "team"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe look forward to his medical leadership.\u201d", "object": {"text": "to his medical leadership", "keywords": [{"text": "medical leadership"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "I"}, "sentence": " \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "urinary bladder"}, {"text": "Anchiano\u2019s mission"}, {"text": "malignancies"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"type": "Anatomy", "text": "urinary bladder"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "am", "normalized": "be"}}, {"subject": {"text": "Anchiano\u2019s", "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}]}, "sentence": " \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "a DNA-based cancer therapy for the treatment of malignancies", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "malignancies"}, {"text": "treatment"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "I am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "urinary bladder"}, {"text": "Anchiano\u2019s mission"}, {"text": "malignancies"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"type": "Anatomy", "text": "urinary bladder"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "object": {"text": "Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company", "keywords": [{"text": "Takeda Pharmaceuticals International"}, {"text": "development-driven pharmaceutical company"}, {"text": "global research"}, {"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Ltd."}, {"type": "Company", "text": "Takeda Pharmaceuticals International Co."}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joins", "normalized": "join"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "object": {"text": "as Senior Medical Director of Oncology Clinical Research", "keywords": [{"text": "Oncology Clinical Research"}, {"text": "Senior Medical Director"}], "entities": [{"type": "JobTitle", "text": "Senior Medical Director of Oncology Clinical Research"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.", "object": {"text": "the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib", "keywords": [{"text": "cancer clinical portfolio"}, {"text": "global clinical lead"}, {"text": "strategy lead"}, {"text": "lung"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "object": {"text": "Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc.,", "keywords": [{"text": "ARIAD Pharmaceuticals"}, {"text": "Senior Medical Director"}, {"text": "Clinical Research"}], "entities": [{"type": "JobTitle", "text": "Medical Director"}, {"type": "JobTitle", "text": "Senior Medical Director of Clinical Research"}, {"type": "Company", "text": "ARIAD Pharmaceuticals, Inc."}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "object": {"text": "the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib", "keywords": [{"text": "Marketing Authorization Application"}, {"text": "initial New Drug"}, {"text": "clinical development program"}, {"text": "medical lead"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein began his career as a Clinical Research Associate at NormaTec, a medical device company.", "object": {"text": "his career", "keywords": [{"text": "career"}]}, "action": {"verb": {"text": "begin", "tense": "past"}, "text": "began", "normalized": "begin"}}, {"subject": {"text": "He"}, "sentence": " He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "object": {"text": "his M.D.", "keywords": [{"text": "M.D"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "sentence": " Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "object": {"text": "a clinical-stage biopharmaceutical company", "keywords": [{"text": "clinical-stage biopharmaceutical company"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Company", "keywords": [{"text": "Company"}]}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com", "object": {"text": "most advanced product candidate, inodiftagene vixteplasmid (BC-819),", "keywords": [{"text": "advanced product candidate"}, {"text": "inodiftagene vixteplasmid"}, {"text": "BC-819"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819),", "keywords": [{"text": "advanced product candidate"}, {"text": "inodiftagene vixteplasmid"}, {"text": "Company"}, {"text": "BC-819"}]}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com", "object": {"text": "in development", "keywords": [{"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This press release", "keywords": [{"text": "press release"}], "entities": []}, "sentence": " This press release contains \u201cforward-looking statements\u201d that are subject to risks and uncertainties.", "object": {"text": "forward-looking statements\u201d that are subject to risks and uncertainties", "keywords": [{"text": "forward-looking statements"}, {"text": "uncertainties"}, {"text": "risks"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contains", "normalized": "contain"}}, {"subject": {"text": "These forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are based", "normalized": "be base"}}, {"subject": {"text": "These forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "on information Anchiano Therapeutics", "keywords": [{"text": "information Anchiano Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "are based", "normalized": "be base"}}, {"subject": {"text": "Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "uncertainties", "keywords": [{"text": "uncertainties"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "actual performance or results", "keywords": [{"text": "actual performance"}, {"text": "results"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "could cause", "normalized": "could cause"}}, {"subject": {"text": "by the forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "those"}, "action": {"verb": {"text": "suggest", "tense": "past"}, "text": "in or suggested", "normalized": "in or suggest"}}], "concepts": [{"text": "Medicine", "relevance": 0.956365, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmacology", "relevance": 0.918981, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical industry", "relevance": 0.711449, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Drug development", "relevance": 0.685731, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "New Drug Application", "relevance": 0.640891, "dbpedia_resource": "http://dbpedia.org/resource/New_Drug_Application"}, {"text": "Drug discovery", "relevance": 0.639167, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Clinical trial", "relevance": 0.613186, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Cancer", "relevance": 0.512813, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Urinary bladder", "relevance": 0.466846, "dbpedia_resource": "http://dbpedia.org/resource/Urinary_bladder"}, {"text": "Corporate governance", "relevance": 0.45621, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Chief executive officer", "relevance": 0.455769, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Clinical research", "relevance": 0.454929, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "Executive officer", "relevance": 0.433174, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Management occupations", "relevance": 0.414183, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Therapy", "relevance": 0.414051, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Corporate title", "relevance": 0.38369, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_title"}, {"text": "Latin honors", "relevance": 0.379415, "dbpedia_resource": "http://dbpedia.org/resource/Latin_honors"}, {"text": "Food and Drug Administration", "relevance": 0.374154, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Drug design", "relevance": 0.368215, "dbpedia_resource": "http://dbpedia.org/resource/Drug_design"}, {"text": "Chief executives", "relevance": 0.352793, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Pharmaceutical drug", "relevance": 0.352231, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Pre-clinical development", "relevance": 0.330517, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Oncology", "relevance": 0.328065, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Urology", "relevance": 0.323891, "dbpedia_resource": "http://dbpedia.org/resource/Urology"}, {"text": "New chemical entity", "relevance": 0.322861, "dbpedia_resource": "http://dbpedia.org/resource/New_chemical_entity"}, {"text": "Cancer staging", "relevance": 0.319682, "dbpedia_resource": "http://dbpedia.org/resource/Cancer_staging"}, {"text": "Bladder cancer", "relevance": 0.316768, "dbpedia_resource": "http://dbpedia.org/resource/Bladder_cancer"}, {"text": "Doctor of Medicine", "relevance": 0.315992, "dbpedia_resource": "http://dbpedia.org/resource/Doctor_of_Medicine"}], "categories": [{"score": 0.976139, "label": "/science/medicine/oncology"}, {"score": 0.926109, "label": "/health and fitness/disease/cancer"}, {"score": 0.813487, "label": "/health and fitness/therapy"}], "relations": [{"type": "locatedAt", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.987236, "arguments": [{"text": "CAMBRIDGE", "location": [0, 9], "entities": [{"type": "GeopoliticalEntity", "text": "CAMBRIDGE"}]}, {"text": "Mass.", "location": [11, 16], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "locatedAt", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.984425, "arguments": [{"text": "Cambridge", "location": [2140, 2149], "entities": [{"type": "GeopoliticalEntity", "text": "CAMBRIDGE"}]}, {"text": "MA", "location": [2151, 2153], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "employedBy", "sentence": "About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "score": 0.252169, "arguments": [{"text": "Kerstein", "location": [888, 896], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Anchiano Therapeutics", "location": [903, 924], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics\nAnchiano Therapeutics"}]}]}, {"type": "hasAttribute", "sentence": "At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.", "score": 0.820063, "arguments": [{"text": "he", "location": [1122, 1124], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "lung cancer", "location": [1133, 1144], "entities": [{"type": "HealthCondition", "text": "lung cancer"}]}]}, {"type": "employedBy", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.709676, "arguments": [{"text": "Senior Medical Director of Clinical Research", "location": [1273, 1317], "entities": [{"type": "Person", "text": "Senior Medical Director of Clinical Research"}]}, {"text": "ARIAD Pharmaceuticals, Inc.", "location": [1321, 1348], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.385757, "arguments": [{"text": "where", "location": [1350, 1355], "entities": [{"type": "Organization", "text": "where"}]}, {"text": "ARIAD Pharmaceuticals, Inc.", "location": [1321, 1348], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.683487, "arguments": [{"text": "he", "location": [1356, 1358], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "where", "location": [1350, 1355], "entities": [{"type": "Organization", "text": "where"}]}]}, {"type": "partOf", "sentence": "Dr. Kerstein began his career as a Clinical Research Associate at NormaTec, a medical device company.", "score": 0.539604, "arguments": [{"text": "Clinical Research Associate", "location": [1757, 1784], "entities": [{"type": "Organization", "text": "Clinical Research Associate"}]}, {"text": "NormaTec", "location": [1788, 1796], "entities": [{"type": "Organization", "text": "NormaTec"}]}]}, {"type": "partOf", "sentence": "He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "score": 0.963007, "arguments": [{"text": "School of Medicine", "location": [1867, 1885], "entities": [{"type": "Organization", "text": "School of Medicine", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "Tufts University", "location": [1850, 1866], "entities": [{"type": "Organization", "text": "Tufts University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "awardedTo", "sentence": "He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "score": 0.805927, "arguments": [{"text": "B.S.", "location": [1894, 1898], "entities": [{"type": "Degree", "text": "B.S."}]}, {"text": "his", "location": [1890, 1893], "entities": [{"type": "Person", "text": "David Kerstein"}]}]}, {"type": "basedIn", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.638138, "arguments": [{"text": "offices", "location": [2129, 2136], "entities": [{"type": "Organization", "text": "offices"}]}, {"text": "Cambridge", "location": [2140, 2149], "entities": [{"type": "GeopoliticalEntity", "text": "CAMBRIDGE"}]}]}, {"type": "locatedAt", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.977234, "arguments": [{"text": "Jerusalem", "location": [2159, 2168], "entities": [{"type": "GeopoliticalEntity", "text": "Jerusalem"}]}, {"text": "Israel", "location": [2170, 2176], "entities": [{"type": "GeopoliticalEntity", "text": "Israel"}]}]}, {"type": "hasAttribute", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.886958, "arguments": [{"text": "Anchiano Therapeutics Ltd.", "location": [52, 78], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics\nAnchiano Therapeutics"}]}, {"text": "ANCN", "location": [86, 90], "entities": [{"type": "Ticker", "text": "ANCN"}]}]}, {"type": "employedBy", "sentence": "The Company's most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer.", "score": 0.305363, "arguments": [{"text": "candidate", "location": [2214, 2223], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Company", "location": [2182, 2189], "entities": [{"type": "Organization", "text": "biopharmaceutical company"}]}]}, {"type": "employedBy", "sentence": "These risks and uncertainties include, but are not limited to: a lack of history of commercial sales; no anticipated earning operating income over the coming years; a dependence on the success of inodiftagene, the development of which will require significant additional clinical testing before regulatory approval can be sought and commercial sales launched; some scientific or technological difficulties that may be encountered and impede R&D activities; a need to raise substantial additional funds to complete R&D activities; the raising of additional capital may dilute holdings of our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or products; and an ability to obtain and maintain intellectual property protection for product candidates, including pursuant to licensed patents Company Contact: Frank Haluska, M.D., Ph.D. President and Chief Executive Officer info@anchiano.com Investor Contact:", "score": 0.792256, "arguments": [{"text": "shareholders", "location": [3463, 3475], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "our", "location": [3450, 3453], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics\nAnchiano Therapeutics"}]}]}, {"type": "employedBy", "sentence": "These risks and uncertainties include, but are not limited to: a lack of history of commercial sales; no anticipated earning operating income over the coming years; a dependence on the success of inodiftagene, the development of which will require significant additional clinical testing before regulatory approval can be sought and commercial sales launched; some scientific or technological difficulties that may be encountered and impede R&D activities; a need to raise substantial additional funds to complete R&D activities; the raising of additional capital may dilute holdings of our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or products; and an ability to obtain and maintain intellectual property protection for product candidates, including pursuant to licensed patents Company Contact: Frank Haluska, M.D., Ph.D. President and Chief Executive Officer info@anchiano.com Investor Contact:", "score": 0.736132, "arguments": [{"text": "President", "location": [3747, 3756], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "Ph.D.", "location": [3741, 3746], "entities": [{"type": "GeopoliticalEntity", "text": "Ph.D.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "timeOf", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.964138, "arguments": [{"text": "today", "location": [213, 218], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [219, 228], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "affectedBy", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.525427, "arguments": [{"text": "David Kerstein", "location": [248, 262], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "appointment", "location": [233, 244], "entities": [{"type": "EventPersonnel", "text": "appointment"}]}]}, {"type": "managerOf", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.464899, "arguments": [{"text": "Chief Medical Officer", "location": [291, 312], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Company", "location": [277, 284], "entities": [{"type": "Organization", "text": "biopharmaceutical company"}]}]}, {"type": "agentOf", "sentence": "\"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "score": 0.894571, "arguments": [{"text": "Frank Haluska", "location": [569, 582], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "said", "location": [564, 568], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "\"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "score": 0.752093, "arguments": [{"text": "Chief Executive Officer", "location": [598, 621], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "Anchiano Therapeutics", "location": [625, 646], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics\nAnchiano Therapeutics"}]}]}, {"type": "agentOf", "sentence": "\" \"I am eager to contribute to Anchiano's mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\" said Dr. Kerstein.", "score": 0.898861, "arguments": [{"text": "Dr.", "location": [843, 846], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "said", "location": [838, 842], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "score": 0.799571, "arguments": [{"text": "Kerstein", "location": [888, 896], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "joins", "location": [897, 902], "entities": [{"type": "EventPersonnel", "text": "joins"}]}]}], "keywords": [{"text": "clinical-stage biopharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.672189, "count": 2}, {"text": "development of novel therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624121, "count": 2}, {"text": "Anchiano Therapeutics Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.618316, "count": 1}, {"text": "clinical drug development programs", "sentiment": {"score": 0.770762, "label": "positive"}, "relevance": 0.587054, "count": 1}, {"text": "Company\u2019s new Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.579962, "count": 1}, {"text": "appointment of David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.577763, "count": 1}, {"text": "press release", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.573712, "count": 1}, {"text": "Dr. Kerstein", "sentiment": {"score": 0.637429, "label": "positive"}, "relevance": 0.571085, "count": 4}, {"text": "significant additional clinical testing", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.565672, "count": 1}, {"text": "lack of history of commercial sales", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.56399, "count": 1}, {"text": "skilled medical lead", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.559797, "count": 1}, {"text": "cancer therapy", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.556045, "count": 1}, {"text": "urinary bladder", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.555713, "count": 1}, {"text": "R&D activities", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.5526, "count": 1}, {"text": "regulatory approval", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.55137, "count": 1}, {"text": "actual performance", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.551054, "count": 1}, {"text": "cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548266, "count": 2}, {"text": "future events", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.54815, "count": 1}, {"text": "development", "sentiment": {"score": -0.556767, "mixed": "1", "label": "negative"}, "relevance": 0.544807, "count": 3}, {"text": "pharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540481, "count": 1}, {"text": "statements", "sentiment": {"score": -0.400515, "mixed": "1", "label": "negative"}, "relevance": 0.540039, "count": 4}, {"text": "Statements", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.540039, "count": 1}, {"text": "advanced product candidate", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.539731, "count": 1}, {"text": "lung cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539595, "count": 1}, {"text": "risks", "sentiment": {"score": -0.400515, "mixed": "1", "label": "negative"}, "relevance": 0.536495, "count": 3}, {"text": "uncertainties", "sentiment": {"score": 0.570817, "label": "positive"}, "relevance": 0.53435, "count": 3}, {"text": "clinical development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533659, "count": 1}, {"text": "clinical drug strategist", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.533135, "count": 1}, {"text": "products", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.532951, "count": 1}, {"text": "management\u2019s good faith belief", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.532271, "count": 1}, {"text": "CAMBRIDGE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530604, "count": 1}, {"text": "Cambridge", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530604, "count": 1}, {"text": "Anchiano", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.52934, "count": 1}, {"text": "Medical Director", "sentiment": {"score": 0.454515, "label": "positive"}, "relevance": 0.528562, "count": 1}, {"text": "substantial additional funds", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.528226, "count": 1}, {"text": "Takeda Pharmaceuticals International Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527769, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526813, "count": 1}, {"text": "Chief Executive Officer of Anchiano Therapeutics", "sentiment": {"score": 0.845002, "label": "positive"}, "relevance": 0.525544, "count": 1}, {"text": "David", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.52548, "count": 1}, {"text": "treatment", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.524724, "count": 1}, {"text": "ARIAD Pharmaceuticals", "sentiment": {"score": 0.454515, "label": "positive"}, "relevance": 0.524122, "count": 1}, {"text": "treatment of malignancies", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.523986, "count": 1}, {"text": "global research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523765, "count": 1}, {"text": "discovery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52268, "count": 2}, {"text": "clinical portfolio strategy lead", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521295, "count": 1}, {"text": "raising of additional capital", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.519734, "count": 1}, {"text": "Tufts University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518626, "count": 1}, {"text": "results", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.518402, "count": 1}, {"text": "complete R&D activities", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.517874, "count": 1}, {"text": "holdings", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.517828, "count": 1}]}, "extracted_metadata": {"sha1": "d97ffa34cb9e786ba6ab66dd7242a5a54dc2166d", "filename": "1543240094638.zip-1e3ccf2c6dc872f1213925b27c64e980.xml", "file_type": "json"}, "external_links": ["https://www.globenewswire.com/Tracker?data=q3OUTH-SpvKNYFAGYEXBpG9s_jvGxQuHF1a70sg_rqb6ydEDpoNvVBYbhB0APsvFMzEujK3mQjie069OmmyGYg==", "https://www.globenewswire.com/newsroom/ti?nf=NzQzNDAwMCMyNjAwODU4IzUwMDA0NTI2NQ==", "http://www.globenewswire.com/styles/gnw_nitf.css", "https://www.globenewswire.com/NewsRoom/AttachmentNg/914eb52e-b21d-486e-b035-9d50f249ccec"], "title": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "_1zuwlfYZdHShavXB_JDrPBsumXHNljWES527afGfpfXEedXwUGYF43TQbiS_LoS", "result_metadata": {"score": 36.3201}, "author": "PRESS RELEASE GlobeNewswire", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. David Kerstein", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New Chief Medical Officer", "relevance": 0.33, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.909247, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Physician", "relevance": 0.615714, "dbpedia_resource": "http://dbpedia.org/resource/Physician"}], "categories": [{"score": 0.772817, "label": "/science/medicine/pharmacology"}, {"score": 0.692055, "label": "/science/medicine/oncology"}, {"score": 0.570508, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "managerOf", "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer", "score": 0.617534, "arguments": [{"text": "Chief Medical Officer", "location": [73, 94], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "New", "location": [69, 72], "entities": [{"type": "Organization", "text": "New", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Anchiano Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.955242, "count": 1}, {"text": "Appointment of Dr. David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.399959, "count": 1}, {"text": "New Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.065678, "count": 1}]}, "crawl_date": "2018-11-26T14:16:37Z", "url": "https://markets.businessinsider.com/news/stocks/anchiano-therapeutics-announces-appointment-of-dr-david-kerstein-as-new-chief-medical-officer-1027754994", "host": "markets.businessinsider.com", "text": "Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T08:30:00-06:00", "enriched_text": {"entities": [{"count": 14, "sentiment": {"score": 0, "label": "neutral"}, "text": "David Kerstein", "relevance": 0.898821, "type": "Person"}, {"count": 7, "sentiment": {"score": -0.295754, "label": "negative"}, "text": "Anchiano Therapeutics Ltd.", "relevance": 0.566813, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Medical Director of Oncology Clinical Research", "relevance": 0.397126, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer", "relevance": 0.328898, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Medical Director of Clinical Research", "relevance": 0.327905, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Medical Officer", "relevance": 0.320519, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics", "relevance": 0.306527, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Frank Haluska", "relevance": 0.293738, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Clinical Research Associate", "relevance": 0.278867, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano", "relevance": 0.257696, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Director", "relevance": 0.244424, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "CAMBRIDGE", "relevance": 0.244194, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dainippon Sumitomo Pharma Global Oncology", "relevance": 0.240402, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "Tufts University School of Medicine", "relevance": 0.230511, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity"], "name": "Tufts University School of Medicine", "dbpedia_resource": "http://dbpedia.org/resource/Tufts_University_School_of_Medicine"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Managing Director", "relevance": 0.224322, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.416504, "label": "positive"}, "text": "urinary bladder", "relevance": 0.222644, "type": "Anatomy"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.217272, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tufts University", "relevance": 0.214864, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "Tufts University", "dbpedia_resource": "http://dbpedia.org/resource/Tufts_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "bladder cancer.", "relevance": 0.214721, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mass.", "relevance": 0.213876, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LifeSci Advisors", "relevance": 0.202864, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.494432, "label": "negative"}, "text": "Takeda Pharmaceuticals International Co.", "relevance": 0.202214, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "ARIAD Pharmaceuticals, Inc.", "relevance": 0.198326, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "Boston Biomedical", "relevance": 0.188658, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jerusalem", "relevance": 0.187862, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Jerusalem", "dbpedia_resource": "http://dbpedia.org/resource/Jerusalem"}}, {"count": 1, "sentiment": {"score": 0.433481, "label": "positive"}, "text": "Ashley R. Robinson", "relevance": 0.185971, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Israel", "relevance": 0.177167, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MA", "relevance": 0.1691, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "arr@lifesciadvisors.com", "relevance": 0.1691, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "info@anchiano.com", "relevance": 0.1691, "type": "EmailAddress"}], "sentiment": {"document": {"score": 0.393281, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "the Company", "keywords": [{"text": "Company"}]}, "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company\u2019s new Chief Medical Officer.", "object": {"text": "new Chief Medical Officer", "keywords": [{"text": "Chief Medical Officer"}], "entities": [{"type": "JobTitle", "text": "Chief Medical Officer"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "object": {"text": "an accomplished physician experienced in leading clinical drug development programs for oncology therapies", "keywords": [{"text": "oncology therapies"}, {"text": "clinical drug development"}, {"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an accomplished physician", "keywords": [{"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "action": {"verb": {"text": "experience", "tense": "past"}, "text": "experienced", "normalized": "experience"}}, {"subject": {"text": "an accomplished physician", "keywords": [{"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "object": {"text": "clinical drug development programs", "keywords": [{"text": "clinical drug development"}, {"text": "programs"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\u201d said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "object": {"text": "David, a skilled medical lead and accomplished clinical drug strategist,", "keywords": [{"text": "clinical drug strategist"}, {"text": "skilled medical lead"}, {"text": "David"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "are thrilled to have", "normalized": "be thrill to have"}}, {"subject": {"text": "Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics", "keywords": [{"text": "Chief Executive Officer"}, {"text": "Frank Haluska"}, {"text": "Anchiano Therapeutics"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Frank Haluska"}, {"type": "JobTitle", "text": "President and Chief Executive Officer"}, {"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "sentence": " \u201cWe are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\u201d said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "object": {"text": "We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano", "keywords": [{"text": "clinical drug strategist"}, {"text": "skilled medical lead"}, {"text": "David"}, {"text": "team"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe look forward to his medical leadership.\u201d", "object": {"text": "to his medical leadership", "keywords": [{"text": "medical leadership"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "I"}, "sentence": " \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "urinary bladder"}, {"text": "Anchiano\u2019s mission"}, {"text": "malignancies"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"type": "Anatomy", "text": "urinary bladder"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "am", "normalized": "be"}}, {"subject": {"text": "Anchiano\u2019s", "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}]}, "sentence": " \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "a DNA-based cancer therapy for the treatment of malignancies", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "malignancies"}, {"text": "treatment"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "I am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "urinary bladder"}, {"text": "Anchiano\u2019s mission"}, {"text": "malignancies"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"type": "Anatomy", "text": "urinary bladder"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "object": {"text": "Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company", "keywords": [{"text": "Takeda Pharmaceuticals International"}, {"text": "development-driven pharmaceutical company"}, {"text": "global research"}, {"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Ltd."}, {"type": "Company", "text": "Takeda Pharmaceuticals International Co."}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joins", "normalized": "join"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "object": {"text": "as Senior Medical Director of Oncology Clinical Research", "keywords": [{"text": "Oncology Clinical Research"}, {"text": "Senior Medical Director"}], "entities": [{"type": "JobTitle", "text": "Senior Medical Director of Oncology Clinical Research"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.", "object": {"text": "the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib", "keywords": [{"text": "cancer clinical portfolio"}, {"text": "global clinical lead"}, {"text": "strategy lead"}, {"text": "lung"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "object": {"text": "Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc.,", "keywords": [{"text": "ARIAD Pharmaceuticals"}, {"text": "Senior Medical Director"}, {"text": "Clinical Research"}], "entities": [{"type": "JobTitle", "text": "Medical Director"}, {"type": "JobTitle", "text": "Senior Medical Director of Clinical Research"}, {"type": "Company", "text": "ARIAD Pharmaceuticals, Inc."}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "object": {"text": "the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib", "keywords": [{"text": "Marketing Authorization Application"}, {"text": "initial New Drug"}, {"text": "clinical development program"}, {"text": "medical lead"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein began his career as a Clinical Research Associate at NormaTec, a medical device company.", "object": {"text": "his career", "keywords": [{"text": "career"}]}, "action": {"verb": {"text": "begin", "tense": "past"}, "text": "began", "normalized": "begin"}}, {"subject": {"text": "He"}, "sentence": " He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "object": {"text": "his M.D.", "keywords": [{"text": "M.D"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "sentence": " Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "object": {"text": "a clinical-stage biopharmaceutical company", "keywords": [{"text": "clinical-stage biopharmaceutical company"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Company", "keywords": [{"text": "Company"}]}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com", "object": {"text": "most advanced product candidate, inodiftagene vixteplasmid (BC-819),", "keywords": [{"text": "advanced product candidate"}, {"text": "inodiftagene vixteplasmid"}, {"text": "BC-819"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819),", "keywords": [{"text": "advanced product candidate"}, {"text": "inodiftagene vixteplasmid"}, {"text": "Company"}, {"text": "BC-819"}]}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com", "object": {"text": "in development", "keywords": [{"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This press release", "keywords": [{"text": "press release"}], "entities": []}, "sentence": " This press release contains \u201cforward-looking statements\u201d that are subject to risks and uncertainties.", "object": {"text": "forward-looking statements\u201d that are subject to risks and uncertainties", "keywords": [{"text": "forward-looking statements"}, {"text": "uncertainties"}, {"text": "risks"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contains", "normalized": "contain"}}, {"subject": {"text": "These forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are based", "normalized": "be base"}}, {"subject": {"text": "These forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "on information Anchiano Therapeutics", "keywords": [{"text": "information Anchiano Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "are based", "normalized": "be base"}}, {"subject": {"text": "Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "uncertainties", "keywords": [{"text": "uncertainties"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "actual performance or results", "keywords": [{"text": "actual performance"}, {"text": "results"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "could cause", "normalized": "could cause"}}, {"subject": {"text": "by the forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "those"}, "action": {"verb": {"text": "suggest", "tense": "past"}, "text": "in or suggested", "normalized": "in or suggest"}}], "concepts": [{"text": "Medicine", "relevance": 0.956365, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmacology", "relevance": 0.918981, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical industry", "relevance": 0.711449, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Drug development", "relevance": 0.685731, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "New Drug Application", "relevance": 0.640891, "dbpedia_resource": "http://dbpedia.org/resource/New_Drug_Application"}, {"text": "Drug discovery", "relevance": 0.639167, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Clinical trial", "relevance": 0.613186, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Cancer", "relevance": 0.512813, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Urinary bladder", "relevance": 0.466846, "dbpedia_resource": "http://dbpedia.org/resource/Urinary_bladder"}, {"text": "Corporate governance", "relevance": 0.45621, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Chief executive officer", "relevance": 0.455769, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Clinical research", "relevance": 0.454929, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "Executive officer", "relevance": 0.433174, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Management occupations", "relevance": 0.414183, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Therapy", "relevance": 0.414051, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Corporate title", "relevance": 0.38369, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_title"}, {"text": "Latin honors", "relevance": 0.379415, "dbpedia_resource": "http://dbpedia.org/resource/Latin_honors"}, {"text": "Food and Drug Administration", "relevance": 0.374154, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Drug design", "relevance": 0.368215, "dbpedia_resource": "http://dbpedia.org/resource/Drug_design"}, {"text": "Chief executives", "relevance": 0.352793, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Pharmaceutical drug", "relevance": 0.352231, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Pre-clinical development", "relevance": 0.330517, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Oncology", "relevance": 0.328065, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Urology", "relevance": 0.323891, "dbpedia_resource": "http://dbpedia.org/resource/Urology"}, {"text": "New chemical entity", "relevance": 0.322861, "dbpedia_resource": "http://dbpedia.org/resource/New_chemical_entity"}, {"text": "Cancer staging", "relevance": 0.319682, "dbpedia_resource": "http://dbpedia.org/resource/Cancer_staging"}, {"text": "Bladder cancer", "relevance": 0.316768, "dbpedia_resource": "http://dbpedia.org/resource/Bladder_cancer"}, {"text": "Doctor of Medicine", "relevance": 0.315992, "dbpedia_resource": "http://dbpedia.org/resource/Doctor_of_Medicine"}], "categories": [{"score": 0.976139, "label": "/science/medicine/oncology"}, {"score": 0.926109, "label": "/health and fitness/disease/cancer"}, {"score": 0.813487, "label": "/health and fitness/therapy"}], "relations": [{"type": "locatedAt", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.987236, "arguments": [{"text": "CAMBRIDGE", "location": [0, 9], "entities": [{"type": "GeopoliticalEntity", "text": "CAMBRIDGE"}]}, {"text": "Mass.", "location": [11, 16], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "locatedAt", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.984425, "arguments": [{"text": "Cambridge", "location": [2140, 2149], "entities": [{"type": "GeopoliticalEntity", "text": "CAMBRIDGE"}]}, {"text": "MA", "location": [2151, 2153], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "employedBy", "sentence": "About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "score": 0.252169, "arguments": [{"text": "Kerstein", "location": [888, 896], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Anchiano Therapeutics", "location": [903, 924], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics\nAnchiano Therapeutics"}]}]}, {"type": "hasAttribute", "sentence": "At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.", "score": 0.820063, "arguments": [{"text": "he", "location": [1122, 1124], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "lung cancer", "location": [1133, 1144], "entities": [{"type": "HealthCondition", "text": "lung cancer"}]}]}, {"type": "employedBy", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.709676, "arguments": [{"text": "Senior Medical Director of Clinical Research", "location": [1273, 1317], "entities": [{"type": "Person", "text": "Senior Medical Director of Clinical Research"}]}, {"text": "ARIAD Pharmaceuticals, Inc.", "location": [1321, 1348], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.385757, "arguments": [{"text": "where", "location": [1350, 1355], "entities": [{"type": "Organization", "text": "where"}]}, {"text": "ARIAD Pharmaceuticals, Inc.", "location": [1321, 1348], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.683487, "arguments": [{"text": "he", "location": [1356, 1358], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "where", "location": [1350, 1355], "entities": [{"type": "Organization", "text": "where"}]}]}, {"type": "partOf", "sentence": "Dr. Kerstein began his career as a Clinical Research Associate at NormaTec, a medical device company.", "score": 0.539604, "arguments": [{"text": "Clinical Research Associate", "location": [1757, 1784], "entities": [{"type": "Organization", "text": "Clinical Research Associate"}]}, {"text": "NormaTec", "location": [1788, 1796], "entities": [{"type": "Organization", "text": "NormaTec"}]}]}, {"type": "partOf", "sentence": "He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "score": 0.963007, "arguments": [{"text": "School of Medicine", "location": [1867, 1885], "entities": [{"type": "Organization", "text": "School of Medicine", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "Tufts University", "location": [1850, 1866], "entities": [{"type": "Organization", "text": "Tufts University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "awardedTo", "sentence": "He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "score": 0.805927, "arguments": [{"text": "B.S.", "location": [1894, 1898], "entities": [{"type": "Degree", "text": "B.S."}]}, {"text": "his", "location": [1890, 1893], "entities": [{"type": "Person", "text": "David Kerstein"}]}]}, {"type": "basedIn", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.638138, "arguments": [{"text": "offices", "location": [2129, 2136], "entities": [{"type": "Organization", "text": "offices"}]}, {"text": "Cambridge", "location": [2140, 2149], "entities": [{"type": "GeopoliticalEntity", "text": "CAMBRIDGE"}]}]}, {"type": "locatedAt", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.977234, "arguments": [{"text": "Jerusalem", "location": [2159, 2168], "entities": [{"type": "GeopoliticalEntity", "text": "Jerusalem"}]}, {"text": "Israel", "location": [2170, 2176], "entities": [{"type": "GeopoliticalEntity", "text": "Israel"}]}]}, {"type": "hasAttribute", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.886958, "arguments": [{"text": "Anchiano Therapeutics Ltd.", "location": [52, 78], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics\nAnchiano Therapeutics"}]}, {"text": "ANCN", "location": [86, 90], "entities": [{"type": "Ticker", "text": "ANCN"}]}]}, {"type": "employedBy", "sentence": "The Company's most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer.", "score": 0.305363, "arguments": [{"text": "candidate", "location": [2214, 2223], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Company", "location": [2182, 2189], "entities": [{"type": "Organization", "text": "biopharmaceutical company"}]}]}, {"type": "employedBy", "sentence": "These risks and uncertainties include, but are not limited to: a lack of history of commercial sales; no anticipated earning operating income over the coming years; a dependence on the success of inodiftagene, the development of which will require significant additional clinical testing before regulatory approval can be sought and commercial sales launched; some scientific or technological difficulties that may be encountered and impede R&D activities; a need to raise substantial additional funds to complete R&D activities; the raising of additional capital may dilute holdings of our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or products; and an ability to obtain and maintain intellectual property protection for product candidates, including pursuant to licensed patents Company Contact: Frank Haluska, M.D., Ph.D. President and Chief Executive Officer info@anchiano.com Investor Contact:", "score": 0.792256, "arguments": [{"text": "shareholders", "location": [3463, 3475], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "our", "location": [3450, 3453], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics\nAnchiano Therapeutics"}]}]}, {"type": "employedBy", "sentence": "These risks and uncertainties include, but are not limited to: a lack of history of commercial sales; no anticipated earning operating income over the coming years; a dependence on the success of inodiftagene, the development of which will require significant additional clinical testing before regulatory approval can be sought and commercial sales launched; some scientific or technological difficulties that may be encountered and impede R&D activities; a need to raise substantial additional funds to complete R&D activities; the raising of additional capital may dilute holdings of our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or products; and an ability to obtain and maintain intellectual property protection for product candidates, including pursuant to licensed patents Company Contact: Frank Haluska, M.D., Ph.D. President and Chief Executive Officer info@anchiano.com Investor Contact:", "score": 0.736132, "arguments": [{"text": "President", "location": [3747, 3756], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "Ph.D.", "location": [3741, 3746], "entities": [{"type": "GeopoliticalEntity", "text": "Ph.D.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "timeOf", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.964138, "arguments": [{"text": "today", "location": [213, 218], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [219, 228], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "affectedBy", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.525427, "arguments": [{"text": "David Kerstein", "location": [248, 262], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "appointment", "location": [233, 244], "entities": [{"type": "EventPersonnel", "text": "appointment"}]}]}, {"type": "managerOf", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.464899, "arguments": [{"text": "Chief Medical Officer", "location": [291, 312], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Company", "location": [277, 284], "entities": [{"type": "Organization", "text": "biopharmaceutical company"}]}]}, {"type": "agentOf", "sentence": "\"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "score": 0.894571, "arguments": [{"text": "Frank Haluska", "location": [569, 582], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "said", "location": [564, 568], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "\"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "score": 0.752093, "arguments": [{"text": "Chief Executive Officer", "location": [598, 621], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "Anchiano Therapeutics", "location": [625, 646], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics\nAnchiano Therapeutics"}]}]}, {"type": "agentOf", "sentence": "\" \"I am eager to contribute to Anchiano's mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\" said Dr. Kerstein.", "score": 0.898861, "arguments": [{"text": "Dr.", "location": [843, 846], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "said", "location": [838, 842], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "score": 0.799571, "arguments": [{"text": "Kerstein", "location": [888, 896], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "joins", "location": [897, 902], "entities": [{"type": "EventPersonnel", "text": "joins"}]}]}], "keywords": [{"text": "clinical-stage biopharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.672189, "count": 2}, {"text": "development of novel therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624121, "count": 2}, {"text": "Anchiano Therapeutics Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.618316, "count": 1}, {"text": "clinical drug development programs", "sentiment": {"score": 0.770762, "label": "positive"}, "relevance": 0.587054, "count": 1}, {"text": "Company\u2019s new Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.579962, "count": 1}, {"text": "appointment of David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.577763, "count": 1}, {"text": "press release", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.573712, "count": 1}, {"text": "Dr. Kerstein", "sentiment": {"score": 0.637429, "label": "positive"}, "relevance": 0.571085, "count": 4}, {"text": "significant additional clinical testing", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.565672, "count": 1}, {"text": "lack of history of commercial sales", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.56399, "count": 1}, {"text": "skilled medical lead", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.559797, "count": 1}, {"text": "cancer therapy", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.556045, "count": 1}, {"text": "urinary bladder", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.555713, "count": 1}, {"text": "R&D activities", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.5526, "count": 1}, {"text": "regulatory approval", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.55137, "count": 1}, {"text": "actual performance", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.551054, "count": 1}, {"text": "cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548266, "count": 2}, {"text": "future events", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.54815, "count": 1}, {"text": "development", "sentiment": {"score": -0.556767, "mixed": "1", "label": "negative"}, "relevance": 0.544807, "count": 3}, {"text": "pharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540481, "count": 1}, {"text": "statements", "sentiment": {"score": -0.400515, "mixed": "1", "label": "negative"}, "relevance": 0.540039, "count": 4}, {"text": "Statements", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.540039, "count": 1}, {"text": "advanced product candidate", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.539731, "count": 1}, {"text": "lung cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539595, "count": 1}, {"text": "risks", "sentiment": {"score": -0.400515, "mixed": "1", "label": "negative"}, "relevance": 0.536495, "count": 3}, {"text": "uncertainties", "sentiment": {"score": 0.570817, "label": "positive"}, "relevance": 0.53435, "count": 3}, {"text": "clinical development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533659, "count": 1}, {"text": "clinical drug strategist", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.533135, "count": 1}, {"text": "products", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.532951, "count": 1}, {"text": "management\u2019s good faith belief", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.532271, "count": 1}, {"text": "CAMBRIDGE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530604, "count": 1}, {"text": "Cambridge", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530604, "count": 1}, {"text": "Anchiano", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.52934, "count": 1}, {"text": "Medical Director", "sentiment": {"score": 0.454515, "label": "positive"}, "relevance": 0.528562, "count": 1}, {"text": "substantial additional funds", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.528226, "count": 1}, {"text": "Takeda Pharmaceuticals International Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527769, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526813, "count": 1}, {"text": "Chief Executive Officer of Anchiano Therapeutics", "sentiment": {"score": 0.845002, "label": "positive"}, "relevance": 0.525544, "count": 1}, {"text": "David", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.52548, "count": 1}, {"text": "treatment", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.524724, "count": 1}, {"text": "ARIAD Pharmaceuticals", "sentiment": {"score": 0.454515, "label": "positive"}, "relevance": 0.524122, "count": 1}, {"text": "treatment of malignancies", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.523986, "count": 1}, {"text": "global research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523765, "count": 1}, {"text": "discovery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52268, "count": 2}, {"text": "clinical portfolio strategy lead", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521295, "count": 1}, {"text": "raising of additional capital", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.519734, "count": 1}, {"text": "Tufts University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518626, "count": 1}, {"text": "results", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.518402, "count": 1}, {"text": "complete R&D activities", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.517874, "count": 1}, {"text": "holdings", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.517828, "count": 1}]}, "extracted_metadata": {"sha1": "5b6c52a2468e94ca2891017e0fe2016931fa8a94", "filename": "1543241797353.zip-cd0840bda0dcbdaf1c45240208d3713f.xml", "file_type": "json"}, "external_links": ["https://www.globenewswire.com/Tracker?data=q3OUTH-SpvKNYFAGYEXBpG9s_jvGxQuHF1a70sg_rqb6ydEDpoNvVBYbhB0APsvFMzEujK3mQjie069OmmyGYg==", "https://www.globenewswire.com/styles/gnw_nitf.css"], "title": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer", "forum_title": "Stock Market News | Financial &amp; Business News | Markets Insider"}, {"id": "TyqCUARy51oQL6Yw6OY2L9IDKK0bI_Hj4sDcpE8e_nUblEVizaQmjmp89TTiWORG", "result_metadata": {"score": 36.292774}, "author": "Swapna", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Orphan Products Development", "relevance": 0.33, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prurigo", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Prurigo nodularis", "relevance": 0.932431, "dbpedia_resource": "http://dbpedia.org/resource/Prurigo_nodularis"}], "categories": [{"score": 0.841198, "label": "/business and industrial/metals"}, {"score": 0.755872, "label": "/health and fitness"}, {"score": 0.747354, "label": "/health and fitness/therapy"}], "relations": [{"type": "partOf", "sentence": "Global Prurigo Nodularis Treatment to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development", "score": 0.81168, "arguments": [{"text": "Favourable Regulations", "location": [81, 103], "entities": [{"type": "Organization", "text": "Favourable Regulations"}]}, {"text": "Orphan Products Development", "location": [108, 135], "entities": [{"type": "Organization", "text": "Orphan Products Development"}]}]}], "keywords": [{"text": "Global Prurigo Nodularis Treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.99202, "count": 1}, {"text": "Gain Traction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.959897, "count": 1}, {"text": "Favourable Regulations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.23993, "count": 1}, {"text": "Orphan Products Development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.167994, "count": 1}, {"text": "Years", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.102965, "count": 1}]}, "crawl_date": "2018-11-26T09:55:46Z", "url": "https://www.findmarketresearch.org/2018/11/global-prurigo-nodularis-treatment-market-to-gain-traction-in-the-coming-years-owing-to-favourable-regulations-for-orphan-products-development/", "host": "findmarketresearch.org", "text": "., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T09:55:00+05:00", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": 0.0633362, "label": "positive"}, "text": "Prurigo", "relevance": 0.913207, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mn", "relevance": 0.168443, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Segmental Insights", "relevance": 0.126495, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "\u2018Prurigo", "relevance": 0.122337, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.120458, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.117417, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.111087, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0.702921, "label": "positive"}, "text": "China", "relevance": 0.108256, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": -0.358157, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.10745, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.702921, "label": "positive"}, "text": "Asia Pacific", "relevance": 0.107274, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.106916, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Western Europe", "relevance": 0.105902, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer AG", "relevance": 0.105384, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.A", "relevance": 0.0956229, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd", "relevance": 0.0928132, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.0924472, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.0924391, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.0924153, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.090825, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson Services Inc.", "relevance": 0.089944, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.0878478, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": -0.449951, "label": "negative"}, "text": "Sanofi SA", "relevance": 0.0866051, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3.4%", "relevance": 0.0866051, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.8%", "relevance": 0.0866051, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "40%", "relevance": 0.0866051, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "45%", "relevance": 0.0866051, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.0866051, "type": "TwitterHandle"}], "sentiment": {"document": {"score": 0.51871, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "by Future Market Insights titled \u2018Prurigo Nodularis Treatment Market", "keywords": [{"text": "\u2018Prurigo Nodularis Treatment"}, {"text": "Future Market Insights"}], "entities": [{"type": "HealthCondition", "text": "\u2018Prurigo"}]}, "sentence": "According to the latest report published by Future Market Insights titled \u2018Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 \u2013 2017 and Opportunity Assessment 2018 \u2013 2028\u2019, the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018\u20132028.", "object": {"text": "the latest report", "keywords": [{"text": "latest report"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Future Market Insights", "keywords": [{"text": "Future Market Insights"}]}, "sentence": "According to the latest report published by Future Market Insights titled \u2018Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 \u2013 2017 and Opportunity Assessment 2018 \u2013 2028\u2019, the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018\u20132028.", "object": {"text": "\u2018Prurigo Nodularis Treatment Market", "keywords": [{"text": "\u2018Prurigo Nodularis Treatment"}], "entities": [{"type": "HealthCondition", "text": "\u2018Prurigo"}]}, "action": {"verb": {"text": "title", "tense": "past"}, "text": "titled", "normalized": "title"}}, {"subject": {"text": "The global market for prurigo nodularis treatment", "keywords": [{"text": "prurigo nodularis"}, {"text": "global market"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018\u20132028.", "object": {"text": "a valuation of US$ 697.9 Mn", "keywords": [{"text": "valuation"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is expected to reach", "normalized": "be expect to reach"}}, {"subject": {"text": "Factors", "keywords": [{"text": "Factors"}]}, "sentence": " Global Prurigo Nodularis Treatment Market: Factors Influencing Growth", "object": {"text": "Growth", "keywords": [{"text": "Growth"}]}, "action": {"verb": {"text": "Influencing", "tense": "present"}, "text": "Influencing", "normalized": "Influencing"}}, {"subject": {"text": "awareness programmes", "keywords": [{"text": "awareness programmes"}]}, "sentence": " The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China", "keywords": [{"text": "highly populated regions"}, {"text": "rapidly developing healthcare"}, {"text": "awareness programmes"}, {"text": "Asia Pacific"}], "entities": [{"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "sentence": " The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "object": {"text": "an important role", "keywords": [{"text": "important role"}]}, "action": {"verb": {"text": "play", "tense": "future"}, "text": "is expected to play", "normalized": "be expect to play"}}, {"subject": {"text": "The global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "treatment market"}], "entities": []}, "sentence": " The global prurigo nodularis treatment market has been segmented on the basis of product type, distribution channel and region.", "object": {"text": "on the basis of product type, distribution channel and region", "keywords": [{"text": "product type"}, {"text": "distribution channel"}, {"text": "basis"}, {"text": "region"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "Prurigo", "keywords": [{"text": "Prurigo"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " Prurigo nodularis treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others.", "object": {"text": "treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others", "keywords": [{"text": "treatment product types"}, {"text": "capsacin cream"}, {"text": "corticosteroids"}, {"text": "antihistamines"}]}, "action": {"verb": {"text": "nodularis", "tense": "present"}, "text": "nodularis", "normalized": "nodularis"}}, {"subject": {"text": "corticosteroids, emollients, capsacin cream, antihistamines and others", "keywords": [{"text": "capsacin cream"}, {"text": "corticosteroids"}, {"text": "antihistamines"}, {"text": "emollients"}]}, "sentence": " Prurigo nodularis treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others.", "object": {"text": "Prurigo nodularis treatment product types", "keywords": [{"text": "Prurigo"}, {"text": "treatment product types"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "capsacin cream under the product type segment", "keywords": [{"text": "product type segment"}, {"text": "capsacin cream"}]}, "sentence": " Globally, capsacin cream under the product type segment stands the most attractive product form amongst the different product types.", "object": {"text": "the most attractive product form amongst the different product types", "keywords": [{"text": "attractive product form"}, {"text": "different product types"}]}, "action": {"verb": {"text": "stand", "tense": "present"}, "text": "stands", "normalized": "stand"}}, {"subject": {"text": "retail pharmacies", "keywords": [{"text": "retail pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "object": {"text": "anticipated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "retail pharmacies", "keywords": [{"text": "retail pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "action": {"verb": {"text": "anticipate", "tense": "past"}, "text": "are anticipated to be", "normalized": "be anticipate to be"}}, {"subject": {"text": "retail pharmacies", "keywords": [{"text": "retail pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "object": {"text": "the most lucrative distribution channel", "keywords": [{"text": "lucrative distribution channel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are anticipated to be", "normalized": "be anticipate to be"}}, {"subject": {"text": "by hospital pharmacies", "keywords": [{"text": "hospital pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "object": {"text": "the most lucrative distribution channel", "keywords": [{"text": "lucrative distribution channel"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "Western Europe", "keywords": [{"text": "Western Europe"}], "entities": [{"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " With nearly 40% \u2013 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "object": {"text": "the global prurigo nodularis treatment Market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "treatment Market"}], "entities": []}, "action": {"verb": {"text": "dominate", "tense": "past"}, "text": "dominated", "normalized": "dominate"}}, {"subject": {"text": "by governments", "keywords": [{"text": "governments"}]}, "sentence": " With nearly 40% \u2013 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "object": {"text": "key research and development initiatives", "keywords": [{"text": "development initiatives"}, {"text": "key research"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "taken", "normalized": "take"}}, {"subject": {"text": "advanced medical facilities", "keywords": [{"text": "advanced medical facilities"}]}, "sentence": " Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis.", "object": {"text": "the region cope with the current healthcare crisis", "keywords": [{"text": "current healthcare crisis"}, {"text": "region cope"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "are helping", "normalized": "be help"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America is the second largest regional market for prurigo nodularis treatment and is expected to be valued at US$ 75.6 Mn by 2028, with the markets in U.S.A and Canada growing at a faster rate.", "object": {"text": "the second largest regional market for prurigo nodularis treatment", "keywords": [{"text": "prurigo nodularis"}, {"text": "largest regional market"}, {"text": "treatment"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}, {"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the markets in U.S.A and Canada", "keywords": [{"text": "U.S.A"}, {"text": "markets"}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "U.S.A", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}]}, "sentence": " North America is the second largest regional market for prurigo nodularis treatment and is expected to be valued at US$ 75.6 Mn by 2028, with the markets in U.S.A and Canada growing at a faster rate.", "object": {"text": "at a faster rate", "keywords": [{"text": "faster rate"}]}, "action": {"verb": {"text": "grow", "tense": "present"}, "text": "growing", "normalized": "grow"}}, {"subject": {"text": "Eastern Europe", "keywords": [{"text": "Eastern Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Eastern Europe is projected to be the third largest market for prurigo nodularis treatment.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "treatment market"}], "entities": []}, "sentence": " The global prurigo nodularis treatment market is expected to create incremental opportunity of US$ 197.9 Mn between 2018 and 2028.", "object": {"text": "incremental opportunity of US$ 197.9 Mn between 2018 and 2028", "keywords": [{"text": "incremental opportunity"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "is expected to create", "normalized": "be expect to create"}}, {"subject": {"text": "The prurigo", "keywords": [{"text": "prurigo"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " The prurigo nodularis treatment market is expected to witness fast and steady growth, partly due to the rising government support across various regions and increasing demand for prurigo nodularis treatment across the world.", "object": {"text": "treatment market", "keywords": [{"text": "treatment market"}]}, "action": {"verb": {"text": "nodularis", "tense": "present"}, "text": "nodularis", "normalized": "nodularis"}}, {"subject": {"text": "The prurigo nodularis treatment market", "keywords": [{"text": "prurigo"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " The prurigo nodularis treatment market is expected to witness fast and steady growth, partly due to the rising government support across various regions and increasing demand for prurigo nodularis treatment across the world.", "object": {"text": "steady growth", "keywords": [{"text": "steady growth"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "is expected to witness", "normalized": "be expect to witness"}}, {"subject": {"text": "The global market for prurigo nodularis treatment", "keywords": [{"text": "prurigo nodularis"}, {"text": "global market"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market.", "object": {"text": "highly competitive"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "many players", "keywords": [{"text": "players"}]}, "sentence": " The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Some of the companies", "keywords": [{"text": "companies"}]}, "sentence": " Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "action": {"verb": {"text": "identify", "tense": "past"}, "text": "identified", "normalized": "identify"}}, {"subject": {"text": "Some of the companies identified in global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "treatment market"}], "entities": []}, "sentence": " Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "object": {"text": "Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others", "keywords": [{"text": "Teva Pharmaceutical Industries"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "GlaxoSmithKline plc"}, {"text": "Sanofi SA"}], "entities": [{"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd"}, {"type": "Company", "text": "Johnson & Johnson Services Inc."}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Sanofi SA"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "companies", "keywords": [{"text": "companies"}]}, "sentence": " In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.a", "object": {"text": "close collaborations", "keywords": [{"text": "close collaborations"}]}, "action": {"verb": {"text": "build", "tense": "future"}, "text": "building", "normalized": "build"}}, {"subject": {"text": "these partnerships", "keywords": [{"text": "partnerships"}]}, "sentence": " In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.a", "object": {"text": "firms to grow and expand in the global market", "keywords": [{"text": "global market"}, {"text": "firms"}], "entities": []}, "action": {"verb": {"text": "allow", "tense": "present"}, "text": "allow", "normalized": "allow"}}, {"subject": {"text": "firms", "keywords": [{"text": "firms"}]}, "sentence": " In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.a", "action": {"verb": {"text": "expand", "tense": "present"}, "text": "expand", "normalized": "expand"}}], "concepts": [{"text": "Marketing", "relevance": 0.971057, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.876553, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Prurigo nodularis", "relevance": 0.684684, "dbpedia_resource": "http://dbpedia.org/resource/Prurigo_nodularis"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.643559, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Distribution", "relevance": 0.635045, "dbpedia_resource": "http://dbpedia.org/resource/Distribution_(business)"}, {"text": "Pharmaceutical industry", "relevance": 0.609712, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Pharmacy", "relevance": 0.603115, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Region", "relevance": 0.557598, "dbpedia_resource": "http://dbpedia.org/resource/Region"}, {"text": "GlaxoSmithKline", "relevance": 0.542753, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Pfizer", "relevance": 0.52779, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Economics", "relevance": 0.474982, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}], "categories": [{"score": 0.785369, "label": "/finance/financial news"}, {"score": 0.767865, "label": "/finance/investing"}, {"score": 0.767865, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "partOf", "sentence": "According to the latest report published by Future Market Insights titled \u02bbPrurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.387339, "arguments": [{"text": "published", "location": [31, 40], "entities": [{"type": "EventCommunication", "text": "published"}]}, {"text": "report", "location": [24, 30], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.647654, "arguments": [{"text": "regions", "location": [883, 890], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "China", "location": [911, 916], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.614891, "arguments": [{"text": "Asia", "location": [894, 898], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [899, 906], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Global Prurigo Nodularis Treatment Market: Regional Highlights With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "score": 0.875969, "arguments": [{"text": "Western", "location": [1752, 1759], "entities": [{"type": "Location", "text": "Western"}]}, {"text": "Europe", "location": [1760, 1766], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Global Prurigo Nodularis Treatment Market: Regional Highlights With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "score": 0.457949, "arguments": [{"text": "governments", "location": [1939, 1950], "entities": [{"type": "GeopoliticalEntity", "text": "Regional Highlights\nWith nearly"}]}, {"text": "region", "location": [1958, 1964], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis.", "score": 0.82137, "arguments": [{"text": "regions", "location": [1990, 1997], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [2006, 2019], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis.", "score": 0.667622, "arguments": [{"text": "facilities", "location": [2038, 2048], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "region", "location": [2065, 2071], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}]}, {"type": "agentOf", "sentence": "Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-3339 Global Prurigo Nodularis Treatment Market: Vendor Insights The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market.", "score": 0.494528, "arguments": [{"text": "Global Prurigo Nodularis Treatment Market", "location": [2892, 2933], "entities": [{"type": "Organization", "text": "Global Prurigo Nodularis Treatment Market", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Report", "location": [2795, 2801], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.473218, "arguments": [{"text": "Bayer AG", "location": [3155, 3163], "entities": [{"type": "Organization", "text": "Bayer AG", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3085, 3094], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.671821, "arguments": [{"text": "Pfizer Inc.", "location": [3165, 3176], "entities": [{"type": "Organization", "text": "Pfizer Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3085, 3094], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.607119, "arguments": [{"text": "GlaxoSmithKline plc", "location": [3178, 3197], "entities": [{"type": "Organization", "text": "GlaxoSmithKline plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3085, 3094], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "According to the latest report published by Future Market Insights titled \u02bbPrurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.61155, "arguments": [{"text": "Future Market Insights", "location": [44, 66], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "report", "location": [24, 30], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.598112, "arguments": [{"text": "Johnson & Johnson Services Inc.", "location": [3235, 3266], "entities": [{"type": "Organization", "text": "Johnson & Johnson Services Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3085, 3094], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.507685, "arguments": [{"text": "Merck & Co. Inc.", "location": [3268, 3284], "entities": [{"type": "Organization", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3085, 3094], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.577551, "arguments": [{"text": "Sanofi SA", "location": [3286, 3295], "entities": [{"type": "Organization", "text": "Sanofi SA", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3085, 3094], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "According to the latest report published by Future Market Insights titled \u02bbPrurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.899785, "arguments": [{"text": "Future Market Insights", "location": [44, 66], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "published", "location": [31, 40], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "populationOf", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.577512, "arguments": [{"text": "697.9", "location": [397, 402], "entities": [{"type": "Cardinal", "text": "697.9"}]}, {"text": "US$", "location": [393, 396], "entities": [{"type": "GeopoliticalEntity", "text": "US$"}]}]}, {"type": "agentOf", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.516048, "arguments": [{"text": "Mn", "location": [403, 405], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "attesting", "location": [419, 428], "entities": [{"type": "EventCommunication", "text": "attesting"}]}]}, {"type": "agentOf", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.42228, "arguments": [{"text": "& Africa", "location": [468, 476], "entities": [{"type": "Organization", "text": "& Africa"}]}, {"text": "attesting", "location": [419, 428], "entities": [{"type": "EventCommunication", "text": "attesting"}]}]}, {"type": "basedIn", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.611012, "arguments": [{"text": "& Africa", "location": [468, 476], "entities": [{"type": "Organization", "text": "& Africa"}]}, {"text": "Middle East", "location": [456, 467], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.891549, "arguments": [{"text": "regions", "location": [883, 890], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Asia", "location": [894, 898], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.848801, "arguments": [{"text": "regions", "location": [883, 890], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Pacific", "location": [899, 906], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}], "keywords": [{"text": "Prurigo Nodularis Treatment Market", "sentiment": {"score": 0.399122, "label": "positive"}, "relevance": 0.895826, "count": 1}, {"text": "Future Market Insights", "sentiment": {"score": 0.399122, "label": "positive"}, "relevance": 0.809512, "count": 1}, {"text": "global prurigo nodularis treatment market", "sentiment": {"score": -0.610313, "mixed": "1", "label": "negative"}, "relevance": 0.753592, "count": 4}, {"text": "Global Industry Analysis", "sentiment": {"score": 0.399122, "label": "positive"}, "relevance": 0.698379, "count": 1}, {"text": "various regions", "sentiment": {"score": 0.76579, "label": "positive"}, "relevance": 0.653946, "count": 2}, {"text": "global market", "sentiment": {"score": 0.768755, "label": "positive"}, "relevance": 0.633082, "count": 4}, {"text": "prurigo nodularis treatment", "sentiment": {"score": 0.663131, "mixed": "1", "label": "positive"}, "relevance": 0.624328, "count": 6}, {"text": "Global Prurigo Nodularis Treatment Market", "sentiment": {"score": 0.495328, "mixed": "1", "label": "positive"}, "relevance": 0.614172, "count": 4}, {"text": "Western Europe", "sentiment": {"score": 0.534574, "label": "positive"}, "relevance": 0.577962, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.57161, "count": 1}, {"text": "market", "sentiment": {"score": 0.879527, "label": "positive"}, "relevance": 0.569435, "count": 1}, {"text": "market share", "sentiment": {"score": 0.534574, "label": "positive"}, "relevance": 0.560294, "count": 1}, {"text": "Eastern Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558065, "count": 1}, {"text": "basis of product type", "sentiment": {"score": -0.944322, "label": "negative"}, "relevance": 0.556992, "count": 1}, {"text": "region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549687, "count": 2}, {"text": "North America", "sentiment": {"score": 0.522431, "label": "positive"}, "relevance": 0.549487, "count": 1}, {"text": "important role", "sentiment": {"score": 0.771773, "label": "positive"}, "relevance": 0.54878, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544019, "count": 2}, {"text": "Pfizer Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53848, "count": 1}, {"text": "Growth", "sentiment": {"score": 0.879527, "label": "positive"}, "relevance": 0.536515, "count": 1}, {"text": "steady growth", "sentiment": {"score": 0.623716, "label": "positive"}, "relevance": 0.535902, "count": 1}, {"text": "faster rate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535782, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533551, "count": 1}, {"text": "Middle East", "sentiment": {"score": 0.69688, "label": "positive"}, "relevance": 0.533154, "count": 1}, {"text": "regions of Asia Pacific", "sentiment": {"score": 0.771773, "label": "positive"}, "relevance": 0.530923, "count": 1}, {"text": "regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529875, "count": 1}, {"text": "markets", "sentiment": {"score": 0.522431, "label": "positive"}, "relevance": 0.527926, "count": 1}, {"text": "US", "sentiment": {"score": 0.522431, "label": "positive"}, "relevance": 0.52724, "count": 1}, {"text": "players", "sentiment": {"score": 0.836049, "label": "positive"}, "relevance": 0.526043, "count": 1}, {"text": "Prurigo nodularis treatment product types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524738, "count": 1}, {"text": "initiatives", "sentiment": {"score": 0.879527, "label": "positive"}, "relevance": 0.524038, "count": 1}, {"text": "highest growth rate", "sentiment": {"score": 0.69688, "label": "positive"}, "relevance": 0.522662, "count": 1}, {"text": "order", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521787, "count": 1}, {"text": "governments", "sentiment": {"score": 0.534574, "label": "positive"}, "relevance": 0.520768, "count": 1}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5183, "count": 1}, {"text": "China", "sentiment": {"score": 0.771773, "label": "positive"}, "relevance": 0.517829, "count": 1}, {"text": "near future", "sentiment": {"score": 0.825717, "label": "positive"}, "relevance": 0.517737, "count": 1}, {"text": "Teva Pharmaceutical Industries Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517476, "count": 1}, {"text": "presence", "sentiment": {"score": 0.534574, "label": "positive"}, "relevance": 0.516873, "count": 1}, {"text": "corticosteroids", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514391, "count": 1}, {"text": "firms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513673, "count": 1}, {"text": "partnerships", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513255, "count": 1}, {"text": "end", "sentiment": {"score": 0.69688, "label": "positive"}, "relevance": 0.513222, "count": 1}, {"text": "demand", "sentiment": {"score": 0.623716, "label": "positive"}, "relevance": 0.512515, "count": 1}, {"text": "Request", "sentiment": {"score": 0.836049, "label": "positive"}, "relevance": 0.512444, "count": 1}, {"text": "Favourable regulations", "sentiment": {"score": 0.879527, "label": "positive"}, "relevance": 0.511179, "count": 1}, {"text": "Africa", "sentiment": {"score": 0.69688, "label": "positive"}, "relevance": 0.51033, "count": 1}, {"text": "Canada", "sentiment": {"score": 0.522431, "label": "positive"}, "relevance": 0.50918, "count": 1}, {"text": "healthcare infrastructure", "sentiment": {"score": 0.771773, "label": "positive"}, "relevance": 0.508499, "count": 1}, {"text": "Johnson Services Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507787, "count": 1}]}, "extracted_metadata": {"sha1": "025a03c58671403ccf1831091e8ef58772e7f9c1", "filename": "1543226146725.zip-6aba22b80f3a2c6595a6623c844cd539.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/reports/prurigo-nodularis-treatment-and-management-market", "https://www.futuremarketinsights.com/customization-available/rep-gb-3339"], "title": "Global Prurigo Nodularis Treatment to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development", "forum_title": "Packaging | Find Market Research - Part 4"}, {"id": "cgNFE4MbbQS7-a9OWbAxy3qx2y410Gm5MHpjxhYdUXVEJdNMT6bRicNOUb7IWh25", "result_metadata": {"score": 36.266727}, "author": "Globe Newswire", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. David Kerstein", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New Chief Medical Officer", "relevance": 0.33, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.909247, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Physician", "relevance": 0.615714, "dbpedia_resource": "http://dbpedia.org/resource/Physician"}], "categories": [{"score": 0.772817, "label": "/science/medicine/pharmacology"}, {"score": 0.692055, "label": "/science/medicine/oncology"}, {"score": 0.570508, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "managerOf", "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer", "score": 0.617534, "arguments": [{"text": "Chief Medical Officer", "location": [73, 94], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "New", "location": [69, 72], "entities": [{"type": "Organization", "text": "New", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Anchiano Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.955242, "count": 1}, {"text": "Appointment of Dr. David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.399959, "count": 1}, {"text": "New Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.065678, "count": 1}]}, "crawl_date": "2018-11-26T14:12:29Z", "url": "https://www.benzinga.com/pressreleases/18/11/g12749082/anchiano-therapeutics-announces-appointment-of-dr-david-kerstein-as-ne", "host": "benzinga.com", "text": "Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T08:30:00Z", "enriched_text": {"entities": [{"count": 14, "sentiment": {"score": 0, "label": "neutral"}, "text": "David Kerstein", "relevance": 0.898589, "type": "Person"}, {"count": 7, "sentiment": {"score": -0.295754, "label": "negative"}, "text": "Anchiano Therapeutics Ltd.", "relevance": 0.566407, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Medical Director of Oncology Clinical Research", "relevance": 0.397126, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Medical Director of Clinical Research", "relevance": 0.327905, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer", "relevance": 0.327685, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Medical Officer", "relevance": 0.320519, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0.416504, "label": "positive"}, "text": "Anchiano", "relevance": 0.314264, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics", "relevance": 0.306527, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Frank Haluska", "relevance": 0.292656, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Clinical Research Associate", "relevance": 0.278867, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Director", "relevance": 0.244424, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "CAMBRIDGE", "relevance": 0.244194, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dainippon Sumitomo Pharma Global Oncology", "relevance": 0.240402, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "Tufts University School of Medicine", "relevance": 0.230511, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity"], "name": "Tufts University School of Medicine", "dbpedia_resource": "http://dbpedia.org/resource/Tufts_University_School_of_Medicine"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Managing Director", "relevance": 0.224322, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.125719, "label": "negative"}, "text": "urinary bladder", "relevance": 0.222644, "type": "Anatomy"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.217272, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tufts University", "relevance": 0.214864, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "Tufts University", "dbpedia_resource": "http://dbpedia.org/resource/Tufts_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "bladder cancer.", "relevance": 0.214721, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mass.", "relevance": 0.213876, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LifeSci Advisors", "relevance": 0.202864, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.47292, "label": "negative"}, "text": "Takeda Pharmaceuticals International Co.", "relevance": 0.202214, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "ARIAD Pharmaceuticals, Inc.", "relevance": 0.198326, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.385441, "label": "negative"}, "text": "Boston Biomedical", "relevance": 0.188658, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jerusalem", "relevance": 0.187862, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Jerusalem", "dbpedia_resource": "http://dbpedia.org/resource/Jerusalem"}}, {"count": 1, "sentiment": {"score": 0.453397, "label": "positive"}, "text": "Ashley R. Robinson", "relevance": 0.185971, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Israel", "relevance": 0.177167, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MA", "relevance": 0.1691, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "arr@lifesciadvisors.com", "relevance": 0.1691, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "info@anchiano.com", "relevance": 0.1691, "type": "EmailAddress"}], "sentiment": {"document": {"score": 0.394732, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "the discovery and development of novel therapies to treat cancer,", "keywords": [{"text": "novel therapies"}, {"text": "discovery"}, {"text": "development"}, {"text": "cancer"}]}, "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "object": {"text": "the appointment of David Kerstein", "keywords": [{"text": "David Kerstein"}, {"text": "appointment"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "object": {"text": "an accomplished physician experienced in leading clinical drug development programs for oncology therapies", "keywords": [{"text": "oncology therapies"}, {"text": "clinical drug development"}, {"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an accomplished physician", "keywords": [{"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "action": {"verb": {"text": "experience", "tense": "past"}, "text": "experienced", "normalized": "experience"}}, {"subject": {"text": "an accomplished physician", "keywords": [{"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "object": {"text": "clinical drug development programs", "keywords": [{"text": "clinical drug development"}, {"text": "programs"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "We"}, "sentence": " \"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "object": {"text": "David, a skilled medical lead and accomplished clinical drug strategist,", "keywords": [{"text": "clinical drug strategist"}, {"text": "skilled medical lead"}, {"text": "David"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "are thrilled to have", "normalized": "be thrill to have"}}, {"subject": {"text": "Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics", "keywords": [{"text": "Chief Executive Officer"}, {"text": "Frank Haluska"}, {"text": "Anchiano Therapeutics"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Frank Haluska"}, {"type": "JobTitle", "text": "President and Chief Executive Officer"}, {"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "sentence": " \"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "object": {"text": "We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano", "keywords": [{"text": "clinical drug strategist"}, {"text": "skilled medical lead"}, {"text": "David"}, {"text": "team"}], "entities": [{"type": "Person", "text": "David Kerstein"}, {"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " \"We look forward to his medical leadership.\"", "object": {"text": "to his medical leadership", "keywords": [{"text": "medical leadership"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "I"}, "sentence": " \"I am eager to contribute to Anchiano's mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\" said Dr. Kerstein.", "object": {"text": "eager to contribute to Anchiano's mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "urinary bladder"}, {"text": "malignancies"}, {"text": "Anchiano"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"type": "Anatomy", "text": "urinary bladder"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "am", "normalized": "be"}}, {"subject": {"text": "Anchiano", "keywords": [{"text": "Anchiano"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}]}, "sentence": " \"I am eager to contribute to Anchiano's mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\" said Dr. Kerstein.", "object": {"text": "a DNA-based cancer therapy for the treatment of malignancies", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "malignancies"}, {"text": "treatment"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " \"I am eager to contribute to Anchiano's mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\" said Dr. Kerstein.", "object": {"text": "I am eager to contribute to Anchiano's mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "urinary bladder"}, {"text": "malignancies"}, {"text": "Anchiano"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"type": "Anatomy", "text": "urinary bladder"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "object": {"text": "Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company", "keywords": [{"text": "Takeda Pharmaceuticals International"}, {"text": "development-driven pharmaceutical company"}, {"text": "global research"}, {"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Ltd."}, {"type": "Company", "text": "Takeda Pharmaceuticals International Co."}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joins", "normalized": "join"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "object": {"text": "as Senior Medical Director of Oncology Clinical Research", "keywords": [{"text": "Oncology Clinical Research"}, {"text": "Senior Medical Director"}], "entities": [{"type": "JobTitle", "text": "Senior Medical Director of Oncology Clinical Research"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.", "object": {"text": "the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib", "keywords": [{"text": "cancer clinical portfolio"}, {"text": "global clinical lead"}, {"text": "strategy lead"}, {"text": "lung"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "object": {"text": "Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc.,", "keywords": [{"text": "ARIAD Pharmaceuticals"}, {"text": "Senior Medical Director"}, {"text": "Clinical Research"}], "entities": [{"type": "JobTitle", "text": "Medical Director"}, {"type": "JobTitle", "text": "Senior Medical Director of Clinical Research"}, {"type": "Company", "text": "ARIAD Pharmaceuticals, Inc."}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "object": {"text": "the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib", "keywords": [{"text": "Marketing Authorization Application"}, {"text": "initial New Drug"}, {"text": "clinical development program"}, {"text": "medical lead"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "David Kerstein"}]}, "sentence": " Dr. Kerstein began his career as a Clinical Research Associate at NormaTec, a medical device company.", "object": {"text": "his career", "keywords": [{"text": "career"}]}, "action": {"verb": {"text": "begin", "tense": "past"}, "text": "began", "normalized": "begin"}}, {"subject": {"text": "He"}, "sentence": " He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "object": {"text": "his M.D.", "keywords": [{"text": "M.D"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "sentence": " Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "object": {"text": "a clinical-stage biopharmaceutical company", "keywords": [{"text": "clinical-stage biopharmaceutical company"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Company's most advanced product candidate, inodiftagene vixteplasmid (BC-819),", "keywords": [{"text": "product candidate"}, {"text": "inodiftagene vixteplasmid"}, {"text": "Company"}, {"text": "BC-819"}]}, "sentence": " The Company's most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com", "object": {"text": "in development", "keywords": [{"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This press release", "keywords": [{"text": "press release"}], "entities": []}, "sentence": " This press release contains \"forward-looking statements\" that are subject to risks and uncertainties.", "object": {"text": "forward-looking statements\" that are subject to risks and uncertainties", "keywords": [{"text": "forward-looking statements"}, {"text": "uncertainties"}, {"text": "risks"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contains", "normalized": "contain"}}, {"subject": {"text": "These forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are based", "normalized": "be base"}}, {"subject": {"text": "These forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "on information Anchiano Therapeutics", "keywords": [{"text": "information Anchiano Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "are based", "normalized": "be base"}}, {"subject": {"text": "Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "uncertainties", "keywords": [{"text": "uncertainties"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "actual performance or results", "keywords": [{"text": "actual performance"}, {"text": "results"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "could cause", "normalized": "could cause"}}, {"subject": {"text": "by the forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "those"}, "action": {"verb": {"text": "suggest", "tense": "past"}, "text": "in or suggested", "normalized": "in or suggest"}}], "concepts": [{"text": "Medicine", "relevance": 0.956365, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmacology", "relevance": 0.918981, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical industry", "relevance": 0.711449, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Drug development", "relevance": 0.685731, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "New Drug Application", "relevance": 0.640891, "dbpedia_resource": "http://dbpedia.org/resource/New_Drug_Application"}, {"text": "Drug discovery", "relevance": 0.639167, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Clinical trial", "relevance": 0.613186, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Cancer", "relevance": 0.512813, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Urinary bladder", "relevance": 0.466846, "dbpedia_resource": "http://dbpedia.org/resource/Urinary_bladder"}, {"text": "Corporate governance", "relevance": 0.45621, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Chief executive officer", "relevance": 0.455769, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Clinical research", "relevance": 0.454929, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "Executive officer", "relevance": 0.433174, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Management occupations", "relevance": 0.414183, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Therapy", "relevance": 0.414051, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Corporate title", "relevance": 0.38369, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_title"}, {"text": "Latin honors", "relevance": 0.379415, "dbpedia_resource": "http://dbpedia.org/resource/Latin_honors"}, {"text": "Food and Drug Administration", "relevance": 0.374154, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Drug design", "relevance": 0.368215, "dbpedia_resource": "http://dbpedia.org/resource/Drug_design"}, {"text": "Chief executives", "relevance": 0.352793, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Pharmaceutical drug", "relevance": 0.352231, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Pre-clinical development", "relevance": 0.330517, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Oncology", "relevance": 0.328065, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Urology", "relevance": 0.323891, "dbpedia_resource": "http://dbpedia.org/resource/Urology"}, {"text": "New chemical entity", "relevance": 0.322861, "dbpedia_resource": "http://dbpedia.org/resource/New_chemical_entity"}, {"text": "Cancer staging", "relevance": 0.319682, "dbpedia_resource": "http://dbpedia.org/resource/Cancer_staging"}, {"text": "Bladder cancer", "relevance": 0.316768, "dbpedia_resource": "http://dbpedia.org/resource/Bladder_cancer"}, {"text": "Doctor of Medicine", "relevance": 0.315992, "dbpedia_resource": "http://dbpedia.org/resource/Doctor_of_Medicine"}], "categories": [{"score": 0.973426, "label": "/science/medicine/oncology"}, {"score": 0.917185, "label": "/health and fitness/disease/cancer"}, {"score": 0.793303, "label": "/health and fitness/therapy"}], "relations": [{"type": "locatedAt", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.987236, "arguments": [{"text": "CAMBRIDGE", "location": [0, 9], "entities": [{"type": "GeopoliticalEntity", "text": "CAMBRIDGE"}]}, {"text": "Mass.", "location": [11, 16], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "locatedAt", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.984425, "arguments": [{"text": "Cambridge", "location": [2140, 2149], "entities": [{"type": "GeopoliticalEntity", "text": "CAMBRIDGE"}]}, {"text": "MA", "location": [2151, 2153], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "employedBy", "sentence": "About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "score": 0.252169, "arguments": [{"text": "Kerstein", "location": [888, 896], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Anchiano Therapeutics", "location": [903, 924], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics\nAnchiano Therapeutics"}]}]}, {"type": "hasAttribute", "sentence": "At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.", "score": 0.820063, "arguments": [{"text": "he", "location": [1122, 1124], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "lung cancer", "location": [1133, 1144], "entities": [{"type": "HealthCondition", "text": "lung cancer"}]}]}, {"type": "employedBy", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.709676, "arguments": [{"text": "Senior Medical Director of Clinical Research", "location": [1273, 1317], "entities": [{"type": "Person", "text": "Senior Medical Director of Clinical Research"}]}, {"text": "ARIAD Pharmaceuticals, Inc.", "location": [1321, 1348], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.385757, "arguments": [{"text": "where", "location": [1350, 1355], "entities": [{"type": "Organization", "text": "where"}]}, {"text": "ARIAD Pharmaceuticals, Inc.", "location": [1321, 1348], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for initial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.683487, "arguments": [{"text": "he", "location": [1356, 1358], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "where", "location": [1350, 1355], "entities": [{"type": "Organization", "text": "where"}]}]}, {"type": "partOf", "sentence": "Dr. Kerstein began his career as a Clinical Research Associate at NormaTec, a medical device company.", "score": 0.539604, "arguments": [{"text": "Clinical Research Associate", "location": [1757, 1784], "entities": [{"type": "Organization", "text": "Clinical Research Associate"}]}, {"text": "NormaTec", "location": [1788, 1796], "entities": [{"type": "Organization", "text": "NormaTec"}]}]}, {"type": "partOf", "sentence": "He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "score": 0.963007, "arguments": [{"text": "School of Medicine", "location": [1867, 1885], "entities": [{"type": "Organization", "text": "School of Medicine", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "Tufts University", "location": [1850, 1866], "entities": [{"type": "Organization", "text": "Tufts University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "awardedTo", "sentence": "He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "score": 0.805927, "arguments": [{"text": "B.S.", "location": [1894, 1898], "entities": [{"type": "Degree", "text": "B.S."}]}, {"text": "his", "location": [1890, 1893], "entities": [{"type": "Person", "text": "David Kerstein"}]}]}, {"type": "basedIn", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.638138, "arguments": [{"text": "offices", "location": [2129, 2136], "entities": [{"type": "Organization", "text": "offices"}]}, {"text": "Cambridge", "location": [2140, 2149], "entities": [{"type": "GeopoliticalEntity", "text": "CAMBRIDGE"}]}]}, {"type": "locatedAt", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.977234, "arguments": [{"text": "Jerusalem", "location": [2159, 2168], "entities": [{"type": "GeopoliticalEntity", "text": "Jerusalem"}]}, {"text": "Israel", "location": [2170, 2176], "entities": [{"type": "GeopoliticalEntity", "text": "Israel"}]}]}, {"type": "hasAttribute", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.886958, "arguments": [{"text": "Anchiano Therapeutics Ltd.", "location": [52, 78], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics\nAnchiano Therapeutics"}]}, {"text": "ANCN", "location": [86, 90], "entities": [{"type": "Ticker", "text": "ANCN"}]}]}, {"type": "employedBy", "sentence": "The Company's most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer.", "score": 0.305363, "arguments": [{"text": "candidate", "location": [2214, 2223], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Company", "location": [2182, 2189], "entities": [{"type": "Organization", "text": "biopharmaceutical company"}]}]}, {"type": "employedBy", "sentence": "These risks and uncertainties include, but are not limited to: a lack of history of commercial sales; no anticipated earning operating income over the coming years; a dependence on the success of inodiftagene, the development of which will require significant additional clinical testing before regulatory approval can be sought and commercial sales launched; some scientific or technological difficulties that may be encountered and impede R&D activities; a need to raise substantial additional funds to complete R&D activities; the raising of additional capital may dilute holdings of our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or products; and an ability to obtain and maintain intellectual property protection for product candidates, including pursuant to licensed patents Company Contact: Frank Haluska, M.D., Ph.D. President and Chief Executive Officer info@anchiano.com Investor Contact:", "score": 0.792256, "arguments": [{"text": "shareholders", "location": [3463, 3475], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "our", "location": [3450, 3453], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics\nAnchiano Therapeutics"}]}]}, {"type": "employedBy", "sentence": "These risks and uncertainties include, but are not limited to: a lack of history of commercial sales; no anticipated earning operating income over the coming years; a dependence on the success of inodiftagene, the development of which will require significant additional clinical testing before regulatory approval can be sought and commercial sales launched; some scientific or technological difficulties that may be encountered and impede R&D activities; a need to raise substantial additional funds to complete R&D activities; the raising of additional capital may dilute holdings of our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or products; and an ability to obtain and maintain intellectual property protection for product candidates, including pursuant to licensed patents Company Contact: Frank Haluska, M.D., Ph.D. President and Chief Executive Officer info@anchiano.com Investor Contact:", "score": 0.736132, "arguments": [{"text": "President", "location": [3747, 3756], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "Ph.D.", "location": [3741, 3746], "entities": [{"type": "GeopoliticalEntity", "text": "Ph.D.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "timeOf", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.964138, "arguments": [{"text": "today", "location": [213, 218], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [219, 228], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "affectedBy", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.525427, "arguments": [{"text": "David Kerstein", "location": [248, 262], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "appointment", "location": [233, 244], "entities": [{"type": "EventPersonnel", "text": "appointment"}]}]}, {"type": "managerOf", "sentence": "CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.464899, "arguments": [{"text": "Chief Medical Officer", "location": [291, 312], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Company", "location": [277, 284], "entities": [{"type": "Organization", "text": "biopharmaceutical company"}]}]}, {"type": "agentOf", "sentence": "\"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "score": 0.894571, "arguments": [{"text": "Frank Haluska", "location": [569, 582], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "said", "location": [564, 568], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "\"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "score": 0.752093, "arguments": [{"text": "Chief Executive Officer", "location": [598, 621], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "Anchiano Therapeutics", "location": [625, 646], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics\nAnchiano Therapeutics"}]}]}, {"type": "agentOf", "sentence": "\" \"I am eager to contribute to Anchiano's mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\" said Dr. Kerstein.", "score": 0.898861, "arguments": [{"text": "Dr.", "location": [843, 846], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "said", "location": [838, 842], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "score": 0.799571, "arguments": [{"text": "Kerstein", "location": [888, 896], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "joins", "location": [897, 902], "entities": [{"type": "EventPersonnel", "text": "joins"}]}]}], "keywords": [{"text": "clinical-stage biopharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.672189, "count": 2}, {"text": "development of novel therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624121, "count": 2}, {"text": "Anchiano Therapeutics Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.618316, "count": 1}, {"text": "clinical drug development programs", "sentiment": {"score": 0.770762, "label": "positive"}, "relevance": 0.587054, "count": 1}, {"text": "Company's new Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.579962, "count": 1}, {"text": "appointment of David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.577763, "count": 1}, {"text": "press release", "sentiment": {"score": -0.87189, "label": "negative"}, "relevance": 0.573712, "count": 1}, {"text": "Dr. Kerstein", "sentiment": {"score": 0.637429, "label": "positive"}, "relevance": 0.571085, "count": 4}, {"text": "significant additional clinical testing", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.565672, "count": 1}, {"text": "lack of history of commercial sales", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.56399, "count": 1}, {"text": "skilled medical lead", "sentiment": {"score": 0.973569, "label": "positive"}, "relevance": 0.559797, "count": 1}, {"text": "cancer therapy", "sentiment": {"score": -0.7016, "label": "negative"}, "relevance": 0.556045, "count": 1}, {"text": "urinary bladder", "sentiment": {"score": -0.7016, "label": "negative"}, "relevance": 0.555713, "count": 1}, {"text": "R&D activities", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.5526, "count": 1}, {"text": "regulatory approval", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.55137, "count": 1}, {"text": "actual performance", "sentiment": {"score": 0.636298, "label": "positive"}, "relevance": 0.551054, "count": 1}, {"text": "cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548266, "count": 2}, {"text": "future events", "sentiment": {"score": 0.636298, "label": "positive"}, "relevance": 0.54815, "count": 1}, {"text": "development", "sentiment": {"score": -0.623039, "mixed": "1", "label": "negative"}, "relevance": 0.544807, "count": 3}, {"text": "pharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540481, "count": 1}, {"text": "Statements", "sentiment": {"score": -0.87189, "label": "negative"}, "relevance": 0.540039, "count": 1}, {"text": "statements", "sentiment": {"score": -0.456325, "mixed": "1", "label": "negative"}, "relevance": 0.540039, "count": 4}, {"text": "advanced product candidate", "sentiment": {"score": -0.87189, "label": "negative"}, "relevance": 0.539731, "count": 1}, {"text": "lung cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539595, "count": 1}, {"text": "risks", "sentiment": {"score": -0.456325, "mixed": "1", "label": "negative"}, "relevance": 0.536495, "count": 3}, {"text": "uncertainties", "sentiment": {"score": 0.551722, "label": "positive"}, "relevance": 0.53435, "count": 3}, {"text": "clinical development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533659, "count": 1}, {"text": "clinical drug strategist", "sentiment": {"score": 0.973569, "label": "positive"}, "relevance": 0.533135, "count": 1}, {"text": "products", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.532951, "count": 1}, {"text": "management's good faith belief", "sentiment": {"score": 0.636298, "label": "positive"}, "relevance": 0.532271, "count": 1}, {"text": "CAMBRIDGE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530604, "count": 1}, {"text": "Cambridge", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530604, "count": 1}, {"text": "Anchiano", "sentiment": {"score": 0.973569, "label": "positive"}, "relevance": 0.52934, "count": 1}, {"text": "Medical Director", "sentiment": {"score": 0.454515, "label": "positive"}, "relevance": 0.528562, "count": 1}, {"text": "substantial additional funds", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.528226, "count": 1}, {"text": "Takeda Pharmaceuticals International Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527769, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526813, "count": 1}, {"text": "Chief Executive Officer of Anchiano Therapeutics", "sentiment": {"score": 0.973569, "label": "positive"}, "relevance": 0.525544, "count": 1}, {"text": "David", "sentiment": {"score": 0.973569, "label": "positive"}, "relevance": 0.52548, "count": 1}, {"text": "treatment", "sentiment": {"score": -0.87189, "label": "negative"}, "relevance": 0.524724, "count": 1}, {"text": "ARIAD Pharmaceuticals", "sentiment": {"score": 0.454515, "label": "positive"}, "relevance": 0.524122, "count": 1}, {"text": "treatment of malignancies", "sentiment": {"score": -0.7016, "label": "negative"}, "relevance": 0.523986, "count": 1}, {"text": "global research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523765, "count": 1}, {"text": "discovery", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52268, "count": 2}, {"text": "clinical portfolio strategy lead", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521295, "count": 1}, {"text": "raising of additional capital", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.519734, "count": 1}, {"text": "Tufts University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518626, "count": 1}, {"text": "results", "sentiment": {"score": 0.636298, "label": "positive"}, "relevance": 0.518402, "count": 1}, {"text": "complete R&D activities", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.517874, "count": 1}, {"text": "holdings", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.517828, "count": 1}]}, "extracted_metadata": {"sha1": "f0d662f2c12b921f3867e99aaa7021d8707cb7cc", "filename": "1543241549037.zip-e9be1bdb0df9bebd4ba79272849f91bd.xml", "file_type": "json"}, "external_links": ["https://www.globenewswire.com/Tracker?data=q3OUTH-SpvKNYFAGYEXBpG9s_jvGxQuHF1a70sg_rqb6ydEDpoNvVBYbhB0APsvFMzEujK3mQjie069OmmyGYg==", "https://www.globenewswire.com/newsroom/ti?nf=NzQzNDAwMCMyNjAwODU4IzUwMDA0NTI2NQ==", "http://www.globenewswire.com/newsroom/ti?ndecode=MTM0Izc0MzQwMDA=", "http://www.globenewswire.com/styles/gnw_nitf.css", "https://www.globenewswire.com/NewsRoom/AttachmentNg/914eb52e-b21d-486e-b035-9d50f249ccec"], "title": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer", "forum_title": "News"}, {"id": "6ZdhbS3iadCY8l_jGNLo8xnjpuYf5FOt68shsdFEahJ9XyH6SwbmFJcCdqeat9BF", "result_metadata": {"score": 35.021496}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Meda Consumer Healthcare Inc.", "relevance": 0.33, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Co., Ltd.", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "U.S. Insomnia Market | Global Industry Growth Analysis, Size & Share | Eisai Co., Ltd. (Japan), Meda Consumer Healthcare Inc. (U.S.)", "keywords": [{"text": "Meda Consumer Healthcare"}, {"text": "U.S. Insomnia Market"}, {"text": "Global Industry Growth"}, {"text": "Share | Eisai"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "Eisai Co., Ltd."}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Company", "text": "Meda Consumer Healthcare Inc."}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": "U.S. Insomnia Market | Global Industry Growth Analysis, Size & Share | Eisai Co., Ltd. (Japan), Meda Consumer Healthcare Inc. (U.S.) To Dominate The Market \u2013 iCrowdNewswire", "object": {"text": "The Market \u2013 iCrowdNewswire", "keywords": [{"text": "Market"}, {"text": "iCrowdNewswire"}]}, "action": {"verb": {"text": "Dominate", "tense": "future"}, "text": "To Dominate", "normalized": "To Dominate"}}], "concepts": [{"text": "Capitalism", "relevance": 0.881203, "dbpedia_resource": "http://dbpedia.org/resource/Capitalism"}, {"text": "Stock market", "relevance": 0.822259, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}], "categories": [{"score": 0.751912, "label": "/real estate/buying and selling homes"}, {"score": 0.713745, "label": "/finance/financial news"}, {"score": 0.707379, "label": "/finance/investing"}], "relations": [{"type": "partOf", "sentence": "U.S. Insomnia Market | Global Industry Growth Analysis, Size & Share | Eisai Co., Ltd. (Japan), Meda Consumer Healthcare Inc. (U.S.) To Dominate The Market - iCrowdNewswire", "score": 0.992873, "arguments": [{"text": "Insomnia Market | Global Industry Growth Analysis", "location": [5, 54], "entities": [{"type": "Organization", "text": "Insomnia Market | Global Industry Growth Analysis"}]}, {"text": "U.S.", "location": [0, 4], "entities": [{"type": "GeopoliticalEntity", "text": "U.S."}]}]}], "keywords": [{"text": "Meda Consumer Healthcare Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.923187, "count": 1}, {"text": "Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.89658, "count": 1}, {"text": "U.S. Insomnia Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.888294, "count": 1}, {"text": "Global Industry Growth Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.758041, "count": 1}, {"text": "Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.690444, "count": 1}, {"text": "Size", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.63074, "count": 1}, {"text": "Share", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.617126, "count": 1}, {"text": "Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550896, "count": 1}, {"text": "U.S.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.476117, "count": 1}, {"text": "Eisai Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.318714, "count": 1}, {"text": "iCrowdNewswire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.208495, "count": 1}]}, "crawl_date": "2018-11-26T08:49:42Z", "url": "http://icrowdnewswire.com/2018/11/24/u-s-insomnia-market-global-industry-growth-analysis-size-share-eisai-co-ltd-japan-meda-consumer-healthcare-inc-u-s-to-dominate-the-market/", "host": "icrowdnewswire.com", "text": "(France), Takeda Pharmaceutical Company Ltd.", "main_image_url": "http://s3-us-west-2.amazonaws.com/icnimage/wp-content/uploads/2018/04/19061635/post_default_thumbnail.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-04-19T00:00:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0.0835375, "label": "positive"}, "text": "insomnia", "relevance": 0.921729, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}, {"count": 7, "sentiment": {"score": 0.469913, "label": "positive"}, "text": "CBTI", "relevance": 0.782817, "type": "Company"}, {"count": 8, "sentiment": {"score": -0.346575, "label": "negative"}, "text": "U.S.", "relevance": 0.685881, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.463704, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Meda Consumer Healthcare Inc.", "relevance": 0.453831, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "USD", "relevance": 0.446922, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pernix Therapeutics Holdings", "relevance": 0.4346, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Orexin Antagonist", "relevance": 0.430641, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.428244, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": -0.238414, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.421179, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": -0.39785, "label": "negative"}, "text": "Vanda Pharmaceuticals", "relevance": 0.420067, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.41684, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SRT", "relevance": 0.389462, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.276172, "label": "negative"}, "text": "Melatonin", "relevance": 0.384432, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.242086, "label": "negative"}, "text": "Eisai Co., Ltd.", "relevance": 0.379091, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zaleplon", "relevance": 0.367568, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.365503, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": -0.412125, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "https://www.marketsandmarkets.com/Market-Reports/us-insomnia-market-55727597.htmlBased on type of treatment, the U.S. insomnia market", "keywords": [{"text": "U.S. insomnia market"}, {"text": "type"}, {"text": "treatment"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": "https://www.marketsandmarkets.com/Market-Reports/us-insomnia-market-55727597.html Based on type of treatment, the U.S. insomnia market is categorized into pharmacological treatments and non-pharmacological treatments.", "object": {"text": "categorized into pharmacological treatments and non-pharmacological treatments", "keywords": [{"text": "non-pharmacological treatments"}, {"text": "pharmacological treatments"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the U.S. insomnia market", "keywords": [{"text": "U.S. insomnia market"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": "https://www.marketsandmarkets.com/Market-Reports/us-insomnia-market-55727597.html Based on type of treatment, the U.S. insomnia market is categorized into pharmacological treatments and non-pharmacological treatments.", "object": {"text": "into pharmacological treatments and non-pharmacological treatments", "keywords": [{"text": "non-pharmacological treatments"}, {"text": "pharmacological treatments"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "The pharmacological treatments segment", "keywords": [{"text": "pharmacological treatments segment"}]}, "sentence": " The pharmacological treatments segment is further categorized into prescription sleep aids and over-the-counter sleep aids.", "object": {"text": "further categorized into prescription", "keywords": [{"text": "prescription"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The pharmacological treatments segment", "keywords": [{"text": "pharmacological treatments segment"}]}, "sentence": " The pharmacological treatments segment is further categorized into prescription sleep aids and over-the-counter sleep aids.", "object": {"text": "into prescription sleep aids and over-the-counter sleep aids", "keywords": [{"text": "over-the-counter sleep aids"}, {"text": "prescription sleep aids"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "categorized", "normalized": "categorize"}}, {"subject": {"text": "The over-the-counter sleep aids segment", "keywords": [{"text": "over-the-counter sleep aids"}, {"text": "segment"}]}, "sentence": " The over-the-counter sleep aids segment is estimated to grow at the highest CAGR during the forecast period due to easier availability and low price as compared to prescription sleep aids.", "object": {"text": "estimated to grow at the highest CAGR", "keywords": [{"text": "highest CAGR"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The over-the-counter sleep aids segment", "keywords": [{"text": "over-the-counter sleep aids"}, {"text": "segment"}]}, "sentence": " The over-the-counter sleep aids segment is estimated to grow at the highest CAGR during the forecast period due to easier availability and low price as compared to prescription sleep aids.", "object": {"text": "to grow at the highest CAGR", "keywords": [{"text": "highest CAGR"}]}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "The over-the-counter sleep aids segment", "keywords": [{"text": "over-the-counter sleep aids"}, {"text": "segment"}]}, "sentence": " The over-the-counter sleep aids segment is estimated to grow at the highest CAGR during the forecast period due to easier availability and low price as compared to prescription sleep aids.", "object": {"text": "at the highest CAGR", "keywords": [{"text": "highest CAGR"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is estimated to grow", "normalized": "be estimate to grow"}}, {"subject": {"text": "a patient", "keywords": [{"text": "patient"}]}, "sentence": " Moreover, according to consumer reports, a patient can save up to USD 47 a week using OTC sleep aids.", "action": {"verb": {"text": "save", "tense": "future"}, "text": "can save", "normalized": "can save"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Based on non-pharmacological treatment, the market is categorized into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies.", "object": {"text": "on non-pharmacological treatment", "keywords": [{"text": "non-pharmacological treatment"}]}, "action": {"verb": {"text": "Based", "tense": "past"}, "text": "Based", "normalized": "Based"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " Based on non-pharmacological treatment, the market is categorized into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies.", "object": {"text": "into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies", "keywords": [{"text": "cognitive behavioural therapy"}, {"text": "alternative therapies"}, {"text": "insomnia"}, {"text": "hypnotherapy"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "CBTI", "keywords": [{"text": "CBTI"}], "entities": [{"type": "Company", "text": "CBTI"}]}, "sentence": " CBTI is highly recommended therapy for insomnia patients due as its can be used with multiple approaches that enables physicians to understand and cure patients comprehensibly.", "object": {"text": "highly recommended therapy for insomnia patients due", "keywords": [{"text": "highly recommended therapy"}, {"text": "insomnia patients"}], "entities": [{"type": "Company", "text": "CBTI"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "its", "entities": [{"type": "Company", "text": "CBTI"}]}, "sentence": " CBTI is highly recommended therapy for insomnia patients due as its can be used with multiple approaches that enables physicians to understand and cure patients comprehensibly.", "object": {"text": "with multiple approaches that enables physicians to understand and cure patients comprehensibly", "keywords": [{"text": "multiple approaches"}, {"text": "physicians"}, {"text": "patients"}]}, "action": {"verb": {"text": "use", "tense": "future"}, "text": "can be used", "normalized": "can be use"}}, {"subject": {"text": "multiple approaches", "keywords": [{"text": "multiple approaches"}]}, "sentence": " CBTI is highly recommended therapy for insomnia patients due as its can be used with multiple approaches that enables physicians to understand and cure patients comprehensibly.", "object": {"text": "physicians", "keywords": [{"text": "physicians"}]}, "action": {"verb": {"text": "enable", "tense": "present"}, "text": "enables", "normalized": "enable"}}, {"subject": {"text": "exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy", "keywords": [{"text": "bright light therapy"}, {"text": "aroma therapy"}, {"text": "biofeedback"}, {"text": "music therapy"}]}, "sentence": " The other alternative therapies include exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.", "object": {"text": "The other alternative therapies", "keywords": [{"text": "alternative therapies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "The non-pharmacological treatment market", "keywords": [{"text": "non-pharmacological treatment market"}]}, "sentence": " The non-pharmacological treatment market is categorised into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies.", "object": {"text": "categorised into cognitive behavioural therapy", "keywords": [{"text": "cognitive behavioural therapy"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The non-pharmacological treatment market", "keywords": [{"text": "non-pharmacological treatment market"}]}, "sentence": " The non-pharmacological treatment market is categorised into cognitive behavioural therapy for insomnia (CBTI), hypnotherapy, and other alternative therapies.", "object": {"text": "into cognitive behavioural therapy", "keywords": [{"text": "cognitive behavioural therapy"}]}, "action": {"verb": {"text": "categorise", "tense": "past"}, "text": "is categorised", "normalized": "be categorise"}}, {"subject": {"text": "exercise/ yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy", "keywords": [{"text": "bright light therapy"}, {"text": "aroma therapy"}, {"text": "biofeedback"}, {"text": "music therapy"}]}, "sentence": " The other alternative therapies include exercise/ yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.", "object": {"text": "The other alternative therapies", "keywords": [{"text": "alternative therapies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Most of these therapies", "keywords": [{"text": "therapies"}]}, "sentence": " Most of these therapies are given in combination with CBTI and hypnotherapies in order to provide better results for insomnia patients.", "object": {"text": "better results", "keywords": [{"text": "better results"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "CBTI", "keywords": [{"text": "CBTI"}], "entities": [{"type": "Company", "text": "CBTI"}]}, "sentence": " CBTI is the highly recommended treatment option for insomnia patients due to its most effective use with multiple approaches such as relaxation training, cognitive therapy, stimulus control (SC), sleep restriction therapy (SRT), sleep hygiene, biofeedback, and others that help doctors to understand and cure patient comprehensively.", "object": {"text": "the highly recommended treatment option for insomnia patients", "keywords": [{"text": "highly recommended treatment"}, {"text": "insomnia patients"}, {"text": "option"}], "entities": [{"type": "Company", "text": "CBTI"}, {"type": "HealthCondition", "text": "insomnia", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Symptom", "Disease"], "name": "Insomnia", "dbpedia_resource": "http://dbpedia.org/resource/Insomnia"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "others"}, "sentence": " CBTI is the highly recommended treatment option for insomnia patients due to its most effective use with multiple approaches such as relaxation training, cognitive therapy, stimulus control (SC), sleep restriction therapy (SRT), sleep hygiene, biofeedback, and others that help doctors to understand and cure patient comprehensively.", "object": {"text": "doctors to understand", "keywords": [{"text": "doctors"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "help", "normalized": "help"}}, {"subject": {"text": "others"}, "sentence": " CBTI is the highly recommended treatment option for insomnia patients due to its most effective use with multiple approaches such as relaxation training, cognitive therapy, stimulus control (SC), sleep restriction therapy (SRT), sleep hygiene, biofeedback, and others that help doctors to understand and cure patient comprehensively.", "object": {"text": "patient", "keywords": [{"text": "patient"}]}, "action": {"verb": {"text": "cure", "tense": "present"}, "text": "cure", "normalized": "cure"}}, {"subject": {"text": "CBTI", "keywords": [{"text": "CBTI"}], "entities": [{"type": "Company", "text": "CBTI"}]}, "sentence": " CBTI is followed by hypnotherapy, due to its advantage of curing insomnia with its root cause.", "object": {"text": "followed by hypnotherapy", "keywords": [{"text": "hypnotherapy"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Eisai Co., Ltd. (Japan), Meda Consumer Healthcare Inc. (U.S.), Merck & Co., Inc. (U.S.), Pernix Therapeutics Holdings (U.S.), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Takeda Pharmaceutical Company Ltd. (Japan), and Vanda Pharmaceuticals, Inc (U.S.)", "keywords": [{"text": "Meda Consumer Healthcare"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Vanda Pharmaceuticals"}, {"text": "Therapeutics Holdings"}], "entities": [{"type": "Company", "text": "Eisai Co., Ltd."}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Meda Consumer Healthcare Inc."}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "Pernix Therapeutics Holdings"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Company", "text": "Pfizer", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "France", "disambiguation": {"subtype": ["Country"]}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Company", "text": "Vanda Pharmaceuticals"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " Some of the major players in the U.S. insomnia market market include Eisai Co., Ltd. (Japan), Meda Consumer Healthcare Inc. (U.S.), Merck & Co., Inc. (U.S.), Pernix Therapeutics Holdings (U.S.), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Takeda Pharmaceutical Company Ltd. (Japan), and Vanda Pharmaceuticals, Inc (U.S.).", "object": {"text": "Some of the major players in the U.S. insomnia market market", "keywords": [{"text": "U.S. insomnia market"}, {"text": "major players"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}], "concepts": [{"text": "Therapy", "relevance": 0.967415, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Medicine", "relevance": 0.630939, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Psychotherapy", "relevance": 0.484923, "dbpedia_resource": "http://dbpedia.org/resource/Psychotherapy"}, {"text": "Sleep disorder", "relevance": 0.444538, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_disorder"}, {"text": "Alternative medicine", "relevance": 0.441303, "dbpedia_resource": "http://dbpedia.org/resource/Alternative_medicine"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.438211, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Delayed sleep phase syndrome", "relevance": 0.434729, "dbpedia_resource": "http://dbpedia.org/resource/Delayed_sleep_phase_syndrome"}, {"text": "Ramelteon", "relevance": 0.432769, "dbpedia_resource": "http://dbpedia.org/resource/Ramelteon"}, {"text": "Cure", "relevance": 0.432412, "dbpedia_resource": "http://dbpedia.org/resource/Cure"}, {"text": "Sleep", "relevance": 0.41943, "dbpedia_resource": "http://dbpedia.org/resource/Sleep"}, {"text": "Over-the-counter drug", "relevance": 0.418004, "dbpedia_resource": "http://dbpedia.org/resource/Over-the-counter_drug"}, {"text": "Circadian rhythm", "relevance": 0.417881, "dbpedia_resource": "http://dbpedia.org/resource/Circadian_rhythm"}, {"text": "Cognitive behavioral therapy", "relevance": 0.41679, "dbpedia_resource": "http://dbpedia.org/resource/Cognitive_behavioral_therapy"}, {"text": "Hypnotic", "relevance": 0.409536, "dbpedia_resource": "http://dbpedia.org/resource/Hypnotic"}, {"text": "Pharmacology", "relevance": 0.404903, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Music therapy", "relevance": 0.402996, "dbpedia_resource": "http://dbpedia.org/resource/Music_therapy"}, {"text": "Major depressive disorder", "relevance": 0.40095, "dbpedia_resource": "http://dbpedia.org/resource/Major_depressive_disorder"}, {"text": "Melatonin", "relevance": 0.392913, "dbpedia_resource": "http://dbpedia.org/resource/Melatonin"}, {"text": "Jet lag", "relevance": 0.384653, "dbpedia_resource": "http://dbpedia.org/resource/Jet_lag"}, {"text": "Sleep hygiene", "relevance": 0.383041, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_hygiene"}, {"text": "Zopiclone", "relevance": 0.381761, "dbpedia_resource": "http://dbpedia.org/resource/Zopiclone"}, {"text": "Light", "relevance": 0.374405, "dbpedia_resource": "http://dbpedia.org/resource/Light"}, {"text": "Classification of Pharmaco-Therapeutic Referrals", "relevance": 0.360393, "dbpedia_resource": "http://dbpedia.org/resource/Classification_of_Pharmaco-Therapeutic_Referrals"}, {"text": "Psychology", "relevance": 0.359806, "dbpedia_resource": "http://dbpedia.org/resource/Psychology"}, {"text": "Pharmacotherapy", "relevance": 0.351956, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacotherapy"}, {"text": "Light therapy", "relevance": 0.345665, "dbpedia_resource": "http://dbpedia.org/resource/Light_therapy"}, {"text": "Seasonal affective disorder", "relevance": 0.33136, "dbpedia_resource": "http://dbpedia.org/resource/Seasonal_affective_disorder"}, {"text": "Benzodiazepine", "relevance": 0.317155, "dbpedia_resource": "http://dbpedia.org/resource/Benzodiazepine"}, {"text": "Bipolar disorder", "relevance": 0.316465, "dbpedia_resource": "http://dbpedia.org/resource/Bipolar_disorder"}, {"text": "Treatment of bipolar disorder", "relevance": 0.310172, "dbpedia_resource": "http://dbpedia.org/resource/Treatment_of_bipolar_disorder"}, {"text": "Phase response curve", "relevance": 0.30928, "dbpedia_resource": "http://dbpedia.org/resource/Phase_response_curve"}, {"text": "Essential oil", "relevance": 0.302284, "dbpedia_resource": "http://dbpedia.org/resource/Essential_oil"}, {"text": "TAP Pharmaceuticals", "relevance": 0.302149, "dbpedia_resource": "http://dbpedia.org/resource/TAP_Pharmaceuticals"}, {"text": "Narcolepsy", "relevance": 0.295156, "dbpedia_resource": "http://dbpedia.org/resource/Narcolepsy"}, {"text": "Prescription drug", "relevance": 0.293159, "dbpedia_resource": "http://dbpedia.org/resource/Prescription_drug"}, {"text": "Patient", "relevance": 0.292197, "dbpedia_resource": "http://dbpedia.org/resource/Patient"}, {"text": "Valerian", "relevance": 0.29169, "dbpedia_resource": "http://dbpedia.org/resource/Valerian_(herb)"}, {"text": "Fluorescent lamp", "relevance": 0.29114, "dbpedia_resource": "http://dbpedia.org/resource/Fluorescent_lamp"}, {"text": "Physician", "relevance": 0.2904, "dbpedia_resource": "http://dbpedia.org/resource/Physician"}, {"text": "Medical error", "relevance": 0.286475, "dbpedia_resource": "http://dbpedia.org/resource/Medical_error"}, {"text": "Non-24-hour sleep-wake syndrome", "relevance": 0.282213, "dbpedia_resource": "http://dbpedia.org/resource/Non-24-hour_sleep-wake_syndrome"}, {"text": "Sunlight", "relevance": 0.280308, "dbpedia_resource": "http://dbpedia.org/resource/Sunlight"}, {"text": "Valeriana", "relevance": 0.27849, "dbpedia_resource": "http://dbpedia.org/resource/Valeriana"}, {"text": "Therapy?", "relevance": 0.27786, "dbpedia_resource": "http://dbpedia.org/resource/Therapy?"}, {"text": "Sleep medicine", "relevance": 0.274485, "dbpedia_resource": "http://dbpedia.org/resource/Sleep_medicine"}, {"text": "Memory", "relevance": 0.274127, "dbpedia_resource": "http://dbpedia.org/resource/Memory"}, {"text": "Herbalism", "relevance": 0.268854, "dbpedia_resource": "http://dbpedia.org/resource/Herbalism"}], "categories": [{"score": 0.997782, "label": "/health and fitness/therapy"}, {"score": 0.915476, "label": "/health and fitness/alternative medicine"}, {"score": 0.913015, "label": "/health and fitness/disorders/mental disorder/panic and anxiety"}], "relations": [{"type": "hasAttribute", "sentence": "CBTI is highly recommended therapy for insomnia patients due as its can be used with multiple approaches that enables physicians to understand and cure patients comprehensibly.", "score": 0.852785, "arguments": [{"text": "patients", "location": [850, 858], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "insomnia", "location": [841, 849], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}]}, {"type": "hasAttribute", "sentence": "Most of these therapies are given in combination with CBTI and hypnotherapies in order to provide better results for insomnia patients.", "score": 0.831198, "arguments": [{"text": "patients", "location": [1628, 1636], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "insomnia", "location": [1619, 1627], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}]}, {"type": "hasAttribute", "sentence": "CBTI is the highly recommended treatment option for insomnia patients due to its most effective use with multiple approaches such as relaxation training, cognitive therapy, stimulus control (SC), sleep restriction therapy (SRT), sleep hygiene, biofeedback, and others that help doctors to understand and cure patient comprehensively.", "score": 0.847475, "arguments": [{"text": "patients", "location": [1699, 1707], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "insomnia", "location": [1690, 1698], "entities": [{"type": "HealthCondition", "text": "insomnia"}]}]}, {"type": "employedBy", "sentence": "CBTI is the highly recommended treatment option for insomnia patients due to its most effective use with multiple approaches such as relaxation training, cognitive therapy, stimulus control (SC), sleep restriction therapy (SRT), sleep hygiene, biofeedback, and others that help doctors to understand and cure patient comprehensively.", "score": 0.375248, "arguments": [{"text": "patients", "location": [1699, 1707], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "its", "location": [1715, 1718], "entities": [{"type": "Organization", "text": "CBTI"}]}]}, {"type": "partOfMany", "sentence": "CBTI is the highly recommended treatment option for insomnia patients due to its most effective use with multiple approaches such as relaxation training, cognitive therapy, stimulus control (SC), sleep restriction therapy (SRT), sleep hygiene, biofeedback, and others that help doctors to understand and cure patient comprehensively.", "score": 0.377129, "arguments": [{"text": "doctors", "location": [1916, 1923], "entities": [{"type": "Person", "text": "doctors"}]}, {"text": "others", "location": [1899, 1905], "entities": [{"type": "Person", "text": "others"}]}]}, {"type": "partOf", "sentence": "Request Free Sample Report: U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021 Contact Information:", "score": 0.987643, "arguments": [{"text": "Insomnia Market", "location": [2441, 2456], "entities": [{"type": "Organization", "text": "Insomnia Market"}]}, {"text": "U.S.", "location": [2436, 2440], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "cognitive behavioural therapy", "sentiment": {"score": -0.872786, "label": "negative"}, "relevance": 0.81869, "count": 2}, {"text": "U.S. insomnia market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.798639, "count": 1}, {"text": "alternative therapies", "sentiment": {"score": 0.341416, "mixed": "1", "label": "positive"}, "relevance": 0.680681, "count": 4}, {"text": "prescription sleep aids", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.657661, "count": 2}, {"text": "type of treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.655619, "count": 1}, {"text": "pharmacological treatments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.650342, "count": 2}, {"text": "insomnia", "sentiment": {"score": -0.876405, "label": "negative"}, "relevance": 0.620371, "count": 3}, {"text": "therapy", "sentiment": {"score": 0.543267, "label": "positive"}, "relevance": 0.615103, "count": 1}, {"text": "market", "sentiment": {"score": -0.866894, "label": "negative"}, "relevance": 0.605221, "count": 1}, {"text": "consumer reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.58928, "count": 1}, {"text": "Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.57933, "count": 2}, {"text": "Meda Consumer Healthcare Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.57791, "count": 1}, {"text": "U.S. insomnia market market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573537, "count": 1}, {"text": "music therapy", "sentiment": {"score": 0.745419, "label": "positive"}, "relevance": 0.569715, "count": 2}, {"text": "CBTI", "sentiment": {"score": -0.590737, "mixed": "1", "label": "negative"}, "relevance": 0.563142, "count": 7}, {"text": "major players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555827, "count": 1}, {"text": "counter sleep aids", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555051, "count": 1}, {"text": "treatment option", "sentiment": {"score": 0.939155, "label": "positive"}, "relevance": 0.550367, "count": 1}, {"text": "pharmacological treatments segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549041, "count": 1}, {"text": "others", "sentiment": {"score": 0.939155, "label": "positive"}, "relevance": 0.54854, "count": 1}, {"text": "hypnotherapy", "sentiment": {"score": -0.876405, "label": "negative"}, "relevance": 0.546929, "count": 3}, {"text": "cognitive therapy", "sentiment": {"score": 0.939155, "label": "positive"}, "relevance": 0.544068, "count": 1}, {"text": "Benzodiazepines", "sentiment": {"score": -0.938384, "label": "negative"}, "relevance": 0.54346, "count": 1}, {"text": "better results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537432, "count": 1}, {"text": "biofeedback", "sentiment": {"score": 0.824975, "label": "positive"}, "relevance": 0.536285, "count": 3}, {"text": "approaches", "sentiment": {"score": 0.777654, "label": "positive"}, "relevance": 0.532719, "count": 2}, {"text": "bright light therapy", "sentiment": {"score": 0.745419, "label": "positive"}, "relevance": 0.532395, "count": 2}, {"text": "root cause", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531305, "count": 1}, {"text": "effective use", "sentiment": {"score": 0.939155, "label": "positive"}, "relevance": 0.530733, "count": 1}, {"text": "insomnia patients", "sentiment": {"score": 0.83939, "label": "positive"}, "relevance": 0.529845, "count": 3}, {"text": "Non-Pharmacological Therapy", "sentiment": {"score": -0.938384, "label": "negative"}, "relevance": 0.529564, "count": 1}, {"text": "exercise", "sentiment": {"score": 0.745419, "label": "positive"}, "relevance": 0.529076, "count": 2}, {"text": "yoga", "sentiment": {"score": 0.745419, "label": "positive"}, "relevance": 0.528079, "count": 2}, {"text": "Forecasts", "sentiment": {"score": -0.938384, "label": "negative"}, "relevance": 0.52774, "count": 1}, {"text": "acupuncture", "sentiment": {"score": 0.745419, "label": "positive"}, "relevance": 0.527333, "count": 2}, {"text": "Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526466, "count": 1}, {"text": "combination", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525686, "count": 1}, {"text": "therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525094, "count": 1}, {"text": "Hypnotherapy", "sentiment": {"score": -0.938384, "label": "negative"}, "relevance": 0.523517, "count": 1}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523313, "count": 1}, {"text": "pharmacological treatment market", "sentiment": {"score": -0.879003, "label": "negative"}, "relevance": 0.522348, "count": 1}, {"text": "Pfizer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522097, "count": 1}, {"text": "Contact Information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520968, "count": 1}, {"text": "counter sleep aids segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520119, "count": 1}, {"text": "SC", "sentiment": {"score": 0.939155, "label": "positive"}, "relevance": 0.520076, "count": 1}, {"text": "Pernix Therapeutics Holdings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519709, "count": 1}, {"text": "order", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519368, "count": 1}, {"text": "SRT", "sentiment": {"score": 0.939155, "label": "positive"}, "relevance": 0.519123, "count": 1}, {"text": "USD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518914, "count": 1}, {"text": "week", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517503, "count": 1}]}, "extracted_metadata": {"sha1": "e057fdd0ff8784a7289c14691d25179b20017c15", "filename": "1543222182279.zip-ca57485e64dc6c3b35ba5790f85a807b.xml", "file_type": "json"}, "title": "U.S. Insomnia Market | Global Industry Growth Analysis, Size & Share | Eisai Co., Ltd. (Japan), Meda Consumer Healthcare Inc. (U.S.) To Dominate The Market \u2013 iCrowdNewswire"}, {"id": "gIHeaMsnqWi1YiRT_CuoDRlBb_zYm8YncLaJ9Waoed0wTor0tZ5di7FAlZDTPSIc", "result_metadata": {"score": 34.54684}, "author": "mylubbocktv.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biolo", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Visiongain Report", "keywords": [{"text": "Visiongain Report"}]}, "sentence": "Visiongain Report Looks at Opportunities Within the $250bn Biolo", "object": {"text": "at Opportunities Within the $250bn Biolo", "keywords": [{"text": "Opportunities"}, {"text": "Biolo"}], "entities": [{"type": "Company", "text": "Biolo"}]}, "action": {"verb": {"text": "Looks", "tense": "present"}, "text": "Looks", "normalized": "Looks"}}], "concepts": [], "categories": [{"score": 0.699643, "label": "/education/homework and study tips"}, {"score": 0.687911, "label": "/law, govt and politics"}, {"score": 0.650019, "label": "/education/studying business"}], "relations": [], "keywords": [{"text": "Visiongain Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999711, "count": 1}, {"text": "Opportunities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.858499, "count": 1}, {"text": "Biolo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.014315, "count": 1}]}, "crawl_date": "2018-11-26T14:22:50Z", "url": "http://www.mylubbocktv.com/story/39536780/visiongain-report-looks-at-opportunities-within-the-250bn-biologics-sector", "host": "mylubbocktv.com", "text": "Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T00:00:00-05:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": -0.906031, "label": "negative"}, "text": "Fibrosis Foundation Therapeutics Inc", "relevance": 0.891909, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.440371, "label": "positive"}, "text": "Bamboo Therapeutics, Inc", "relevance": 0.882282, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Biologics Submarkets", "relevance": 0.832755, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.788545, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": -0.611089, "label": "negative"}, "text": "Portola Pharmaceuticals Inc", "relevance": 0.772738, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BrainStorm Cell Therapeutics", "relevance": 0.771226, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Proteon Therapeutics", "relevance": 0.766662, "type": "Company", "disambiguation": {"subtype": [], "name": "Proteon Therapeutics", "dbpedia_resource": "http://dbpedia.org/resource/Proteon_Therapeutics"}}, {"count": 2, "sentiment": {"score": 0.488663, "label": "positive"}, "text": "Amgen", "relevance": 0.761035, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca", "relevance": 0.755316, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 2, "sentiment": {"score": -0.367244, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.752781, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer", "relevance": 0.747581, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BioXpress Therapeutics", "relevance": 0.744992, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.7408, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.740555, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CytomX Therapeutics", "relevance": 0.740254, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.739923, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Harpoon Therapeutics", "relevance": 0.733578, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tissue Engineered Products", "relevance": 0.732885, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Heptares Therapeutics", "relevance": 0.731867, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United Therapeutics", "relevance": 0.730616, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sara Peerun", "relevance": 0.7274, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "US", "relevance": 0.72677, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Moderna Therapeutics", "relevance": 0.724014, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma", "relevance": 0.723791, "type": "Company", "disambiguation": {"subtype": [], "name": "Astellas Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mirati Therapeutics", "relevance": 0.721445, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Apeiron Biologics", "relevance": 0.719324, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sangamo Therapeutics", "relevance": 0.717703, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Anthera Pharmaceuticals", "relevance": 0.717581, "type": "Company", "disambiguation": {"subtype": [], "name": "Anthera Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Anthera_Pharmaceuticals"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Toronto University", "relevance": 0.715396, "type": "Organization", "disambiguation": {"subtype": ["Location", "TouristAttraction", "CollegeUniversity", "University"], "name": "University of Toronto", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Toronto"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sigilon Therapeutics", "relevance": 0.7092, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.544801, "label": "positive"}, "text": "Spark Therapeutics", "relevance": 0.706252, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Emcure Pharmaceuticals", "relevance": 0.70454, "type": "Company", "disambiguation": {"subtype": [], "name": "Emcure Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Emcure_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Intas Pharmaceuticals", "relevance": 0.700881, "type": "Company", "disambiguation": {"subtype": [], "name": "Intas Biopharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Intas_Biopharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0.464702, "label": "positive"}, "text": "Voyager Therapeutics", "relevance": 0.700477, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.458561, "label": "positive"}, "text": "Merz Pharma", "relevance": 0.698652, "type": "Company", "disambiguation": {"subtype": [], "name": "Merz Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Merz_Pharma"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.690698, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.567864, "label": "negative"}, "text": "Regeneron Pharmaceuticals", "relevance": 0.689613, "type": "Company", "disambiguation": {"subtype": [], "name": "Regeneron", "dbpedia_resource": "http://dbpedia.org/resource/Regeneron"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Acceleron Pharma", "relevance": 0.682272, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.503849, "label": "negative"}, "text": "Afferent Pharmaceuticals", "relevance": 0.679327, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AurKa Pharma", "relevance": 0.676706, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Valeant Pharmaceuticals", "relevance": 0.675141, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Turnstone Biologics", "relevance": 0.673831, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.599843, "label": "negative"}, "text": "Vertex Pharmaceuticals", "relevance": 0.673441, "type": "Company", "disambiguation": {"subtype": [], "name": "Vertex Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Vertex_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.567864, "label": "negative"}, "text": "Anacor Pharmaceuticals", "relevance": 0.671836, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.752006, "label": "negative"}, "text": "University of Texas", "relevance": 0.669201, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Benda Pharmaceuticals", "relevance": 0.668483, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of California", "relevance": 0.6679, "type": "Organization", "disambiguation": {"subtype": [], "name": "David Geffen School of Medicine at UCLA", "dbpedia_resource": "http://dbpedia.org/resource/David_Geffen_School_of_Medicine_at_UCLA"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dezima Pharma", "relevance": 0.66723, "type": "Company"}], "sentiment": {"document": {"score": 0.407764, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "The global biologics market", "keywords": [{"text": "global biologics market"}]}, "sentence": " The global biologics market is estimated to reach $250bn in 2023.", "object": {"text": "estimated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global biologics market", "keywords": [{"text": "global biologics market"}]}, "sentence": " The global biologics market is estimated to reach $250bn in 2023.", "object": {"text": "to reach $250bn in 2023"}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "The global biologics market", "keywords": [{"text": "global biologics market"}]}, "sentence": " The global biologics market is estimated to reach $250bn in 2023.", "object": {"text": "$250bn in 2023"}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is estimated to reach", "normalized": "be estimate to reach"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}]}, "sentence": " The market is expected to grow at a CAGR of 4.8% from 2018 to 2023.", "object": {"text": "at a CAGR of 4.8%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "4.8"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "the monoclonal antibodies submarket", "keywords": [{"text": "monoclonal antibodies submarket"}]}, "sentence": " In 2017, the monoclonal antibodies submarket held 36.3% share of the global biologics market.", "object": {"text": "36.3% share of the global biologics market", "keywords": [{"text": "global biologics market"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "36.3"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "How this report", "keywords": [{"text": "report"}]}, "sentence": " How this report will benefit you", "object": {"text": "you"}, "action": {"verb": {"text": "benefit", "tense": "future"}, "text": "will benefit", "normalized": "will benefit"}}, {"subject": {"text": "you"}, "sentence": " Read on to discover how you can exploit the future business opportunities emerging in this sector.", "object": {"text": "the future business opportunities emerging in this sector", "keywords": [{"text": "future business opportunities"}, {"text": "sector"}]}, "action": {"verb": {"text": "exploit", "tense": "future"}, "text": "can exploit", "normalized": "can exploit"}}, {"subject": {"text": "the future business opportunities", "keywords": [{"text": "future business opportunities"}]}, "sentence": " Read on to discover how you can exploit the future business opportunities emerging in this sector.", "action": {"verb": {"text": "emerge", "tense": "present"}, "text": "emerging", "normalized": "emerge"}}, {"subject": {"text": "you"}, "sentence": " In this brand new 303-page report you will receive 166 charts - all unavailable elsewhere.", "object": {"text": "166 charts", "keywords": [{"text": "charts"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "the key drivers and challenges", "keywords": [{"text": "challenges"}, {"text": "key drivers"}]}, "sentence": " Discover the key drivers and challenges affecting the market.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "you"}, "sentence": " By ordering and reading our brand-new report today you stay better informed and ready to act.", "object": {"text": "our brand-new report", "keywords": [{"text": "brand-new report"}]}, "action": {"verb": {"text": "read", "tense": "present"}, "text": "reading", "normalized": "read"}}, {"subject": {"text": "\u2022 This report", "keywords": [{"text": "report"}]}, "sentence": " \u2022 This report provides individual revenue forecasts from 2018-2028 for these national markets :", "object": {"text": "individual revenue forecasts", "keywords": [{"text": "individual revenue forecasts"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "\u2022 Our study", "keywords": [{"text": "study"}]}, "sentence": " \u2022 Our study discusses the selected leading companies that are the major players in the biologics market:", "object": {"text": "the selected leading companies that are the major players in the biologics market", "keywords": [{"text": "biologics market"}, {"text": "major players"}, {"text": "companies"}]}, "action": {"verb": {"text": "discuss", "tense": "present"}, "text": "discusses", "normalized": "discuss"}}, {"subject": {"text": "\u2022 This report", "keywords": [{"text": "report"}]}, "sentence": " \u2022 This report discusses factors that drive and restrain this market.", "object": {"text": "factors that drive and restrain this market", "keywords": [{"text": "factors"}, {"text": "market"}]}, "action": {"verb": {"text": "discuss", "tense": "present"}, "text": "discusses", "normalized": "discuss"}}, {"subject": {"text": "factors", "keywords": [{"text": "factors"}]}, "sentence": " \u2022 This report discusses factors that drive and restrain this market.", "object": {"text": "this market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "restrain", "tense": "present"}, "text": "restrain", "normalized": "restrain"}}, {"subject": {"text": "\u2022 This report", "keywords": [{"text": "report"}]}, "sentence": " \u2022 This report discusses the SWOT and STEP Analysis of the biologics market.", "object": {"text": "the SWOT and STEP Analysis of the biologics market", "keywords": [{"text": "biologics market"}, {"text": "SWOT"}, {"text": "STEP Analysis"}]}, "action": {"verb": {"text": "discuss", "tense": "present"}, "text": "discusses", "normalized": "discuss"}}, {"subject": {"text": "Visiongain's study", "keywords": [{"text": "Visiongain"}], "entities": [{"type": "Person", "text": "Visiongain"}]}, "sentence": " Visiongain's study is intended for anyone requiring commercial analyses for the biologics market.", "object": {"text": "intended for anyone requiring commercial analyses for the biologics market", "keywords": [{"text": "biologics market"}, {"text": "commercial analyses"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "for anyone requiring commercial analyses for the biologics market", "keywords": [{"text": "biologics market"}, {"text": "commercial analyses"}]}, "sentence": " Visiongain's study is intended for anyone requiring commercial analyses for the biologics market.", "object": {"text": "Visiongain's study", "keywords": [{"text": "Visiongain"}], "entities": [{"type": "Person", "text": "Visiongain"}]}, "action": {"verb": {"text": "intend", "tense": "past"}, "text": "is intended", "normalized": "be intend"}}, {"subject": {"text": "You"}, "sentence": " You find data, trends and predictions.", "object": {"text": "data, trends and predictions", "keywords": [{"text": "predictions"}, {"text": "trends"}, {"text": "data"}]}, "action": {"verb": {"text": "find", "tense": "present"}, "text": "find", "normalized": "find"}}, {"subject": {"text": "you"}, "sentence": " Did you know that we also offer a report add-on service?", "object": {"text": "that we also offer a report add-on service", "keywords": [{"text": "report add-on service"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "know", "normalized": "know"}}, {"subject": {"text": "we"}, "sentence": " Did you know that we also offer a report add-on service?", "object": {"text": "a report add-on service", "keywords": [{"text": "report add-on service"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offer", "normalized": "offer"}}, {"subject": {"text": "Email sara.peerun@visiongain.com", "keywords": [{"text": "Email sara.peerun"}], "entities": [{"type": "EmailAddress", "text": "sara.peerun@visiongain.com"}]}, "sentence": " Email sara.peerun@visiongain.com to discuss any customized research needs you may have.", "object": {"text": "any customized research needs", "keywords": [{"text": "customized research"}]}, "action": {"verb": {"text": "discuss", "tense": "future"}, "text": "to discuss", "normalized": "to discuss"}}, {"subject": {"text": "any customized research", "keywords": [{"text": "customized research"}]}, "sentence": " Email sara.peerun@visiongain.com to discuss any customized research needs you may have.", "object": {"text": "you"}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "needs", "normalized": "need"}}, {"subject": {"text": "Daiichi", "keywords": [{"text": "Daiichi"}], "entities": [{"type": "Company", "text": "Daiichi Sankyo Company"}]}, "sentence": " Daiichi Sankyo Company, Limited", "object": {"text": "Company", "keywords": [{"text": "Company"}]}, "action": {"verb": {"text": "Sankyo", "tense": "present"}, "text": "Sankyo", "normalized": "Sankyo"}}, {"subject": {"text": "Xiamen", "keywords": [{"text": "Xiamen"}], "entities": [{"type": "Company", "text": "Xiamen Amoytop Biotech"}]}, "sentence": " Xiamen Amoytop Biotech", "object": {"text": "Biotech", "keywords": [{"text": "Biotech"}]}, "action": {"verb": {"text": "Amoytop", "tense": "present"}, "text": "Amoytop", "normalized": "Amoytop"}}, {"subject": {"text": "Organizations", "keywords": [{"text": "Organizations"}]}, "sentence": " Organizations Mentioned in the Report", "action": {"verb": {"text": "Mentioned", "tense": "past"}, "text": "Mentioned", "normalized": "Mentioned"}}], "concepts": [{"text": "Medicine", "relevance": 0.974275, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmaceutical industry", "relevance": 0.876917, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Biotechnology", "relevance": 0.866938, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "Stem cell", "relevance": 0.841131, "dbpedia_resource": "http://dbpedia.org/resource/Stem_cell"}, {"text": "Pharmacology", "relevance": 0.79856, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Food and Drug Administration", "relevance": 0.699236, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.686262, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Pharmaceutical drug", "relevance": 0.685804, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Monoclonal antibodies", "relevance": 0.645842, "dbpedia_resource": "http://dbpedia.org/resource/Monoclonal_antibodies"}, {"text": "Pharmacy", "relevance": 0.584904, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Association of American Universities", "relevance": 0.573346, "dbpedia_resource": "http://dbpedia.org/resource/Association_of_American_Universities"}, {"text": "Biotechnology companies", "relevance": 0.508781, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Stem cell treatments", "relevance": 0.474326, "dbpedia_resource": "http://dbpedia.org/resource/Stem_cell_treatments"}, {"text": "Drug", "relevance": 0.439922, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Generic drug", "relevance": 0.425247, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.417541, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Centocor", "relevance": 0.411426, "dbpedia_resource": "http://dbpedia.org/resource/Centocor"}, {"text": "Therapy", "relevance": 0.401867, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Novartis", "relevance": 0.40145, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Corticosteroid", "relevance": 0.391753, "dbpedia_resource": "http://dbpedia.org/resource/Corticosteroid"}, {"text": "Protein", "relevance": 0.389533, "dbpedia_resource": "http://dbpedia.org/resource/Protein"}, {"text": "Stem cells", "relevance": 0.383218, "dbpedia_resource": "http://dbpedia.org/resource/Stem_cells"}, {"text": "University of Toronto", "relevance": 0.382546, "dbpedia_resource": "http://dbpedia.org/resource/University_of_Toronto"}, {"text": "Ranbaxy Laboratories", "relevance": 0.378509, "dbpedia_resource": "http://dbpedia.org/resource/Ranbaxy_Laboratories"}, {"text": "GlaxoSmithKline", "relevance": 0.369266, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Etanercept", "relevance": 0.365628, "dbpedia_resource": "http://dbpedia.org/resource/Etanercept"}, {"text": "Cord blood", "relevance": 0.36109, "dbpedia_resource": "http://dbpedia.org/resource/Cord_blood"}, {"text": "Pharmacotherapy", "relevance": 0.352335, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacotherapy"}, {"text": "Pharmaceutical companies of Japan", "relevance": 0.351145, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_Japan"}, {"text": "Blood", "relevance": 0.344528, "dbpedia_resource": "http://dbpedia.org/resource/Blood"}, {"text": "Gene therapy", "relevance": 0.340788, "dbpedia_resource": "http://dbpedia.org/resource/Gene_therapy"}, {"text": "Cord blood bank", "relevance": 0.339573, "dbpedia_resource": "http://dbpedia.org/resource/Cord_blood_bank"}, {"text": "Sanofi-Aventis", "relevance": 0.339398, "dbpedia_resource": "http://dbpedia.org/resource/Sanofi-Aventis"}], "categories": [{"score": 0.905302, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.816148, "label": "/science/medicine/oncology"}, {"score": 0.789764, "label": "/science/medicine/medical research"}], "relations": [{"type": "residesIn", "sentence": "Visiongain LONDON , November 26, 2018 /PRNewswire/ -- Biologics Market Trends and Forecasts 2018-2028 Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg ) The global biologics market is estimated to reach $250bn in 2023.", "score": 0.787878, "arguments": [{"text": "Visiongain", "location": [0, 10], "entities": [{"type": "Person", "text": "Visiongain"}]}, {"text": "LONDON", "location": [11, 17], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "timeOf", "sentence": "Buy our report today Biologics Market Trends and Forecasts 2018-2028 : Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.", "score": 0.795984, "arguments": [{"text": "today", "location": [2711, 2716], "entities": [{"type": "Date", "text": "today"}]}, {"text": "report", "location": [2704, 2710], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/biologics-market-trends-and-forecasts-2018-2028/ Did you know that we also offer a report add-on service?", "score": 0.582206, "arguments": [{"text": "Sara Peerun", "location": [3089, 3100], "entities": [{"type": "Person", "text": "Sara Peerun"}]}, {"text": "report", "location": [3067, 3073], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "managerOf", "sentence": "Limited Dako Dendreon Dezima Pharma B.V. DNAtrix Dong-A Pharmaceutical Dr. Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Emcure Pharmaceuticals EMS Epirus Europharm Evotec FDA FibroGen FierceBiotech Finox Biotech Flatiron Health Foundation Medicine, Inc. Fuji Pharma Galencia Gan & Lee GE Healthcare Genentech Gennova GenSci Genzyme Gilead Sciences GlaxoSmithKline (GSK) Hangzhou Jiuyuan Gene Engineering Co. Hanwha Chemical Harpoon Therapeutics Harrisvaccines Inc. Heptares Therapeutics Hexal Hindustan Antibiotic Histogenics Hospira, Inc. Human Genome Sciences Humana Inc. Hypermarcas IBM Watson Health ICU Medical Inc. Ignyta, Inc. Immatics Biotechnologies GmbH Immune Design Immunex Corporation Immunocore Limited Incyte Corporation Innovare R&D Intas Pharmaceuticals IOmet Pharma Ipsen Isis Pharmaceuticals, Inc. Janssen JingYuan Bio Johnson & Johnson Kite Pharma Kyowa Hakko Kirin Laboratorios Delta LG Life Sciences LifeSouth Community Blood Centers Lonza Luye Pharma Group, Ltd. M2Gen MacroGenics,", "score": 0.234394, "arguments": [{"text": "Reddy", "location": [4624, 4629], "entities": [{"type": "Person", "text": "Reddy"}]}, {"text": "Laboratories\nDynavax Technologies Corporation\nEisai Co., Ltd.\nEli Lilly and Company\nEmcure Pharmaceuticals\nEMS\nEpirus\nEuropharm\nEvotec\nFDA\nFibroGen\nFierceBiotech\nFinox Biotech\nFlatiron Health\nFoundation Medicine, Inc.\nFuji Pharma\nGalencia\nGan & Lee\nGE Healthcare\nGenentech\nGennova\nGenSci\nGenzyme\nGilead Sciences\nGlaxoSmithKline", "location": [4632, 4959], "entities": [{"type": "Organization", "text": "Laboratories\nDynavax Technologies Corporation\nEisai Co., Ltd.\nEli Lilly and Company\nEmcure Pharmaceuticals\nEMS\nEpirus\nEuropharm\nEvotec\nFDA\nFibroGen\nFierceBiotech\nFinox Biotech\nFlatiron Health\nFoundation Medicine, Inc.\nFuji Pharma\nGalencia\nGan & Lee\nGE Healthcare\nGenentech\nGennova\nGenSci\nGenzyme\nGilead Sciences\nGlaxoSmithKline"}]}]}, {"type": "employedBy", "sentence": "Limited Dako Dendreon Dezima Pharma B.V. DNAtrix Dong-A Pharmaceutical Dr. Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Emcure Pharmaceuticals EMS Epirus Europharm Evotec FDA FibroGen FierceBiotech Finox Biotech Flatiron Health Foundation Medicine, Inc. Fuji Pharma Galencia Gan & Lee GE Healthcare Genentech Gennova GenSci Genzyme Gilead Sciences GlaxoSmithKline (GSK) Hangzhou Jiuyuan Gene Engineering Co. Hanwha Chemical Harpoon Therapeutics Harrisvaccines Inc. Heptares Therapeutics Hexal Hindustan Antibiotic Histogenics Hospira, Inc. Human Genome Sciences Humana Inc. Hypermarcas IBM Watson Health ICU Medical Inc. Ignyta, Inc. Immatics Biotechnologies GmbH Immune Design Immunex Corporation Immunocore Limited Incyte Corporation Innovare R&D Intas Pharmaceuticals IOmet Pharma Ipsen Isis Pharmaceuticals, Inc. Janssen JingYuan Bio Johnson & Johnson Kite Pharma Kyowa Hakko Kirin Laboratorios Delta LG Life Sciences LifeSouth Community Blood Centers Lonza Luye Pharma Group, Ltd. M2Gen MacroGenics,", "score": 0.598955, "arguments": [{"text": "Gene", "location": [4983, 4987], "entities": [{"type": "Person", "text": "Gene Therapies"}]}, {"text": "Hangzhou Jiuyuan", "location": [4966, 4982], "entities": [{"type": "Organization", "text": "Hangzhou Jiuyuan", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "Limited Dako Dendreon Dezima Pharma B.V. DNAtrix Dong-A Pharmaceutical Dr. Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Emcure Pharmaceuticals EMS Epirus Europharm Evotec FDA FibroGen FierceBiotech Finox Biotech Flatiron Health Foundation Medicine, Inc. Fuji Pharma Galencia Gan & Lee GE Healthcare Genentech Gennova GenSci Genzyme Gilead Sciences GlaxoSmithKline (GSK) Hangzhou Jiuyuan Gene Engineering Co. Hanwha Chemical Harpoon Therapeutics Harrisvaccines Inc. Heptares Therapeutics Hexal Hindustan Antibiotic Histogenics Hospira, Inc. Human Genome Sciences Humana Inc. Hypermarcas IBM Watson Health ICU Medical Inc. Ignyta, Inc. Immatics Biotechnologies GmbH Immune Design Immunex Corporation Immunocore Limited Incyte Corporation Innovare R&D Intas Pharmaceuticals IOmet Pharma Ipsen Isis Pharmaceuticals, Inc. Janssen JingYuan Bio Johnson & Johnson Kite Pharma Kyowa Hakko Kirin Laboratorios Delta LG Life Sciences LifeSouth Community Blood Centers Lonza Luye Pharma Group, Ltd. M2Gen MacroGenics,", "score": 0.49862, "arguments": [{"text": "Janssen\nJingYuan Bio\nJohnson", "location": [5413, 5441], "entities": [{"type": "Person", "text": "Janssen\nJingYuan Bio\nJohnson"}]}, {"text": "& Johnson\nKite Pharma\nKyowa Hakko Kirin\nLaboratorios Delta\nLG Life Sciences\nLifeSouth Community Blood Centers\nLonza\nLuye Pharma Group", "location": [5442, 5575], "entities": [{"type": "Organization", "text": "& Johnson\nKite Pharma\nKyowa Hakko Kirin\nLaboratorios Delta\nLG Life Sciences\nLifeSouth Community Blood Centers\nLonza\nLuye Pharma Group"}]}]}, {"type": "employedBy", "sentence": "Limited Dako Dendreon Dezima Pharma B.V. DNAtrix Dong-A Pharmaceutical Dr. Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Emcure Pharmaceuticals EMS Epirus Europharm Evotec FDA FibroGen FierceBiotech Finox Biotech Flatiron Health Foundation Medicine, Inc. Fuji Pharma Galencia Gan & Lee GE Healthcare Genentech Gennova GenSci Genzyme Gilead Sciences GlaxoSmithKline (GSK) Hangzhou Jiuyuan Gene Engineering Co. Hanwha Chemical Harpoon Therapeutics Harrisvaccines Inc. Heptares Therapeutics Hexal Hindustan Antibiotic Histogenics Hospira, Inc. Human Genome Sciences Humana Inc. Hypermarcas IBM Watson Health ICU Medical Inc. Ignyta, Inc. Immatics Biotechnologies GmbH Immune Design Immunex Corporation Immunocore Limited Incyte Corporation Innovare R&D Intas Pharmaceuticals IOmet Pharma Ipsen Isis Pharmaceuticals, Inc. Janssen JingYuan Bio Johnson & Johnson Kite Pharma Kyowa Hakko Kirin Laboratorios Delta LG Life Sciences LifeSouth Community Blood Centers Lonza Luye Pharma Group, Ltd. M2Gen MacroGenics,", "score": 0.836084, "arguments": [{"text": "M2Gen\nMacroGenics", "location": [5582, 5599], "entities": [{"type": "Person", "text": "M2Gen\nMacroGenics"}]}, {"text": "Ltd.", "location": [5577, 5581], "entities": [{"type": "Organization", "text": "Ltd."}]}]}, {"type": "employedBy", "sentence": "Inc. Massachusetts General Hospital Medice MEDICE Arzneimittel P\u00fctter MedImmune MEDIPOST Medivation, Inc. Medtronic Merck & Co., Inc. Merck KGaA Merz Pharma Mirati Therapeutics, Inc. Mitsubishi Tanabe Mochida Pharmaceutical Moderna Therapeutics Mylan NanoString Technologies, Inc. NGM Biopharmaceuticals, Inc. Nippion Kayaku Northwestern University Novartis Novo Nordisk NuVasive Oanda Organogenes OrLife Bio Orthofix Orygen Peregrine Pharmaceuticals, Inc. Pfizer Pharmacyclics Pharmicell Pharmstandard Plexxikon Inc. Porbiomed Portola Pharmaceuticals Inc. Premier Inc. Principia Probiomed Protein Sciences Proteon Therapeutics Qilu Pharmaceutical Ranbaxy Ratiopharm Redvax GmbH Regeneron Pharmaceuticals, Inc. Regenerys Reliance Life Sciences Rentschler Biotechnologie.", "score": 0.73097, "arguments": [{"text": "Merz Pharma\nMirati Therapeutics", "location": [5746, 5777], "entities": [{"type": "Person", "text": "Merz Pharma\nMirati Therapeutics"}]}, {"text": "Inc.\nMassachusetts General Hospital\nMedice\nMEDICE Arzneimittel P\u00fctter\nMedImmune\nMEDIPOST\nMedivation, Inc.\nMedtronic\nMerck & Co., Inc.\nMerck KGaA", "location": [5601, 5745], "entities": [{"type": "Organization", "text": "Inc.\nMassachusetts General Hospital\nMedice\nMEDICE Arzneimittel P\u00fctter\nMedImmune\nMEDIPOST\nMedivation, Inc.\nMedtronic\nMerck & Co., Inc.\nMerck KGaA", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.643062, "arguments": [{"text": "Bioepis\nSandoz\nSangamo Therapeutics", "location": [6395, 6430], "entities": [{"type": "Person", "text": "Bioepis\nSandoz\nSangamo Therapeutics"}]}, {"text": "Roche\nSamsung", "location": [6381, 6394], "entities": [{"type": "Organization", "text": "Roche\nSamsung", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.976693, "arguments": [{"text": "XO1 Limited\nZenotech\nZS Pharma\nZuventus\nZydus Biovation\nZydus Cadila\nOrganizations", "location": [7163, 7245], "entities": [{"type": "Organization", "text": "XO1 Limited\nZenotech\nZS Pharma\nZuventus\nZydus Biovation\nZydus Cadila\nOrganizations"}]}, {"text": "Inc.\nSanofi\nSchering-Plough\nSciGen\nShandong Kexing Pharma\nShanghai CP Guojian Pharmaceutical\nShanghai Fosun\nShanghai Sunway Biotech\nShantha Biotechnics\nShenzhen SiBiono GeneTech\nShire\nSicor Biotech\nSigilon Therapeutics\nSimcere Pharmaceutical Group\nSmith and Nephew\nSpark Therapeutics\nStada\nStemcentrx\nStragen Pharma\nStratatech Corporation\nSwiss Re\nTakeda Pharmaceutical Company Limited\nTESARO, Inc.\nTetraLogic Pharmaceuticals Corporation\nTeva\nTianjin Hualida Biotechnology\nTiGenix\nTonghua Dongbao\nTrophos\nTurnstone Biologics\nUCB\nUni\u00e3o Qu\u00edmica\nUniQure\nValeant Pharmaceuticals\nVertex Pharmaceuticals\nViralytics Limited\nVital Therapies Inc.\nVoyager Therapeutics\nWockhardt\nWyeth-Ayerst Laboratories\nXencor, Inc.\nXiamen Amoytop Biotech", "location": [6432, 7162], "entities": [{"type": "Organization", "text": "Inc.\nSanofi\nSchering-Plough\nSciGen\nShandong Kexing Pharma\nShanghai CP Guojian Pharmaceutical\nShanghai Fosun\nShanghai Sunway Biotech\nShantha Biotechnics\nShenzhen SiBiono GeneTech\nShire\nSicor Biotech\nSigilon Therapeutics\nSimcere Pharmaceutical Group\nSmith and Nephew\nSpark Therapeutics\nStada\nStemcentrx\nStragen Pharma\nStratatech Corporation\nSwiss Re\nTakeda Pharmaceutical Company Limited\nTESARO, Inc.\nTetraLogic Pharmaceuticals Corporation\nTeva\nTianjin Hualida Biotechnology\nTiGenix\nTonghua Dongbao\nTrophos\nTurnstone Biologics\nUCB\nUni\u00e3o Qu\u00edmica\nUniQure\nValeant Pharmaceuticals\nVertex Pharmaceuticals\nViralytics Limited\nVital Therapies Inc.\nVoyager Therapeutics\nWockhardt\nWyeth-Ayerst Laboratories\nXencor, Inc.\nXiamen Amoytop Biotech"}]}]}, {"type": "agentOf", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.912608, "arguments": [{"text": "XO1 Limited\nZenotech\nZS Pharma\nZuventus\nZydus Biovation\nZydus Cadila\nOrganizations", "location": [7163, 7245], "entities": [{"type": "Organization", "text": "XO1 Limited\nZenotech\nZS Pharma\nZuventus\nZydus Biovation\nZydus Cadila\nOrganizations"}]}, {"text": "Mentioned", "location": [7246, 7255], "entities": [{"type": "EventCommunication", "text": "Mentioned"}]}]}, {"type": "partOf", "sentence": "Visiongain LONDON , November 26, 2018 /PRNewswire/ -- Biologics Market Trends and Forecasts 2018-2028 Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg ) The global biologics market is estimated to reach $250bn in 2023.", "score": 0.525949, "arguments": [{"text": "Protein Therapeutics", "location": [102, 122], "entities": [{"type": "Organization", "text": "Protein Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Biologics Market Trends and Forecasts", "location": [54, 91], "entities": [{"type": "Organization", "text": "Biologics Market Trends and Forecasts"}]}]}, {"type": "basedIn", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.709779, "arguments": [{"text": "Children's Hospital\nCenter for Disease Prevention and Control", "location": [7371, 7432], "entities": [{"type": "Organization", "text": "Children's Hospital\nCenter for Disease Prevention and Control"}]}, {"text": "Boston", "location": [7364, 7370], "entities": [{"type": "GeopoliticalEntity", "text": "Boston"}]}]}, {"type": "partOf", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.655543, "arguments": [{"text": "CDC", "location": [7434, 7437], "entities": [{"type": "Organization", "text": "CDC", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Children's Hospital\nCenter for Disease Prevention and Control", "location": [7371, 7432], "entities": [{"type": "Organization", "text": "Children's Hospital\nCenter for Disease Prevention and Control"}]}]}, {"type": "partOf", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.83705, "arguments": [{"text": "School of Medicine", "location": [7534, 7552], "entities": [{"type": "Organization", "text": "School of Medicine", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "Central Drugs Standard Control Organisation\nChina Food and Drug Administration\nDuke University", "location": [7439, 7533], "entities": [{"type": "Organization", "text": "Central Drugs Standard Control Organisation\nChina Food and Drug Administration\nDuke University"}]}]}, {"type": "employedBy", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.51565, "arguments": [{"text": "EMA", "location": [7553, 7556], "entities": [{"type": "Person", "text": "EMA"}]}, {"text": "School of Medicine", "location": [7534, 7552], "entities": [{"type": "Organization", "text": "School of Medicine", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "employedBy", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.556076, "arguments": [{"text": "EMA", "location": [7553, 7556], "entities": [{"type": "Person", "text": "EMA"}]}, {"text": "European Medicines Agency", "location": [7558, 7583], "entities": [{"type": "Organization", "text": "European Medicines Agency", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.732437, "arguments": [{"text": "European Commission", "location": [7585, 7604], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "EC", "location": [7606, 7608], "entities": [{"type": "Ticker", "text": "EC"}]}]}, {"type": "employedBy", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.827155, "arguments": [{"text": "President", "location": [8104, 8113], "entities": [{"type": "Person", "text": "President"}]}, {"text": "U.S.", "location": [8099, 8103], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.398118, "arguments": [{"text": "President", "location": [8104, 8113], "entities": [{"type": "Person", "text": "President"}]}, {"text": "Emergency Plan for AIDS Relief", "location": [8116, 8146], "entities": [{"type": "Organization", "text": "Emergency Plan for AIDS Relief", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.968039, "arguments": [{"text": "UCSF", "location": [8297, 8301], "entities": [{"type": "Organization", "text": "UCSF"}]}, {"text": "University of Manchester\nThe University of Texas\nThe University of Texas MD Anderson Cancer Center\nToronto University\nToronto University", "location": [8160, 8296], "entities": [{"type": "Organization", "text": "University of Manchester\nThe University of Texas\nThe University of Texas MD Anderson Cancer Center\nToronto University\nToronto University"}]}]}, {"type": "basedIn", "sentence": "Berkeley University of Colorado Cord Blood Bank University of Tokyo US Center for Disease Prevention and Control (CDC) US Food and Drug Administration Walter and Eliza Hall Institute World Bank World Health Organization (WHO) Yonsei University To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com", "score": 0.69082, "arguments": [{"text": "Center for Disease Prevention and Control", "location": [8463, 8504], "entities": [{"type": "Organization", "text": "Children's Hospital\nCenter for Disease Prevention and Control"}]}, {"text": "US", "location": [8460, 8462], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Visiongain LONDON , November 26, 2018 /PRNewswire/ -- Biologics Market Trends and Forecasts 2018-2028 Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg ) The global biologics market is estimated to reach $250bn in 2023.", "score": 0.72303, "arguments": [{"text": "Gene Therapies", "location": [349, 363], "entities": [{"type": "Person", "text": "Gene Therapies"}]}, {"text": "Logo", "location": [365, 369], "entities": [{"type": "Organization", "text": "Logo", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Berkeley University of Colorado Cord Blood Bank University of Tokyo US Center for Disease Prevention and Control (CDC) US Food and Drug Administration Walter and Eliza Hall Institute World Bank World Health Organization (WHO) Yonsei University To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com", "score": 0.985668, "arguments": [{"text": "Food and Drug Administration", "location": [8514, 8542], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "US", "location": [8511, 8513], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Berkeley University of Colorado Cord Blood Bank University of Tokyo US Center for Disease Prevention and Control (CDC) US Food and Drug Administration Walter and Eliza Hall Institute World Bank World Health Organization (WHO) Yonsei University To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com", "score": 0.689392, "arguments": [{"text": "Walter", "location": [8543, 8549], "entities": [{"type": "Person", "text": "Walter"}]}, {"text": "Food and Drug Administration", "location": [8514, 8542], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "partOf", "sentence": "Berkeley University of Colorado Cord Blood Bank University of Tokyo US Center for Disease Prevention and Control (CDC) US Food and Drug Administration Walter and Eliza Hall Institute World Bank World Health Organization (WHO) Yonsei University To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com", "score": 0.849354, "arguments": [{"text": "Bank\nWorld Health Organization", "location": [8581, 8611], "entities": [{"type": "Organization", "text": "Bank\nWorld Health Organization", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "World", "location": [8575, 8580], "entities": [{"type": "Organization", "text": "World", "disambiguation": {"subtype": ["Multigov"]}}]}]}, {"type": "hasAttribute", "sentence": "Visiongain LONDON , November 26, 2018 /PRNewswire/ -- Biologics Market Trends and Forecasts 2018-2028 Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg ) The global biologics market is estimated to reach $250bn in 2023.", "score": 0.448346, "arguments": [{"text": "Logo", "location": [365, 369], "entities": [{"type": "Organization", "text": "Logo", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg", "location": [371, 430], "entities": [{"type": "Web", "text": "https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg"}]}]}, {"type": "timeOf", "sentence": "By ordering and reading our brand-new report today you stay better informed and ready to act.", "score": 0.790505, "arguments": [{"text": "today", "location": [1077, 1082], "entities": [{"type": "Date", "text": "today"}]}, {"text": "ordering", "location": [1035, 1043], "entities": [{"type": "EventLegal", "text": "ordering"}]}]}, {"type": "employedBy", "sentence": "Report Scope \u00b7 Global Biologics Market outlook from 2018-2028 \u00b7 Global Biologics Submarkets analysis and forecast from 2018-2028 : \u00b7 Protein therapeutics , with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents \u00b7 Monoclonal antibodies (mAbs) \u00b7 Fusion proteins \u00b7 Regenerative medicine , with sub-forecasting for stem cell treatment, tissue engineering and gene therapy \u00b7 Vaccines \u00b7 Analysis and forecast from 2018-2028 for selected leading biologics in the market: \u00b7 Lantus \u00b7 NovoLog/NovoRapid \u00b7 Humalog \u00b7 Avonex \u00b7 Rebif \u00b7 Humira \u00b7 Remicade \u00b7 Tysabri \u00b7 Herceptin \u00b7 Kadcyla \u00b7 Perjeta \u00b7 Enbrel \u00b7 Eylea \u00b7 OsteoCel Plus \u00b7 Trinity Evolution and Trinity Elite \u00b7 Apligraf \u00b7 Dermagraft \u00b7 IMLYGIC \u00b7 This report provides individual revenue forecasts from 2018-2028 for these national markets : \u00b7 The US \u00b7", "score": 0.560083, "arguments": [{"text": "Scope", "location": [1133, 1138], "entities": [{"type": "Person", "text": "Scope"}]}, {"text": "Global Biologics Market", "location": [1141, 1164], "entities": [{"type": "Organization", "text": "Global Biologics Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Report Scope \u00b7 Global Biologics Market outlook from 2018-2028 \u00b7 Global Biologics Submarkets analysis and forecast from 2018-2028 : \u00b7 Protein therapeutics , with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents \u00b7 Monoclonal antibodies (mAbs) \u00b7 Fusion proteins \u00b7 Regenerative medicine , with sub-forecasting for stem cell treatment, tissue engineering and gene therapy \u00b7 Vaccines \u00b7 Analysis and forecast from 2018-2028 for selected leading biologics in the market: \u00b7 Lantus \u00b7 NovoLog/NovoRapid \u00b7 Humalog \u00b7 Avonex \u00b7 Rebif \u00b7 Humira \u00b7 Remicade \u00b7 Tysabri \u00b7 Herceptin \u00b7 Kadcyla \u00b7 Perjeta \u00b7 Enbrel \u00b7 Eylea \u00b7 OsteoCel Plus \u00b7 Trinity Evolution and Trinity Elite \u00b7 Apligraf \u00b7 Dermagraft \u00b7 IMLYGIC \u00b7 This report provides individual revenue forecasts from 2018-2028 for these national markets : \u00b7 The US \u00b7", "score": 0.977459, "arguments": [{"text": "Lantus\n\u2022 NovoLog/NovoRapid\n\u2022 Humalog\n\u2022 Avonex\n\u2022 Rebif\n\u2022 Humira\n\u2022 Remicade\n\u2022 Tysabri\n\u2022 Herceptin\n\u2022 Kadcyla\n\u2022 Perjeta\n\u2022 Enbrel\n\u2022 Eylea\n\u2022 OsteoCel Plus\n\u2022 Trinity Evolution and Trinity Elite\n\u2022 Apligraf\n\u2022 Dermagraft\n\u2022 IMLYGIC\n\u2022 This", "location": [1692, 1919], "entities": [{"type": "Organization", "text": "Lantus\n\u2022 NovoLog/NovoRapid\n\u2022 Humalog\n\u2022 Avonex\n\u2022 Rebif\n\u2022 Humira\n\u2022 Remicade\n\u2022 Tysabri\n\u2022 Herceptin\n\u2022 Kadcyla\n\u2022 Perjeta\n\u2022 Enbrel\n\u2022 Eylea\n\u2022 OsteoCel Plus\n\u2022 Trinity Evolution and Trinity Elite\n\u2022 Apligraf\n\u2022 Dermagraft\n\u2022 IMLYGIC\n\u2022 This"}]}, {"text": "report", "location": [1920, 1926], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "Japan \u00b7 Germany \u00b7 France \u00b7 UK \u00b7 Italy \u00b7 Spain \u00b7 China \u00b7 India \u00b7 Russia \u00b7 Brazil \u00b7 Our study discusses the selected leading companies that are the major players in the biologics market: \u00b7 AbbVie \u00b7 Amgen \u00b7 AstraZeneca \u00b7 Bayer \u00b7 Eli Lilly \u00b7 GlaxoSmithKline (GSK) \u00b7 Johnson & Johnson \u00b7 Merck & Co., Inc. \u00b7 Novartis \u00b7 Pfizer \u00b7 Roche \u00b7 Sanofi S.A. \u00b7 This report discusses factors that drive and restrain this market.", "score": 0.963415, "arguments": [{"text": "Johnson & Johnson\n\u2022 Merck & Co., Inc.\n\u2022 Novartis\n\u2022 Pfizer\n\u2022 Roche\n\u2022 Sanofi S.A.\n\u2022 This", "location": [2282, 2368], "entities": [{"type": "Organization", "text": "Johnson & Johnson\n\u2022 Merck & Co., Inc.\n\u2022 Novartis\n\u2022 Pfizer\n\u2022 Roche\n\u2022 Sanofi S.A.\n\u2022 This", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "report", "location": [2369, 2375], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "Buy our report today Biologics Market Trends and Forecasts 2018-2028 : Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.", "score": 0.928663, "arguments": [{"text": "our", "location": [2700, 2703], "entities": [{"type": "Person", "text": "our"}]}, {"text": "report", "location": [2704, 2710], "entities": [{"type": "EventCommunication", "text": "report"}]}]}], "keywords": [{"text": "new 303-page report", "sentiment": {"score": -0.596518, "label": "negative"}, "relevance": 0.598155, "count": 1}, {"text": "Monoclonal Antibodies", "sentiment": {"score": 0.616695, "label": "positive"}, "relevance": 0.591569, "count": 2}, {"text": "report", "sentiment": {"score": 0.414771, "mixed": "1", "label": "positive"}, "relevance": 0.585063, "count": 5}, {"text": "Protein Therapeutics", "sentiment": {"score": 0.616695, "label": "positive"}, "relevance": 0.5849, "count": 2}, {"text": "Trinity Evolution", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.570587, "count": 1}, {"text": "ordering", "sentiment": {"score": 0.77585, "label": "positive"}, "relevance": 0.56486, "count": 1}, {"text": "European Medicines Agency", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.562391, "count": 1}, {"text": "University of Manchester", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562342, "count": 1}, {"text": "Biologics Market Trends", "sentiment": {"score": 0.418485, "label": "positive"}, "relevance": 0.553154, "count": 1}, {"text": "brand-new report today", "sentiment": {"score": 0.77585, "label": "positive"}, "relevance": 0.552575, "count": 1}, {"text": "303-page report", "sentiment": {"score": 0.663354, "label": "positive"}, "relevance": 0.542974, "count": 1}, {"text": "brand", "sentiment": {"score": -0.596518, "label": "negative"}, "relevance": 0.539735, "count": 1}, {"text": "Recombinant Hormones", "sentiment": {"score": 0.616695, "label": "positive"}, "relevance": 0.539648, "count": 2}, {"text": "Fusion Proteins", "sentiment": {"score": 0.616695, "label": "positive"}, "relevance": 0.535557, "count": 2}, {"text": "Visiongain's study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534515, "count": 1}, {"text": "European Commission", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.532307, "count": 1}, {"text": "monoclonal antibodies submarket", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531924, "count": 1}, {"text": "Monoclonal antibodies", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.530832, "count": 1}, {"text": "Regenerative Medicines", "sentiment": {"score": 0.616695, "label": "positive"}, "relevance": 0.529249, "count": 2}, {"text": "Recombinant Coagulating Factors", "sentiment": {"score": 0.616695, "label": "positive"}, "relevance": 0.528452, "count": 2}, {"text": "U.S. President's Emergency Plan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528152, "count": 1}, {"text": "global biologics market", "sentiment": {"score": 0.476188, "label": "positive"}, "relevance": 0.527715, "count": 2}, {"text": "Forecasts", "sentiment": {"score": 0.616695, "label": "positive"}, "relevance": 0.527168, "count": 2}, {"text": "University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526981, "count": 1}, {"text": "University of Texas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525442, "count": 1}, {"text": "report overview of this report", "sentiment": {"score": -0.421302, "label": "negative"}, "relevance": 0.524912, "count": 1}, {"text": "Protein therapeutics", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.524304, "count": 1}, {"text": "Regenerative medicine", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.523944, "count": 1}, {"text": "Yonsei University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521737, "count": 1}, {"text": "Trinity Elite", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.521557, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.521342, "count": 2}, {"text": "European Group", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.519668, "count": 1}, {"text": "study", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.518013, "count": 1}, {"text": "Disease Prevention", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.517367, "count": 2}, {"text": "Stem Cell Therapies", "sentiment": {"score": 0.616695, "label": "positive"}, "relevance": 0.516811, "count": 2}, {"text": "Report Scope", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.516388, "count": 1}, {"text": "trends", "sentiment": {"score": -0.557524, "label": "negative"}, "relevance": 0.515769, "count": 2}, {"text": "market", "sentiment": {"score": 0.310662, "mixed": "1", "label": "positive"}, "relevance": 0.515563, "count": 5}, {"text": "insulin", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.514727, "count": 1}, {"text": "Insulin", "sentiment": {"score": 0.616695, "label": "positive"}, "relevance": 0.514727, "count": 2}, {"text": "individual revenue forecasts", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.514673, "count": 1}, {"text": "Plasma", "sentiment": {"score": 0.616695, "label": "positive"}, "relevance": 0.514164, "count": 2}, {"text": "plasma", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.514164, "count": 1}, {"text": "major players", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.513966, "count": 1}, {"text": "Email sara.peerun@visiongain.com", "sentiment": {"score": 0.467502, "label": "positive"}, "relevance": 0.513347, "count": 1}, {"text": "Marrow Transplantation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513058, "count": 1}, {"text": "tissue engineering", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.512144, "count": 1}, {"text": "US", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.511756, "count": 1}, {"text": "Australia's Walter", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.511295, "count": 1}, {"text": "Analysis", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.511238, "count": 1}]}, "extracted_metadata": {"sha1": "516c057338d4e7ccb13242515482852395ec046d", "filename": "1543242170938.zip-d18ad3d55ac608205cef0cbc97ba3c9d.xml", "file_type": "json"}, "external_links": ["https://www.visiongain.com/report/biologics-market-trends-and-forecasts-2018-2028/", "http://www.xmlnews.org/ns/"], "title": "Visiongain Report Looks at Opportunities Within the $250bn Biolo", "forum_title": "Health Care"}, {"id": "gaScocKRXII4fG2dn31HcHB8GqFB8pC1rCSxjSAzdWe6bJf_k2o888A1jXYFN6xy", "result_metadata": {"score": 34.193573}, "author": "PRESS RELEASE PR Newswire", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biologics Sector", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Visiongain Report", "keywords": [{"text": "Visiongain Report"}]}, "sentence": "Visiongain Report Looks at Opportunities Within the $250bn Biologics Sector", "object": {"text": "at Opportunities Within the $250bn Biologics Sector", "keywords": [{"text": "Biologics Sector"}, {"text": "Opportunities"}], "entities": [{"type": "Company", "text": "Biologics Sector"}]}, "action": {"verb": {"text": "Looks", "tense": "present"}, "text": "Looks", "normalized": "Looks"}}], "concepts": [], "categories": [{"score": 0.699842, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.65289, "label": "/business and industrial/manufacturing"}, {"score": 0.636141, "label": "/health and fitness"}], "relations": [], "keywords": [{"text": "Visiongain Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.998679, "count": 1}, {"text": "Opportunities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.844727, "count": 1}, {"text": "Biologics Sector", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.087056, "count": 1}]}, "crawl_date": "2018-11-26T10:28:06Z", "url": "https://markets.businessinsider.com/news/stocks/visiongain-report-looks-at-opportunities-within-the-250bn-biologics-sector-1027754150", "host": "markets.businessinsider.com", "text": "Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T05:00:00-06:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": -0.906031, "label": "negative"}, "text": "Fibrosis Foundation Therapeutics Inc", "relevance": 0.892468, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.440371, "label": "positive"}, "text": "Bamboo Therapeutics, Inc", "relevance": 0.88282, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Biologics Submarkets", "relevance": 0.833146, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.788671, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": -0.611089, "label": "negative"}, "text": "Portola Pharmaceuticals Inc", "relevance": 0.773159, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BrainStorm Cell Therapeutics", "relevance": 0.771598, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Proteon Therapeutics", "relevance": 0.766994, "type": "Company", "disambiguation": {"subtype": [], "name": "Proteon Therapeutics", "dbpedia_resource": "http://dbpedia.org/resource/Proteon_Therapeutics"}}, {"count": 2, "sentiment": {"score": 0.488663, "label": "positive"}, "text": "Amgen", "relevance": 0.761108, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca", "relevance": 0.755383, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 2, "sentiment": {"score": -0.367244, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.752855, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer", "relevance": 0.74764, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BioXpress Therapeutics", "relevance": 0.745324, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.740859, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.740615, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CytomX Therapeutics", "relevance": 0.740583, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.739984, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Harpoon Therapeutics", "relevance": 0.733906, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tissue Engineered Products", "relevance": 0.732985, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Heptares Therapeutics", "relevance": 0.73219, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United Therapeutics", "relevance": 0.730917, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sara Peerun", "relevance": 0.727466, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "US", "relevance": 0.726815, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Moderna Therapeutics", "relevance": 0.724335, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma", "relevance": 0.724051, "type": "Company", "disambiguation": {"subtype": [], "name": "Astellas Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mirati Therapeutics", "relevance": 0.72176, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Apeiron Biologics", "relevance": 0.71962, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sangamo Therapeutics", "relevance": 0.718021, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Anthera Pharmaceuticals", "relevance": 0.717838, "type": "Company", "disambiguation": {"subtype": [], "name": "Anthera Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Anthera_Pharmaceuticals"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Toronto University", "relevance": 0.715524, "type": "Organization", "disambiguation": {"subtype": ["Location", "TouristAttraction", "CollegeUniversity", "University"], "name": "University of Toronto", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Toronto"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sigilon Therapeutics", "relevance": 0.709507, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.544801, "label": "positive"}, "text": "Spark Therapeutics", "relevance": 0.70656, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Emcure Pharmaceuticals", "relevance": 0.704789, "type": "Company", "disambiguation": {"subtype": [], "name": "Emcure Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Emcure_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Intas Pharmaceuticals", "relevance": 0.701134, "type": "Company", "disambiguation": {"subtype": [], "name": "Intas Biopharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Intas_Biopharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0.464702, "label": "positive"}, "text": "Voyager Therapeutics", "relevance": 0.70078, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.458561, "label": "positive"}, "text": "Merz Pharma", "relevance": 0.698901, "type": "Company", "disambiguation": {"subtype": [], "name": "Merz Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Merz_Pharma"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.69076, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.567864, "label": "negative"}, "text": "Regeneron Pharmaceuticals", "relevance": 0.68986, "type": "Company", "disambiguation": {"subtype": [], "name": "Regeneron", "dbpedia_resource": "http://dbpedia.org/resource/Regeneron"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Acceleron Pharma", "relevance": 0.682521, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.503849, "label": "negative"}, "text": "Afferent Pharmaceuticals", "relevance": 0.67958, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AurKa Pharma", "relevance": 0.676951, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Valeant Pharmaceuticals", "relevance": 0.675372, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Turnstone Biologics", "relevance": 0.674096, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.599843, "label": "negative"}, "text": "Vertex Pharmaceuticals", "relevance": 0.673674, "type": "Company", "disambiguation": {"subtype": [], "name": "Vertex Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Vertex_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.567864, "label": "negative"}, "text": "Anacor Pharmaceuticals", "relevance": 0.672078, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.752006, "label": "negative"}, "text": "University of Texas", "relevance": 0.669316, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Benda Pharmaceuticals", "relevance": 0.668728, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of California", "relevance": 0.668012, "type": "Organization", "disambiguation": {"subtype": [], "name": "David Geffen School of Medicine at UCLA", "dbpedia_resource": "http://dbpedia.org/resource/David_Geffen_School_of_Medicine_at_UCLA"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dezima Pharma", "relevance": 0.667469, "type": "Company"}], "sentiment": {"document": {"score": 0.393209, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "The global biologics market", "keywords": [{"text": "global biologics market"}]}, "sentence": " The global biologics market is estimated to reach $250bn in 2023.", "object": {"text": "estimated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global biologics market", "keywords": [{"text": "global biologics market"}]}, "sentence": " The global biologics market is estimated to reach $250bn in 2023.", "object": {"text": "to reach $250bn in 2023"}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "The global biologics market", "keywords": [{"text": "global biologics market"}]}, "sentence": " The global biologics market is estimated to reach $250bn in 2023.", "object": {"text": "$250bn in 2023"}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is estimated to reach", "normalized": "be estimate to reach"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}]}, "sentence": " The market is expected to grow at a CAGR of 4.8% from 2018 to 2023.", "object": {"text": "at a CAGR of 4.8%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "4.8"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "the monoclonal antibodies submarket", "keywords": [{"text": "monoclonal antibodies submarket"}]}, "sentence": " In 2017, the monoclonal antibodies submarket held 36.3% share of the global biologics market.", "object": {"text": "36.3% share of the global biologics market", "keywords": [{"text": "global biologics market"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "36.3"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "How this report", "keywords": [{"text": "report"}]}, "sentence": " How this report will benefit you", "object": {"text": "you"}, "action": {"verb": {"text": "benefit", "tense": "future"}, "text": "will benefit", "normalized": "will benefit"}}, {"subject": {"text": "you"}, "sentence": " Read on to discover how you can exploit the future business opportunities emerging in this sector.", "object": {"text": "the future business opportunities emerging in this sector", "keywords": [{"text": "future business opportunities"}, {"text": "sector"}]}, "action": {"verb": {"text": "exploit", "tense": "future"}, "text": "can exploit", "normalized": "can exploit"}}, {"subject": {"text": "the future business opportunities", "keywords": [{"text": "future business opportunities"}]}, "sentence": " Read on to discover how you can exploit the future business opportunities emerging in this sector.", "action": {"verb": {"text": "emerge", "tense": "present"}, "text": "emerging", "normalized": "emerge"}}, {"subject": {"text": "you"}, "sentence": " In this brand new 303-page report you will receive 166 charts - all unavailable elsewhere.", "object": {"text": "166 charts", "keywords": [{"text": "charts"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "the key drivers and challenges", "keywords": [{"text": "challenges"}, {"text": "key drivers"}]}, "sentence": " Discover the key drivers and challenges affecting the market.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "you"}, "sentence": " By ordering and reading our brand-new report today you stay better informed and ready to act.", "object": {"text": "our brand-new report", "keywords": [{"text": "brand-new report"}]}, "action": {"verb": {"text": "read", "tense": "present"}, "text": "reading", "normalized": "read"}}, {"subject": {"text": "\u2022 This report", "keywords": [{"text": "report"}]}, "sentence": " \u2022 This report provides individual revenue forecasts from 2018-2028 for these national markets :", "object": {"text": "individual revenue forecasts", "keywords": [{"text": "individual revenue forecasts"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "\u2022 Our study", "keywords": [{"text": "study"}]}, "sentence": " \u2022 Our study discusses the selected leading companies that are the major players in the biologics market:", "object": {"text": "the selected leading companies that are the major players in the biologics market", "keywords": [{"text": "biologics market"}, {"text": "major players"}, {"text": "companies"}]}, "action": {"verb": {"text": "discuss", "tense": "present"}, "text": "discusses", "normalized": "discuss"}}, {"subject": {"text": "\u2022 This report", "keywords": [{"text": "report"}]}, "sentence": " \u2022 This report discusses factors that drive and restrain this market.", "object": {"text": "factors that drive and restrain this market", "keywords": [{"text": "factors"}, {"text": "market"}]}, "action": {"verb": {"text": "discuss", "tense": "present"}, "text": "discusses", "normalized": "discuss"}}, {"subject": {"text": "factors", "keywords": [{"text": "factors"}]}, "sentence": " \u2022 This report discusses factors that drive and restrain this market.", "object": {"text": "this market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "restrain", "tense": "present"}, "text": "restrain", "normalized": "restrain"}}, {"subject": {"text": "\u2022 This report", "keywords": [{"text": "report"}]}, "sentence": " \u2022 This report discusses the SWOT and STEP Analysis of the biologics market.", "object": {"text": "the SWOT and STEP Analysis of the biologics market", "keywords": [{"text": "biologics market"}, {"text": "SWOT"}, {"text": "STEP Analysis"}]}, "action": {"verb": {"text": "discuss", "tense": "present"}, "text": "discusses", "normalized": "discuss"}}, {"subject": {"text": "Visiongain's study", "keywords": [{"text": "Visiongain"}], "entities": [{"type": "Person", "text": "Visiongain"}]}, "sentence": " Visiongain's study is intended for anyone requiring commercial analyses for the biologics market.", "object": {"text": "intended for anyone requiring commercial analyses for the biologics market", "keywords": [{"text": "biologics market"}, {"text": "commercial analyses"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "for anyone requiring commercial analyses for the biologics market", "keywords": [{"text": "biologics market"}, {"text": "commercial analyses"}]}, "sentence": " Visiongain's study is intended for anyone requiring commercial analyses for the biologics market.", "object": {"text": "Visiongain's study", "keywords": [{"text": "Visiongain"}], "entities": [{"type": "Person", "text": "Visiongain"}]}, "action": {"verb": {"text": "intend", "tense": "past"}, "text": "is intended", "normalized": "be intend"}}, {"subject": {"text": "You"}, "sentence": " You find data, trends and predictions.", "object": {"text": "data, trends and predictions", "keywords": [{"text": "predictions"}, {"text": "trends"}, {"text": "data"}]}, "action": {"verb": {"text": "find", "tense": "present"}, "text": "find", "normalized": "find"}}, {"subject": {"text": "you"}, "sentence": " Did you know that we also offer a report add-on service?", "object": {"text": "that we also offer a report add-on service", "keywords": [{"text": "report add-on service"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "know", "normalized": "know"}}, {"subject": {"text": "we"}, "sentence": " Did you know that we also offer a report add-on service?", "object": {"text": "a report add-on service", "keywords": [{"text": "report add-on service"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offer", "normalized": "offer"}}, {"subject": {"text": "Email sara.peerun@visiongain.com", "keywords": [{"text": "Email sara.peerun"}], "entities": [{"type": "EmailAddress", "text": "sara.peerun@visiongain.com"}]}, "sentence": " Email sara.peerun@visiongain.com to discuss any customized research needs you may have.", "object": {"text": "any customized research needs", "keywords": [{"text": "customized research"}]}, "action": {"verb": {"text": "discuss", "tense": "future"}, "text": "to discuss", "normalized": "to discuss"}}, {"subject": {"text": "any customized research", "keywords": [{"text": "customized research"}]}, "sentence": " Email sara.peerun@visiongain.com to discuss any customized research needs you may have.", "object": {"text": "you"}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "needs", "normalized": "need"}}, {"subject": {"text": "Daiichi", "keywords": [{"text": "Daiichi"}], "entities": [{"type": "Company", "text": "Daiichi Sankyo Company"}]}, "sentence": " Daiichi Sankyo Company, Limited", "object": {"text": "Company", "keywords": [{"text": "Company"}]}, "action": {"verb": {"text": "Sankyo", "tense": "present"}, "text": "Sankyo", "normalized": "Sankyo"}}, {"subject": {"text": "Xiamen", "keywords": [{"text": "Xiamen"}], "entities": [{"type": "Company", "text": "Xiamen Amoytop Biotech"}]}, "sentence": " Xiamen Amoytop Biotech", "object": {"text": "Biotech", "keywords": [{"text": "Biotech"}]}, "action": {"verb": {"text": "Amoytop", "tense": "present"}, "text": "Amoytop", "normalized": "Amoytop"}}, {"subject": {"text": "Organizations", "keywords": [{"text": "Organizations"}]}, "sentence": " Organizations Mentioned in the Report", "action": {"verb": {"text": "Mentioned", "tense": "past"}, "text": "Mentioned", "normalized": "Mentioned"}}], "concepts": [{"text": "Medicine", "relevance": 0.974921, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmaceutical industry", "relevance": 0.877365, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Biotechnology", "relevance": 0.867797, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "Stem cell", "relevance": 0.841756, "dbpedia_resource": "http://dbpedia.org/resource/Stem_cell"}, {"text": "Pharmacology", "relevance": 0.798923, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Food and Drug Administration", "relevance": 0.699932, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.686499, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Pharmaceutical drug", "relevance": 0.685997, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Monoclonal antibodies", "relevance": 0.646216, "dbpedia_resource": "http://dbpedia.org/resource/Monoclonal_antibodies"}, {"text": "Pharmacy", "relevance": 0.58524, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Association of American Universities", "relevance": 0.574274, "dbpedia_resource": "http://dbpedia.org/resource/Association_of_American_Universities"}, {"text": "Biotechnology companies", "relevance": 0.509214, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Stem cell treatments", "relevance": 0.474487, "dbpedia_resource": "http://dbpedia.org/resource/Stem_cell_treatments"}, {"text": "Drug", "relevance": 0.440145, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Generic drug", "relevance": 0.425569, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.417601, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Centocor", "relevance": 0.411501, "dbpedia_resource": "http://dbpedia.org/resource/Centocor"}, {"text": "Therapy", "relevance": 0.402147, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Novartis", "relevance": 0.401919, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Corticosteroid", "relevance": 0.392047, "dbpedia_resource": "http://dbpedia.org/resource/Corticosteroid"}, {"text": "Protein", "relevance": 0.390042, "dbpedia_resource": "http://dbpedia.org/resource/Protein"}, {"text": "Stem cells", "relevance": 0.383715, "dbpedia_resource": "http://dbpedia.org/resource/Stem_cells"}, {"text": "University of Toronto", "relevance": 0.382856, "dbpedia_resource": "http://dbpedia.org/resource/University_of_Toronto"}, {"text": "Ranbaxy Laboratories", "relevance": 0.378758, "dbpedia_resource": "http://dbpedia.org/resource/Ranbaxy_Laboratories"}, {"text": "GlaxoSmithKline", "relevance": 0.369748, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Etanercept", "relevance": 0.366073, "dbpedia_resource": "http://dbpedia.org/resource/Etanercept"}, {"text": "Cord blood", "relevance": 0.361341, "dbpedia_resource": "http://dbpedia.org/resource/Cord_blood"}, {"text": "Pharmacotherapy", "relevance": 0.352416, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacotherapy"}, {"text": "Pharmaceutical companies of Japan", "relevance": 0.351416, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_Japan"}, {"text": "Blood", "relevance": 0.344978, "dbpedia_resource": "http://dbpedia.org/resource/Blood"}, {"text": "Gene therapy", "relevance": 0.341005, "dbpedia_resource": "http://dbpedia.org/resource/Gene_therapy"}, {"text": "Sanofi-Aventis", "relevance": 0.339835, "dbpedia_resource": "http://dbpedia.org/resource/Sanofi-Aventis"}, {"text": "Cord blood bank", "relevance": 0.339801, "dbpedia_resource": "http://dbpedia.org/resource/Cord_blood_bank"}], "categories": [{"score": 0.905302, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.816148, "label": "/science/medicine/oncology"}, {"score": 0.789764, "label": "/science/medicine/medical research"}], "relations": [{"type": "partOf", "sentence": "LONDON , November 26, 2018 /PRNewswire/ -- Biologics Market Trends and Forecasts 2018-2028 Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg ) The global biologics market is estimated to reach $250bn in 2023.", "score": 0.526648, "arguments": [{"text": "Protein Therapeutics", "location": [91, 111], "entities": [{"type": "Organization", "text": "Protein Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Biologics Market Trends and Forecasts", "location": [43, 80], "entities": [{"type": "Organization", "text": "Biologics Market Trends and Forecasts"}]}]}, {"type": "agentOf", "sentence": "To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/biologics-market-trends-and-forecasts-2018-2028/ Did you know that we also offer a report add-on service?", "score": 0.582206, "arguments": [{"text": "Sara Peerun", "location": [3078, 3089], "entities": [{"type": "Person", "text": "Sara Peerun"}]}, {"text": "report", "location": [3056, 3062], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "managerOf", "sentence": "Limited Dako Dendreon Dezima Pharma B.V. DNAtrix Dong-A Pharmaceutical Dr. Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Emcure Pharmaceuticals EMS Epirus Europharm Evotec FDA FibroGen FierceBiotech Finox Biotech Flatiron Health Foundation Medicine, Inc. Fuji Pharma Galencia Gan & Lee GE Healthcare Genentech Gennova GenSci Genzyme Gilead Sciences GlaxoSmithKline (GSK) Hangzhou Jiuyuan Gene Engineering Co. Hanwha Chemical Harpoon Therapeutics Harrisvaccines Inc. Heptares Therapeutics Hexal Hindustan Antibiotic Histogenics Hospira, Inc. Human Genome Sciences Humana Inc. Hypermarcas IBM Watson Health ICU Medical Inc. Ignyta, Inc. Immatics Biotechnologies GmbH Immune Design Immunex Corporation Immunocore Limited Incyte Corporation Innovare R&D Intas Pharmaceuticals IOmet Pharma Ipsen Isis Pharmaceuticals, Inc. Janssen JingYuan Bio Johnson & Johnson Kite Pharma Kyowa Hakko Kirin Laboratorios Delta LG Life Sciences LifeSouth Community Blood Centers Lonza Luye Pharma Group, Ltd. M2Gen MacroGenics,", "score": 0.234394, "arguments": [{"text": "Reddy", "location": [4613, 4618], "entities": [{"type": "Person", "text": "Reddy"}]}, {"text": "Laboratories\nDynavax Technologies Corporation\nEisai Co., Ltd.\nEli Lilly and Company\nEmcure Pharmaceuticals\nEMS\nEpirus\nEuropharm\nEvotec\nFDA\nFibroGen\nFierceBiotech\nFinox Biotech\nFlatiron Health\nFoundation Medicine, Inc.\nFuji Pharma\nGalencia\nGan & Lee\nGE Healthcare\nGenentech\nGennova\nGenSci\nGenzyme\nGilead Sciences\nGlaxoSmithKline", "location": [4621, 4948], "entities": [{"type": "Organization", "text": "Laboratories\nDynavax Technologies Corporation\nEisai Co., Ltd.\nEli Lilly and Company\nEmcure Pharmaceuticals\nEMS\nEpirus\nEuropharm\nEvotec\nFDA\nFibroGen\nFierceBiotech\nFinox Biotech\nFlatiron Health\nFoundation Medicine, Inc.\nFuji Pharma\nGalencia\nGan & Lee\nGE Healthcare\nGenentech\nGennova\nGenSci\nGenzyme\nGilead Sciences\nGlaxoSmithKline"}]}]}, {"type": "employedBy", "sentence": "Limited Dako Dendreon Dezima Pharma B.V. DNAtrix Dong-A Pharmaceutical Dr. Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Emcure Pharmaceuticals EMS Epirus Europharm Evotec FDA FibroGen FierceBiotech Finox Biotech Flatiron Health Foundation Medicine, Inc. Fuji Pharma Galencia Gan & Lee GE Healthcare Genentech Gennova GenSci Genzyme Gilead Sciences GlaxoSmithKline (GSK) Hangzhou Jiuyuan Gene Engineering Co. Hanwha Chemical Harpoon Therapeutics Harrisvaccines Inc. Heptares Therapeutics Hexal Hindustan Antibiotic Histogenics Hospira, Inc. Human Genome Sciences Humana Inc. Hypermarcas IBM Watson Health ICU Medical Inc. Ignyta, Inc. Immatics Biotechnologies GmbH Immune Design Immunex Corporation Immunocore Limited Incyte Corporation Innovare R&D Intas Pharmaceuticals IOmet Pharma Ipsen Isis Pharmaceuticals, Inc. Janssen JingYuan Bio Johnson & Johnson Kite Pharma Kyowa Hakko Kirin Laboratorios Delta LG Life Sciences LifeSouth Community Blood Centers Lonza Luye Pharma Group, Ltd. M2Gen MacroGenics,", "score": 0.598955, "arguments": [{"text": "Gene", "location": [4972, 4976], "entities": [{"type": "Person", "text": "Gene Therapies"}]}, {"text": "Hangzhou Jiuyuan", "location": [4955, 4971], "entities": [{"type": "Organization", "text": "Hangzhou Jiuyuan", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "Limited Dako Dendreon Dezima Pharma B.V. DNAtrix Dong-A Pharmaceutical Dr. Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Emcure Pharmaceuticals EMS Epirus Europharm Evotec FDA FibroGen FierceBiotech Finox Biotech Flatiron Health Foundation Medicine, Inc. Fuji Pharma Galencia Gan & Lee GE Healthcare Genentech Gennova GenSci Genzyme Gilead Sciences GlaxoSmithKline (GSK) Hangzhou Jiuyuan Gene Engineering Co. Hanwha Chemical Harpoon Therapeutics Harrisvaccines Inc. Heptares Therapeutics Hexal Hindustan Antibiotic Histogenics Hospira, Inc. Human Genome Sciences Humana Inc. Hypermarcas IBM Watson Health ICU Medical Inc. Ignyta, Inc. Immatics Biotechnologies GmbH Immune Design Immunex Corporation Immunocore Limited Incyte Corporation Innovare R&D Intas Pharmaceuticals IOmet Pharma Ipsen Isis Pharmaceuticals, Inc. Janssen JingYuan Bio Johnson & Johnson Kite Pharma Kyowa Hakko Kirin Laboratorios Delta LG Life Sciences LifeSouth Community Blood Centers Lonza Luye Pharma Group, Ltd. M2Gen MacroGenics,", "score": 0.49862, "arguments": [{"text": "Janssen\nJingYuan Bio\nJohnson", "location": [5402, 5430], "entities": [{"type": "Person", "text": "Janssen\nJingYuan Bio\nJohnson"}]}, {"text": "& Johnson\nKite Pharma\nKyowa Hakko Kirin\nLaboratorios Delta\nLG Life Sciences\nLifeSouth Community Blood Centers\nLonza\nLuye Pharma Group", "location": [5431, 5564], "entities": [{"type": "Organization", "text": "& Johnson\nKite Pharma\nKyowa Hakko Kirin\nLaboratorios Delta\nLG Life Sciences\nLifeSouth Community Blood Centers\nLonza\nLuye Pharma Group"}]}]}, {"type": "employedBy", "sentence": "Limited Dako Dendreon Dezima Pharma B.V. DNAtrix Dong-A Pharmaceutical Dr. Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Emcure Pharmaceuticals EMS Epirus Europharm Evotec FDA FibroGen FierceBiotech Finox Biotech Flatiron Health Foundation Medicine, Inc. Fuji Pharma Galencia Gan & Lee GE Healthcare Genentech Gennova GenSci Genzyme Gilead Sciences GlaxoSmithKline (GSK) Hangzhou Jiuyuan Gene Engineering Co. Hanwha Chemical Harpoon Therapeutics Harrisvaccines Inc. Heptares Therapeutics Hexal Hindustan Antibiotic Histogenics Hospira, Inc. Human Genome Sciences Humana Inc. Hypermarcas IBM Watson Health ICU Medical Inc. Ignyta, Inc. Immatics Biotechnologies GmbH Immune Design Immunex Corporation Immunocore Limited Incyte Corporation Innovare R&D Intas Pharmaceuticals IOmet Pharma Ipsen Isis Pharmaceuticals, Inc. Janssen JingYuan Bio Johnson & Johnson Kite Pharma Kyowa Hakko Kirin Laboratorios Delta LG Life Sciences LifeSouth Community Blood Centers Lonza Luye Pharma Group, Ltd. M2Gen MacroGenics,", "score": 0.836084, "arguments": [{"text": "M2Gen\nMacroGenics", "location": [5571, 5588], "entities": [{"type": "Person", "text": "M2Gen\nMacroGenics"}]}, {"text": "Ltd.", "location": [5566, 5570], "entities": [{"type": "Organization", "text": "Ltd."}]}]}, {"type": "employedBy", "sentence": "Inc. Massachusetts General Hospital Medice MEDICE Arzneimittel P\u00fctter MedImmune MEDIPOST Medivation, Inc. Medtronic Merck & Co., Inc. Merck KGaA Merz Pharma Mirati Therapeutics, Inc. Mitsubishi Tanabe Mochida Pharmaceutical Moderna Therapeutics Mylan NanoString Technologies, Inc. NGM Biopharmaceuticals, Inc. Nippion Kayaku Northwestern University Novartis Novo Nordisk NuVasive Oanda Organogenes OrLife Bio Orthofix Orygen Peregrine Pharmaceuticals, Inc. Pfizer Pharmacyclics Pharmicell Pharmstandard Plexxikon Inc. Porbiomed Portola Pharmaceuticals Inc. Premier Inc. Principia Probiomed Protein Sciences Proteon Therapeutics Qilu Pharmaceutical Ranbaxy Ratiopharm Redvax GmbH Regeneron Pharmaceuticals, Inc. Regenerys Reliance Life Sciences Rentschler Biotechnologie.", "score": 0.73097, "arguments": [{"text": "Merz Pharma\nMirati Therapeutics", "location": [5735, 5766], "entities": [{"type": "Person", "text": "Merz Pharma\nMirati Therapeutics"}]}, {"text": "Inc.\nMassachusetts General Hospital\nMedice\nMEDICE Arzneimittel P\u00fctter\nMedImmune\nMEDIPOST\nMedivation, Inc.\nMedtronic\nMerck & Co., Inc.\nMerck KGaA", "location": [5590, 5734], "entities": [{"type": "Organization", "text": "Inc.\nMassachusetts General Hospital\nMedice\nMEDICE Arzneimittel P\u00fctter\nMedImmune\nMEDIPOST\nMedivation, Inc.\nMedtronic\nMerck & Co., Inc.\nMerck KGaA", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.643062, "arguments": [{"text": "Bioepis\nSandoz\nSangamo Therapeutics", "location": [6384, 6419], "entities": [{"type": "Person", "text": "Bioepis\nSandoz\nSangamo Therapeutics"}]}, {"text": "Roche\nSamsung", "location": [6370, 6383], "entities": [{"type": "Organization", "text": "Roche\nSamsung", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.976693, "arguments": [{"text": "XO1 Limited\nZenotech\nZS Pharma\nZuventus\nZydus Biovation\nZydus Cadila\nOrganizations", "location": [7152, 7234], "entities": [{"type": "Organization", "text": "XO1 Limited\nZenotech\nZS Pharma\nZuventus\nZydus Biovation\nZydus Cadila\nOrganizations"}]}, {"text": "Inc.\nSanofi\nSchering-Plough\nSciGen\nShandong Kexing Pharma\nShanghai CP Guojian Pharmaceutical\nShanghai Fosun\nShanghai Sunway Biotech\nShantha Biotechnics\nShenzhen SiBiono GeneTech\nShire\nSicor Biotech\nSigilon Therapeutics\nSimcere Pharmaceutical Group\nSmith and Nephew\nSpark Therapeutics\nStada\nStemcentrx\nStragen Pharma\nStratatech Corporation\nSwiss Re\nTakeda Pharmaceutical Company Limited\nTESARO, Inc.\nTetraLogic Pharmaceuticals Corporation\nTeva\nTianjin Hualida Biotechnology\nTiGenix\nTonghua Dongbao\nTrophos\nTurnstone Biologics\nUCB\nUni\u00e3o Qu\u00edmica\nUniQure\nValeant Pharmaceuticals\nVertex Pharmaceuticals\nViralytics Limited\nVital Therapies Inc.\nVoyager Therapeutics\nWockhardt\nWyeth-Ayerst Laboratories\nXencor, Inc.\nXiamen Amoytop Biotech", "location": [6421, 7151], "entities": [{"type": "Organization", "text": "Inc.\nSanofi\nSchering-Plough\nSciGen\nShandong Kexing Pharma\nShanghai CP Guojian Pharmaceutical\nShanghai Fosun\nShanghai Sunway Biotech\nShantha Biotechnics\nShenzhen SiBiono GeneTech\nShire\nSicor Biotech\nSigilon Therapeutics\nSimcere Pharmaceutical Group\nSmith and Nephew\nSpark Therapeutics\nStada\nStemcentrx\nStragen Pharma\nStratatech Corporation\nSwiss Re\nTakeda Pharmaceutical Company Limited\nTESARO, Inc.\nTetraLogic Pharmaceuticals Corporation\nTeva\nTianjin Hualida Biotechnology\nTiGenix\nTonghua Dongbao\nTrophos\nTurnstone Biologics\nUCB\nUni\u00e3o Qu\u00edmica\nUniQure\nValeant Pharmaceuticals\nVertex Pharmaceuticals\nViralytics Limited\nVital Therapies Inc.\nVoyager Therapeutics\nWockhardt\nWyeth-Ayerst Laboratories\nXencor, Inc.\nXiamen Amoytop Biotech"}]}]}, {"type": "agentOf", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.912608, "arguments": [{"text": "XO1 Limited\nZenotech\nZS Pharma\nZuventus\nZydus Biovation\nZydus Cadila\nOrganizations", "location": [7152, 7234], "entities": [{"type": "Organization", "text": "XO1 Limited\nZenotech\nZS Pharma\nZuventus\nZydus Biovation\nZydus Cadila\nOrganizations"}]}, {"text": "Mentioned", "location": [7235, 7244], "entities": [{"type": "EventCommunication", "text": "Mentioned"}]}]}, {"type": "basedIn", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.709779, "arguments": [{"text": "Children's Hospital\nCenter for Disease Prevention and Control", "location": [7360, 7421], "entities": [{"type": "Organization", "text": "Children's Hospital\nCenter for Disease Prevention and Control"}]}, {"text": "Boston", "location": [7353, 7359], "entities": [{"type": "GeopoliticalEntity", "text": "Boston"}]}]}, {"type": "employedBy", "sentence": "LONDON , November 26, 2018 /PRNewswire/ -- Biologics Market Trends and Forecasts 2018-2028 Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg ) The global biologics market is estimated to reach $250bn in 2023.", "score": 0.645773, "arguments": [{"text": "Gene Therapies", "location": [338, 352], "entities": [{"type": "Person", "text": "Gene Therapies"}]}, {"text": "Logo", "location": [354, 358], "entities": [{"type": "Organization", "text": "Logo", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.655543, "arguments": [{"text": "CDC", "location": [7423, 7426], "entities": [{"type": "Organization", "text": "CDC", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Children's Hospital\nCenter for Disease Prevention and Control", "location": [7360, 7421], "entities": [{"type": "Organization", "text": "Children's Hospital\nCenter for Disease Prevention and Control"}]}]}, {"type": "partOf", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.83705, "arguments": [{"text": "School of Medicine", "location": [7523, 7541], "entities": [{"type": "Organization", "text": "School of Medicine", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "Central Drugs Standard Control Organisation\nChina Food and Drug Administration\nDuke University", "location": [7428, 7522], "entities": [{"type": "Organization", "text": "Central Drugs Standard Control Organisation\nChina Food and Drug Administration\nDuke University"}]}]}, {"type": "employedBy", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.51565, "arguments": [{"text": "EMA", "location": [7542, 7545], "entities": [{"type": "Person", "text": "EMA"}]}, {"text": "School of Medicine", "location": [7523, 7541], "entities": [{"type": "Organization", "text": "School of Medicine", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "employedBy", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.556076, "arguments": [{"text": "EMA", "location": [7542, 7545], "entities": [{"type": "Person", "text": "EMA"}]}, {"text": "European Medicines Agency", "location": [7547, 7572], "entities": [{"type": "Organization", "text": "European Medicines Agency", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.732437, "arguments": [{"text": "European Commission", "location": [7574, 7593], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "EC", "location": [7595, 7597], "entities": [{"type": "Ticker", "text": "EC"}]}]}, {"type": "employedBy", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.827155, "arguments": [{"text": "President", "location": [8093, 8102], "entities": [{"type": "Person", "text": "President"}]}, {"text": "U.S.", "location": [8088, 8092], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.398118, "arguments": [{"text": "President", "location": [8093, 8102], "entities": [{"type": "Person", "text": "President"}]}, {"text": "Emergency Plan for AIDS Relief", "location": [8105, 8135], "entities": [{"type": "Organization", "text": "Emergency Plan for AIDS Relief", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.968039, "arguments": [{"text": "UCSF", "location": [8286, 8290], "entities": [{"type": "Organization", "text": "UCSF"}]}, {"text": "University of Manchester\nThe University of Texas\nThe University of Texas MD Anderson Cancer Center\nToronto University\nToronto University", "location": [8149, 8285], "entities": [{"type": "Organization", "text": "University of Manchester\nThe University of Texas\nThe University of Texas MD Anderson Cancer Center\nToronto University\nToronto University"}]}]}, {"type": "basedIn", "sentence": "Berkeley University of Colorado Cord Blood Bank University of Tokyo US Center for Disease Prevention and Control (CDC) US Food and Drug Administration Walter and Eliza Hall Institute World Bank World Health Organization (WHO) Yonsei University To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com", "score": 0.69082, "arguments": [{"text": "Center for Disease Prevention and Control", "location": [8452, 8493], "entities": [{"type": "Organization", "text": "Children's Hospital\nCenter for Disease Prevention and Control"}]}, {"text": "US", "location": [8449, 8451], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Berkeley University of Colorado Cord Blood Bank University of Tokyo US Center for Disease Prevention and Control (CDC) US Food and Drug Administration Walter and Eliza Hall Institute World Bank World Health Organization (WHO) Yonsei University To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com", "score": 0.985668, "arguments": [{"text": "Food and Drug Administration", "location": [8503, 8531], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "US", "location": [8500, 8502], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "LONDON , November 26, 2018 /PRNewswire/ -- Biologics Market Trends and Forecasts 2018-2028 Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg ) The global biologics market is estimated to reach $250bn in 2023.", "score": 0.431647, "arguments": [{"text": "Logo", "location": [354, 358], "entities": [{"type": "Organization", "text": "Logo", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg", "location": [360, 419], "entities": [{"type": "Web", "text": "https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg"}]}]}, {"type": "employedBy", "sentence": "Berkeley University of Colorado Cord Blood Bank University of Tokyo US Center for Disease Prevention and Control (CDC) US Food and Drug Administration Walter and Eliza Hall Institute World Bank World Health Organization (WHO) Yonsei University To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com", "score": 0.689392, "arguments": [{"text": "Walter", "location": [8532, 8538], "entities": [{"type": "Person", "text": "Walter"}]}, {"text": "Food and Drug Administration", "location": [8503, 8531], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "partOf", "sentence": "Berkeley University of Colorado Cord Blood Bank University of Tokyo US Center for Disease Prevention and Control (CDC) US Food and Drug Administration Walter and Eliza Hall Institute World Bank World Health Organization (WHO) Yonsei University To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com", "score": 0.849354, "arguments": [{"text": "Bank\nWorld Health Organization", "location": [8570, 8600], "entities": [{"type": "Organization", "text": "Bank\nWorld Health Organization", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "World", "location": [8564, 8569], "entities": [{"type": "Organization", "text": "World", "disambiguation": {"subtype": ["Multigov"]}}]}]}, {"type": "timeOf", "sentence": "By ordering and reading our brand-new report today you stay better informed and ready to act.", "score": 0.790505, "arguments": [{"text": "today", "location": [1066, 1071], "entities": [{"type": "Date", "text": "today"}]}, {"text": "ordering", "location": [1024, 1032], "entities": [{"type": "EventLegal", "text": "ordering"}]}]}, {"type": "employedBy", "sentence": "Report Scope \u00b7 Global Biologics Market outlook from 2018-2028 \u00b7 Global Biologics Submarkets analysis and forecast from 2018-2028 : \u00b7 Protein therapeutics , with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents \u00b7 Monoclonal antibodies (mAbs) \u00b7 Fusion proteins \u00b7 Regenerative medicine , with sub-forecasting for stem cell treatment, tissue engineering and gene therapy \u00b7 Vaccines \u00b7 Analysis and forecast from 2018-2028 for selected leading biologics in the market: \u00b7 Lantus \u00b7 NovoLog/NovoRapid \u00b7 Humalog \u00b7 Avonex \u00b7 Rebif \u00b7 Humira \u00b7 Remicade \u00b7 Tysabri \u00b7 Herceptin \u00b7 Kadcyla \u00b7 Perjeta \u00b7 Enbrel \u00b7 Eylea \u00b7 OsteoCel Plus \u00b7 Trinity Evolution and Trinity Elite \u00b7 Apligraf \u00b7 Dermagraft \u00b7 IMLYGIC \u00b7 This report provides individual revenue forecasts from 2018-2028 for these national markets : \u00b7 The US \u00b7", "score": 0.560083, "arguments": [{"text": "Scope", "location": [1122, 1127], "entities": [{"type": "Person", "text": "Scope"}]}, {"text": "Global Biologics Market", "location": [1130, 1153], "entities": [{"type": "Organization", "text": "Global Biologics Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Report Scope \u00b7 Global Biologics Market outlook from 2018-2028 \u00b7 Global Biologics Submarkets analysis and forecast from 2018-2028 : \u00b7 Protein therapeutics , with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents \u00b7 Monoclonal antibodies (mAbs) \u00b7 Fusion proteins \u00b7 Regenerative medicine , with sub-forecasting for stem cell treatment, tissue engineering and gene therapy \u00b7 Vaccines \u00b7 Analysis and forecast from 2018-2028 for selected leading biologics in the market: \u00b7 Lantus \u00b7 NovoLog/NovoRapid \u00b7 Humalog \u00b7 Avonex \u00b7 Rebif \u00b7 Humira \u00b7 Remicade \u00b7 Tysabri \u00b7 Herceptin \u00b7 Kadcyla \u00b7 Perjeta \u00b7 Enbrel \u00b7 Eylea \u00b7 OsteoCel Plus \u00b7 Trinity Evolution and Trinity Elite \u00b7 Apligraf \u00b7 Dermagraft \u00b7 IMLYGIC \u00b7 This report provides individual revenue forecasts from 2018-2028 for these national markets : \u00b7 The US \u00b7", "score": 0.977459, "arguments": [{"text": "Lantus\n\u2022 NovoLog/NovoRapid\n\u2022 Humalog\n\u2022 Avonex\n\u2022 Rebif\n\u2022 Humira\n\u2022 Remicade\n\u2022 Tysabri\n\u2022 Herceptin\n\u2022 Kadcyla\n\u2022 Perjeta\n\u2022 Enbrel\n\u2022 Eylea\n\u2022 OsteoCel Plus\n\u2022 Trinity Evolution and Trinity Elite\n\u2022 Apligraf\n\u2022 Dermagraft\n\u2022 IMLYGIC\n\u2022 This", "location": [1681, 1908], "entities": [{"type": "Organization", "text": "Lantus\n\u2022 NovoLog/NovoRapid\n\u2022 Humalog\n\u2022 Avonex\n\u2022 Rebif\n\u2022 Humira\n\u2022 Remicade\n\u2022 Tysabri\n\u2022 Herceptin\n\u2022 Kadcyla\n\u2022 Perjeta\n\u2022 Enbrel\n\u2022 Eylea\n\u2022 OsteoCel Plus\n\u2022 Trinity Evolution and Trinity Elite\n\u2022 Apligraf\n\u2022 Dermagraft\n\u2022 IMLYGIC\n\u2022 This"}]}, {"text": "report", "location": [1909, 1915], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "Japan \u00b7 Germany \u00b7 France \u00b7 UK \u00b7 Italy \u00b7 Spain \u00b7 China \u00b7 India \u00b7 Russia \u00b7 Brazil \u00b7 Our study discusses the selected leading companies that are the major players in the biologics market: \u00b7 AbbVie \u00b7 Amgen \u00b7 AstraZeneca \u00b7 Bayer \u00b7 Eli Lilly \u00b7 GlaxoSmithKline (GSK) \u00b7 Johnson & Johnson \u00b7 Merck & Co., Inc. \u00b7 Novartis \u00b7 Pfizer \u00b7 Roche \u00b7 Sanofi S.A. \u00b7 This report discusses factors that drive and restrain this market.", "score": 0.963415, "arguments": [{"text": "Johnson & Johnson\n\u2022 Merck & Co., Inc.\n\u2022 Novartis\n\u2022 Pfizer\n\u2022 Roche\n\u2022 Sanofi S.A.\n\u2022 This", "location": [2271, 2357], "entities": [{"type": "Organization", "text": "Johnson & Johnson\n\u2022 Merck & Co., Inc.\n\u2022 Novartis\n\u2022 Pfizer\n\u2022 Roche\n\u2022 Sanofi S.A.\n\u2022 This", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "report", "location": [2358, 2364], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "Buy our report today Biologics Market Trends and Forecasts 2018-2028 : Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.", "score": 0.928663, "arguments": [{"text": "our", "location": [2689, 2692], "entities": [{"type": "Person", "text": "our"}]}, {"text": "report", "location": [2693, 2699], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "timeOf", "sentence": "Buy our report today Biologics Market Trends and Forecasts 2018-2028 : Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.", "score": 0.795984, "arguments": [{"text": "today", "location": [2700, 2705], "entities": [{"type": "Date", "text": "today"}]}, {"text": "report", "location": [2693, 2699], "entities": [{"type": "EventCommunication", "text": "report"}]}]}], "keywords": [{"text": "new 303-page report", "sentiment": {"score": -0.596518, "label": "negative"}, "relevance": 0.598208, "count": 1}, {"text": "Monoclonal Antibodies", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.591569, "count": 2}, {"text": "report", "sentiment": {"score": 0.414771, "mixed": "1", "label": "positive"}, "relevance": 0.585063, "count": 5}, {"text": "Protein Therapeutics", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.584954, "count": 2}, {"text": "Trinity Evolution", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.570641, "count": 1}, {"text": "ordering", "sentiment": {"score": 0.77585, "label": "positive"}, "relevance": 0.564914, "count": 1}, {"text": "University of Manchester", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562396, "count": 1}, {"text": "European Medicines Agency", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.562391, "count": 1}, {"text": "Biologics Market Trends", "sentiment": {"score": -0.322495, "label": "negative"}, "relevance": 0.553209, "count": 1}, {"text": "brand-new report today", "sentiment": {"score": 0.77585, "label": "positive"}, "relevance": 0.552629, "count": 1}, {"text": "303-page report", "sentiment": {"score": 0.663354, "label": "positive"}, "relevance": 0.543028, "count": 1}, {"text": "brand", "sentiment": {"score": -0.596518, "label": "negative"}, "relevance": 0.539735, "count": 1}, {"text": "Recombinant Hormones", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.539703, "count": 2}, {"text": "Fusion Proteins", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.535611, "count": 2}, {"text": "Visiongain's study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53457, "count": 1}, {"text": "European Commission", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.532307, "count": 1}, {"text": "monoclonal antibodies submarket", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531978, "count": 1}, {"text": "Monoclonal antibodies", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.530832, "count": 1}, {"text": "Regenerative Medicines", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.529304, "count": 2}, {"text": "Recombinant Coagulating Factors", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.528506, "count": 2}, {"text": "U.S. President's Emergency Plan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528207, "count": 1}, {"text": "global biologics market", "sentiment": {"score": 0.401432, "mixed": "1", "label": "positive"}, "relevance": 0.52777, "count": 2}, {"text": "Forecasts", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.527168, "count": 2}, {"text": "University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526981, "count": 1}, {"text": "University of Texas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525497, "count": 1}, {"text": "report overview of this report", "sentiment": {"score": -0.421302, "label": "negative"}, "relevance": 0.524967, "count": 1}, {"text": "Protein therapeutics", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.524359, "count": 1}, {"text": "Regenerative medicine", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.523944, "count": 1}, {"text": "Yonsei University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521737, "count": 1}, {"text": "Trinity Elite", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.521612, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.521342, "count": 2}, {"text": "European Group", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.519668, "count": 1}, {"text": "study", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.518013, "count": 1}, {"text": "Disease Prevention", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.517367, "count": 2}, {"text": "Stem Cell Therapies", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.516866, "count": 2}, {"text": "Report Scope", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.516443, "count": 1}, {"text": "trends", "sentiment": {"score": -0.557524, "label": "negative"}, "relevance": 0.515769, "count": 2}, {"text": "market", "sentiment": {"score": 0.310662, "mixed": "1", "label": "positive"}, "relevance": 0.515563, "count": 5}, {"text": "individual revenue forecasts", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.514727, "count": 1}, {"text": "insulin", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.514727, "count": 1}, {"text": "Insulin", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.514727, "count": 2}, {"text": "Plasma", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.514164, "count": 2}, {"text": "plasma", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.514164, "count": 1}, {"text": "major players", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.513966, "count": 1}, {"text": "Email sara.peerun@visiongain.com", "sentiment": {"score": 0.467502, "label": "positive"}, "relevance": 0.513402, "count": 1}, {"text": "Marrow Transplantation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513058, "count": 1}, {"text": "tissue engineering", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.512144, "count": 1}, {"text": "US", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.511756, "count": 1}, {"text": "Australia's Walter", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.51135, "count": 1}, {"text": "Analysis", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.511238, "count": 1}]}, "extracted_metadata": {"sha1": "b3e210e0415d47f173b8f95f40af190a772e242c", "filename": "1543228086761.zip-16520a7ea14ef9f30a5597bb48c9e90c.xml", "file_type": "json"}, "external_links": ["https://www.visiongain.com/report/biologics-market-trends-and-forecasts-2018-2028/"], "title": "Visiongain Report Looks at Opportunities Within the $250bn Biologics Sector", "forum_title": "Stock Market News | Financial &amp; Business News | Markets Insider"}, {"id": "ieQe-F9mcxx-qgFSUNKCHPd4DmHCdMRNFromVUHVrtkMzY-AepzE5FynB_AjZZYX", "result_metadata": {"score": 33.945797}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nicotine De-Addiction Products Market Growth", "relevance": 0.33, "type": "JobTitle"}], "sentiment": {"document": {"score": -0.528038, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Top Manufacturers Share, Mergers and Acquisitions, Expansion \u2013 iCrowdNewswire", "keywords": [{"text": "Expansion \u2013 iCrowdNewswire"}, {"text": "Manufacturers Share"}, {"text": "Mergers"}, {"text": "Acquisitions"}]}, "sentence": "Smoking Cessation and Nicotine De-Addiction Products Market Growth 2018-2023: Top Manufacturers Share, Mergers and Acquisitions, Expansion \u2013 iCrowdNewswire", "object": {"text": "Cessation and Nicotine De-Addiction Products Market Growth 2018-2023", "keywords": [{"text": "Nicotine De-Addiction Products"}, {"text": "Cessation"}, {"text": "Market Growth"}], "entities": [{"type": "JobTitle", "text": "Nicotine De-Addiction Products Market Growth"}]}, "action": {"verb": {"text": "Smoking", "tense": "present"}, "text": "Smoking", "normalized": "Smoking"}}], "concepts": [{"text": "Smoking cessation", "relevance": 0.978058, "dbpedia_resource": "http://dbpedia.org/resource/Smoking_cessation"}, {"text": "Mergers and acquisitions", "relevance": 0.84105, "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"}, {"text": "Nicotine", "relevance": 0.79065, "dbpedia_resource": "http://dbpedia.org/resource/Nicotine"}], "categories": [{"score": 0.998199, "label": "/health and fitness/addiction/smoking addiction"}], "relations": [], "keywords": [{"text": "Cessation", "sentiment": {"score": -0.528038, "label": "negative"}, "relevance": 0.828262, "count": 1}, {"text": "Top Manufacturers Share", "sentiment": {"score": -0.528038, "label": "negative"}, "relevance": 0.812935, "count": 1}, {"text": "Mergers", "sentiment": {"score": -0.528038, "label": "negative"}, "relevance": 0.623851, "count": 1}, {"text": "Acquisitions", "sentiment": {"score": -0.528038, "label": "negative"}, "relevance": 0.602827, "count": 1}, {"text": "Expansion", "sentiment": {"score": -0.528038, "label": "negative"}, "relevance": 0.585193, "count": 1}, {"text": "Nicotine De-Addiction Products Market Growth", "sentiment": {"score": -0.528038, "label": "negative"}, "relevance": 0.48826, "count": 1}, {"text": "iCrowdNewswire", "sentiment": {"score": -0.528038, "label": "negative"}, "relevance": 0.348526, "count": 1}]}, "crawl_date": "2018-11-26T08:54:34Z", "url": "http://icrowdnewswire.com/2018/11/23/smoking-cessation-and-nicotine-de-addiction-products-market-growth-2018-2023-top-manufacturers-share-mergers-and-acquisitions-expansion/", "host": "icrowdnewswire.com", "text": "Key Manufacturers Like Cipla Ltd., GlaxoSmithKline plc, Imperial Tobacco Company of India Limited., McNeil AB, NJOY, Inc., Novartis International AG, Pfizer, Inc., Revolymer PLC, Takeda Pharmaceutical Co., Ltd., .", "main_image_url": "http://s3-us-west-2.amazonaws.com/icnimage/wp-content/uploads/2018/04/19061635/post_default_thumbnail.jpg", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-04-19T00:00:00Z", "enriched_text": {"entities": [{"count": 19, "sentiment": {"score": -0.442437, "label": "negative"}, "text": "Nicotine", "relevance": 0.865865, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nicotine De-Addiction Products Market Growth", "relevance": 0.668484, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.511068, "label": "negative"}, "text": "Nicotine De-Addiction Products Market Research", "relevance": 0.621631, "type": "JobTitle"}, {"count": 6, "sentiment": {"score": -0.0901812, "label": "negative"}, "text": "Products Market", "relevance": 0.585927, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.605797, "label": "negative"}, "text": "market development", "relevance": 0.201486, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0.307519, "label": "positive"}, "text": "South America", "relevance": 0.194552, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.190271, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.185262, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.605797, "label": "negative"}, "text": "Products productions", "relevance": 0.169937, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.16875, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.162608, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.156359, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis International AG", "relevance": 0.139698, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Southeast Asia", "relevance": 0.137549, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Southeast Asia", "dbpedia_resource": "http://dbpedia.org/resource/Southeast_Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co.", "relevance": 0.1324, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cipla Ltd.", "relevance": 0.131719, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.605797, "label": "negative"}, "text": "industry development", "relevance": 0.127444, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.126036, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Colombia", "relevance": 0.122843, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Colombia", "dbpedia_resource": "http://dbpedia.org/resource/Colombia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.122661, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0.263601, "label": "positive"}, "text": "Saudi Arabia", "relevance": 0.121783, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "MilitaryPost", "CityTown", "Country"], "name": "Saudi Arabia", "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.121759, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.121051, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mexico", "relevance": 0.120463, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "FilmCinematographer", "Country"], "name": "Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Mexico"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "South Africa", "relevance": 0.120199, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "McNeil AB", "relevance": 0.118201, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zyban", "relevance": 0.116932, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UAE", "relevance": 0.116586, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "United Arab Emirates", "dbpedia_resource": "http://dbpedia.org/resource/United_Arab_Emirates"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Argentina", "relevance": 0.114951, "type": "Location", "disambiguation": {"subtype": ["Region", "GovernmentalJurisdiction", "Country"], "name": "Argentina", "dbpedia_resource": "http://dbpedia.org/resource/Argentina"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Korea", "relevance": 0.114826, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "South Korea", "dbpedia_resource": "http://dbpedia.org/resource/South_Korea"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Revolymer PLC", "relevance": 0.11478, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.114704, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Egypt", "relevance": 0.114274, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "CityTown", "Country"], "name": "Egypt", "dbpedia_resource": "http://dbpedia.org/resource/Egypt"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.113923, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.113851, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Imperial Tobacco Company of India Limited.", "relevance": 0.113734, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.113599, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.112581, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.111982, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": -0.3004, "label": "negative"}, "text": "Chantix", "relevance": 0.111541, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.107824, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Varenicline", "relevance": 0.104157, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nigeria", "relevance": 0.102868, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Russia", "relevance": 0.10192, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Italy", "relevance": 0.100713, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.349993, "label": "positive"}, "text": "China", "relevance": 0.100471, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.100471, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "five years", "relevance": 0.100471, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "$ 3500", "relevance": 0.100471, "type": "Quantity"}], "sentiment": {"document": {"score": -0.555975, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Top Manufacturers Share, Mergers and Acquisitions, Expansion iCrowdNewswire", "keywords": [{"text": "Expansion iCrowdNewswire"}, {"text": "Manufacturers Share"}, {"text": "Mergers"}, {"text": "Acquisitions"}]}, "sentence": " Smoking Cessation and Nicotine De-Addiction Products Market Growth 2018-2023: Top Manufacturers Share, Mergers and Acquisitions, Expansion iCrowdNewswire - Nov 23, 2018", "object": {"text": "Cessation and Nicotine De-Addiction Products Market Growth", "keywords": [{"text": "Nicotine De-Addiction Products"}, {"text": "Cessation"}, {"text": "Market Growth"}], "entities": [{"type": "JobTitle", "text": "Nicotine De-Addiction Products Market Growth"}]}, "action": {"verb": {"text": "Smoking", "tense": "present"}, "text": "Smoking", "normalized": "Smoking"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report specialized in the Smoking Cessation and Nicotine De-Addiction Products Market Research in the global market, specifically in North America, Europe and Asia-Pacific, South America, Middle East, and Africa.", "action": {"verb": {"text": "specialize", "tense": "past"}, "text": "specialized", "normalized": "specialize"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report classifies the market based totally on manufacturers, regions, types, and applications.", "object": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Products Market"}]}, "action": {"verb": {"text": "classify", "tense": "present"}, "text": "classifies", "normalized": "classify"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Products Market"}]}, "sentence": " This report classifies the market based totally on manufacturers, regions, types, and applications.", "object": {"text": "on manufacturers, regions, types, and applications", "keywords": [{"text": "regions"}, {"text": "manufacturers"}, {"text": "types"}, {"text": "applications"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}, {"subject": {"text": "The worldwide market for Smoking Cessation and Nicotine De-Addiction Products Market", "keywords": [{"text": "Nicotine De-Addiction Products"}, {"text": "Smoking Cessation"}, {"text": "worldwide market"}], "entities": [{"type": "Drug", "text": "Nicotine"}, {"type": "Company", "text": "Products Market"}]}, "sentence": " The worldwide market for Smoking Cessation and Nicotine De-Addiction Products Market is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023.", "object": {"text": "at a CAGR of roughly xx%", "keywords": [{"text": "CAGR"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "The worldwide market for Smoking Cessation and Nicotine De-Addiction Products Market", "keywords": [{"text": "Nicotine De-Addiction Products"}, {"text": "Smoking Cessation"}, {"text": "worldwide market"}], "entities": [{"type": "Drug", "text": "Nicotine"}, {"type": "Company", "text": "Products Market"}]}, "sentence": " The worldwide market for Smoking Cessation and Nicotine De-Addiction Products Market is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023.", "object": {"text": "xx million US$ in 2023", "keywords": [{"text": "xx"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "will reach", "normalized": "will reach"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report brought the Smoking Cessation and Nicotine De-Addiction Products fundamentals which are definitions, classifications, applications and market assessment, product specifications, production procedures, cost systems, raw material and so forth.", "object": {"text": "the Smoking Cessation and Nicotine De-Addiction Products fundamentals which are definitions, classifications, applications and market assessment, product specifications, production procedures, cost systems, raw material and so forth", "keywords": [{"text": "Nicotine De-Addiction Products"}, {"text": "Smoking Cessation"}, {"text": "market assessment"}, {"text": "product specifications"}], "entities": [{"type": "Drug", "text": "Nicotine"}]}, "action": {"verb": {"text": "bring", "tense": "past"}, "text": "brought", "normalized": "bring"}}, {"subject": {"text": "it"}, "sentence": " Then it analysed the sectors predominant vicinity market situations, consisting of the production rate, income, capacity, production, delivery, demand, and marketplace boom price and forecast etc.", "object": {"text": "the sectors predominant vicinity market situations, consisting of the production rate, income, capacity, production, delivery, demand, and marketplace boom price and forecast etc", "keywords": [{"text": "sectors predominant vicinity"}, {"text": "marketplace boom price"}, {"text": "market situations"}, {"text": "production rate"}]}, "action": {"verb": {"text": "analyse", "tense": "past"}, "text": "analysed", "normalized": "analyse"}}, {"subject": {"text": "market situations", "keywords": [{"text": "market situations"}]}, "sentence": " Then it analysed the sectors predominant vicinity market situations, consisting of the production rate, income, capacity, production, delivery, demand, and marketplace boom price and forecast etc.", "object": {"text": "of the production rate, income, capacity, production, delivery, demand, and marketplace boom price and forecast etc", "keywords": [{"text": "marketplace boom price"}, {"text": "production rate"}, {"text": "forecast"}, {"text": "capacity"}]}, "action": {"verb": {"text": "consist", "tense": "present"}, "text": "consisting", "normalized": "consist"}}, {"subject": {"text": "Charts and Companies", "keywords": [{"text": "Charts"}, {"text": "Companies"}]}, "sentence": " Browse complete TOC, Tables, Figures, Charts and Companies stated in Global Smoking Cessation and Nicotine De-Addiction Products Market Report @ https://www.absolutereports.com/12688587", "action": {"verb": {"text": "state", "tense": "past"}, "text": "stated", "normalized": "state"}}, {"subject": {"text": "Smoking Cessation and Nicotine De-Addiction Products", "keywords": [{"text": "Nicotine De-Addiction Products"}, {"text": "Cessation"}], "entities": [{"type": "Drug", "text": "Nicotine"}]}, "sentence": " Smoking Cessation and Nicotine De-Addiction Products is a good substitute that is the reason that we believe there will be new enterprises and investors entering into this industry.", "object": {"text": "a good substitute", "keywords": [{"text": "good substitute"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a good substitute", "keywords": [{"text": "good substitute"}]}, "sentence": " Smoking Cessation and Nicotine De-Addiction Products is a good substitute that is the reason that we believe there will be new enterprises and investors entering into this industry.", "object": {"text": "the reason that we believe there will be new enterprises and investors entering into this industry", "keywords": [{"text": "new enterprises"}, {"text": "reason"}, {"text": "investors"}, {"text": "industry"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "enterprises those have plans to enter this industry", "keywords": [{"text": "enterprises"}, {"text": "plans"}, {"text": "industry"}]}, "sentence": " But it is suggested that enterprises those have plans to enter this industry have a careful analysis of this market and the advantages or disadvantages of themselves.", "object": {"text": "a careful analysis of this market and the advantages or disadvantages of themselves", "keywords": [{"text": "careful analysis"}, {"text": "disadvantages"}, {"text": "advantages"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Products Market"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Cipla Ltd., GlaxoSmithKline plc, Imperial Tobacco Company of India Limited., McNeil AB, NJOY, Inc.", "keywords": [{"text": "Imperial Tobacco Company"}, {"text": "GlaxoSmithKline plc"}, {"text": "Cipla Ltd."}, {"text": "McNeil AB"}], "entities": [{"type": "Company", "text": "Cipla Ltd."}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Imperial Tobacco Company of India Limited."}, {"type": "Company", "text": "McNeil AB"}]}, "sentence": " Cipla Ltd., GlaxoSmithKline plc, Imperial Tobacco Company of India Limited., McNeil AB, NJOY, Inc., Novartis International AG, Pfizer, Inc., Revolymer PLC, Takeda Pharmaceutical Co., Ltd., .", "object": {"text": "International AG, Pfizer, Inc., Revolymer PLC, Takeda Pharmaceutical Co., Ltd.,", "keywords": [{"text": "International AG"}, {"text": "Revolymer PLC"}, {"text": "Pharmaceutical Co."}, {"text": "Pfizer"}], "entities": [{"type": "Company", "text": "Pfizer, Inc."}, {"type": "Company", "text": "Revolymer PLC"}, {"type": "Company", "text": "Takeda Pharmaceutical Co.", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "Novartis", "tense": "present"}, "text": "Novartis", "normalized": "Novartis"}}, {"subject": {"text": "by Applications", "keywords": [{"text": "Applications"}]}, "sentence": " Smoking Cessation and Nicotine De-Addiction Products Market by Applications: Application1 Application2..", "object": {"text": "Cessation and Nicotine De-Addiction Products Market", "keywords": [{"text": "Nicotine De-Addiction Products"}, {"text": "Cessation"}], "entities": [{"type": "Company", "text": "Products Market"}]}, "action": {"verb": {"text": "Smoking", "tense": "present"}, "text": "Smoking", "normalized": "Smoking"}}, {"subject": {"text": "Major Topics", "keywords": [{"text": "Major Topics"}]}, "sentence": " Major Topics Covered in The Research Report: Smoking Cessation and Nicotine De-Addiction Products industry overview Smoking Cessation and Nicotine De-Addiction Products Up and Downstream industry analysis Global import export Smoking Cessation and Nicotine De-Addiction Products market analysis Smoking Cessation and Nicotine De-Addiction Products marketing channels and investment feasibility Smoking Cessation and Nicotine De-Addiction Products market development proposals analysis Smoking Cessation and Nicotine De-Addiction Products new project investment feasibility analysis Global Smoking Cessation and Nicotine De-Addiction Products productions supply sales demand market status and forecast Global Smoking Cessation and Nicotine De-Addiction Products industry development trend", "action": {"verb": {"text": "Covered", "tense": "past"}, "text": "Covered", "normalized": "Covered"}}, {"subject": {"text": "Global Smoking Cessation and Nicotine De-Addiction Products productions", "keywords": [{"text": "Global Smoking Cessation"}, {"text": "Nicotine De-Addiction Products"}, {"text": "productions"}], "entities": [{"type": "Drug", "text": "Nicotine"}, {"type": "Company", "text": "Products productions"}]}, "sentence": " Major Topics Covered in The Research Report: Smoking Cessation and Nicotine De-Addiction Products industry overview Smoking Cessation and Nicotine De-Addiction Products Up and Downstream industry analysis Global import export Smoking Cessation and Nicotine De-Addiction Products market analysis Smoking Cessation and Nicotine De-Addiction Products marketing channels and investment feasibility Smoking Cessation and Nicotine De-Addiction Products market development proposals analysis Smoking Cessation and Nicotine De-Addiction Products new project investment feasibility analysis Global Smoking Cessation and Nicotine De-Addiction Products productions supply sales demand market status and forecast Global Smoking Cessation and Nicotine De-Addiction Products industry development trend", "object": {"text": "sales demand market status", "keywords": [{"text": "market status"}, {"text": "sales"}]}, "action": {"verb": {"text": "supply", "tense": "present"}, "text": "supply", "normalized": "supply"}}, {"subject": {"text": "the report", "keywords": [{"text": "report"}]}, "sentence": " In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.", "object": {"text": "new project SWOT analysis, investment feasibility analysis, and investment return analysis", "keywords": [{"text": "new project SWOT"}, {"text": "investment feasibility analysis"}, {"text": "investment return"}]}, "action": {"verb": {"text": "introduce", "tense": "past"}, "text": "introduced", "normalized": "introduce"}}], "concepts": [{"text": "Smoking cessation", "relevance": 0.979627, "dbpedia_resource": "http://dbpedia.org/resource/Smoking_cessation"}, {"text": "Bupropion", "relevance": 0.922313, "dbpedia_resource": "http://dbpedia.org/resource/Bupropion"}, {"text": "Nicotine", "relevance": 0.830236, "dbpedia_resource": "http://dbpedia.org/resource/Nicotine"}, {"text": "Nicotine gum", "relevance": 0.797916, "dbpedia_resource": "http://dbpedia.org/resource/Nicotine_gum"}, {"text": "Marketing", "relevance": 0.751288, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Middle East", "relevance": 0.682114, "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}, {"text": "Tobacco", "relevance": 0.652786, "dbpedia_resource": "http://dbpedia.org/resource/Tobacco"}, {"text": "North America", "relevance": 0.615774, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Smoking", "relevance": 0.584557, "dbpedia_resource": "http://dbpedia.org/resource/Smoking"}, {"text": "Saudi Arabia", "relevance": 0.582299, "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}, {"text": "Nicotine patch", "relevance": 0.580693, "dbpedia_resource": "http://dbpedia.org/resource/Nicotine_patch"}, {"text": "Market research", "relevance": 0.550691, "dbpedia_resource": "http://dbpedia.org/resource/Market_research"}, {"text": "Nicotine replacement therapy", "relevance": 0.534334, "dbpedia_resource": "http://dbpedia.org/resource/Nicotine_replacement_therapy"}, {"text": "Pfizer", "relevance": 0.513669, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Varenicline", "relevance": 0.511801, "dbpedia_resource": "http://dbpedia.org/resource/Varenicline"}, {"text": "South America", "relevance": 0.471722, "dbpedia_resource": "http://dbpedia.org/resource/South_America"}, {"text": "Tobacco cessation", "relevance": 0.454416, "dbpedia_resource": "http://dbpedia.org/resource/Tobacco_cessation"}, {"text": "Tobacco smoking", "relevance": 0.421995, "dbpedia_resource": "http://dbpedia.org/resource/Tobacco_smoking"}], "categories": [{"score": 0.984026, "label": "/health and fitness/addiction/smoking addiction"}, {"score": 0.868364, "label": "/finance/investing"}, {"score": 0.868364, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "hasAttribute", "sentence": "Nov 23, 2018 7:02 AM ET Listen to Post Subject to Terms of Use.", "score": 0.933613, "arguments": [{"text": "Nov", "location": [0, 3], "entities": [{"type": "Person", "text": "Nov"}]}, {"text": "23", "location": [4, 6], "entities": [{"type": "Age", "text": "23"}]}]}, {"type": "residesIn", "sentence": "Ask for Sample PDF @ https://www.absolutereports.com/enquiry/request-sample/12688587 Market Segments by Region: North America (United States, Canada, and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Smoking Cessation and Nicotine De-Addiction Products Market by Applications: Application1 Application2.. Smoking Cessation and Nicotine De-Addiction Products Market by Types: Nicotine Gums Nicotine Patches Nicotine Sprays Nicotine Inhalers Nicotine Lozenges Nicotine Sub lingual Tablets Bupropione (Zyban) Varenicline (Champix Chantix) E- CigarettesBy By .", "score": 0.470176, "arguments": [{"text": "Segments", "location": [2033, 2041], "entities": [{"type": "Person", "text": "Segments"}]}, {"text": "Region", "location": [2045, 2051], "entities": [{"type": "GeopoliticalEntity", "text": "Region"}]}]}, {"type": "managerOf", "sentence": "Ask for Sample PDF @ https://www.absolutereports.com/enquiry/request-sample/12688587 Market Segments by Region: North America (United States, Canada, and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Smoking Cessation and Nicotine De-Addiction Products Market by Applications: Application1 Application2.. Smoking Cessation and Nicotine De-Addiction Products Market by Types: Nicotine Gums Nicotine Patches Nicotine Sprays Nicotine Inhalers Nicotine Lozenges Nicotine Sub lingual Tablets Bupropione (Zyban) Varenicline (Champix Chantix) E- CigarettesBy By .", "score": 0.339284, "arguments": [{"text": "Asia-Pacific", "location": [2152, 2164], "entities": [{"type": "Person", "text": "Asia-Pacific"}]}, {"text": "China", "location": [2166, 2171], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Ask for Sample PDF @ https://www.absolutereports.com/enquiry/request-sample/12688587 Market Segments by Region: North America (United States, Canada, and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Smoking Cessation and Nicotine De-Addiction Products Market by Applications: Application1 Application2.. Smoking Cessation and Nicotine De-Addiction Products Market by Types: Nicotine Gums Nicotine Patches Nicotine Sprays Nicotine Inhalers Nicotine Lozenges Nicotine Sub lingual Tablets Bupropione (Zyban) Varenicline (Champix Chantix) E- CigarettesBy By .", "score": 0.952662, "arguments": [{"text": "Brazil", "location": [2229, 2235], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil"}]}, {"text": "Argentina", "location": [2237, 2246], "entities": [{"type": "GeopoliticalEntity", "text": "Argentina", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Ask for Sample PDF @ https://www.absolutereports.com/enquiry/request-sample/12688587 Market Segments by Region: North America (United States, Canada, and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Smoking Cessation and Nicotine De-Addiction Products Market by Applications: Application1 Application2.. Smoking Cessation and Nicotine De-Addiction Products Market by Types: Nicotine Gums Nicotine Patches Nicotine Sprays Nicotine Inhalers Nicotine Lozenges Nicotine Sub lingual Tablets Bupropione (Zyban) Varenicline (Champix Chantix) E- CigarettesBy By .", "score": 0.588281, "arguments": [{"text": "Varenicline", "location": [2650, 2661], "entities": [{"type": "Person", "text": "Varenicline"}]}, {"text": "Champix Chantix", "location": [2663, 2678], "entities": [{"type": "Organization", "text": "Champix Chantix", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Price of Report (single User Licence): $ 3500 Purchase the Smoking Cessation and Nicotine De-Addiction Products Market Report @ https://www.absolutereports.com/purchase/12688587", "score": 0.92251, "arguments": [{"text": "Price", "location": [3615, 3620], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "Report", "location": [3624, 3630], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Price of Report (single User Licence): $ 3500 Purchase the Smoking Cessation and Nicotine De-Addiction Products Market Report @ https://www.absolutereports.com/purchase/12688587", "score": 0.42573, "arguments": [{"text": "User", "location": [3639, 3643], "entities": [{"type": "Person", "text": "Licence"}]}, {"text": "Report", "location": [3624, 3630], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "hasAttribute", "sentence": "Price of Report (single User Licence): $ 3500 Purchase the Smoking Cessation and Nicotine De-Addiction Products Market Report @ https://www.absolutereports.com/purchase/12688587", "score": 0.418781, "arguments": [{"text": "Nicotine De-Addiction Products Market Report @", "location": [3696, 3742], "entities": [{"type": "Organization", "text": "Nicotine De-Addiction Products Market Report @", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "https://www.absolutereports.com/purchase/", "location": [3743, 3784], "entities": [{"type": "Web", "text": "https://www.absolutereports.com/purchase/"}]}]}, {"type": "employedBy", "sentence": "Nov 23, 2018 7:02 AM ET Listen to Post Subject to Terms of Use.", "score": 0.568753, "arguments": [{"text": "AM ET\nListen", "location": [18, 30], "entities": [{"type": "Person", "text": "AM ET\nListen"}]}, {"text": "Post Subject", "location": [34, 46], "entities": [{"type": "Organization", "text": "Post Subject", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "educatedAt", "sentence": "The worldwide market for Smoking Cessation and Nicotine De-Addiction Products Market is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023.", "score": 0.541417, "arguments": [{"text": "xx", "location": [677, 679], "entities": [{"type": "Person", "text": "xx"}]}, {"text": "CAGR of roughly", "location": [661, 676], "entities": [{"type": "Organization", "text": "CAGR of roughly"}]}]}, {"type": "partOfMany", "sentence": "Then it analysed the sectors predominant vicinity market situations, consisting of the production rate, income, capacity, production, delivery, demand, and marketplace boom price and forecast etc. Browse complete TOC, Tables, Figures, Charts and Companies stated in Global Smoking Cessation and Nicotine De-Addiction Products Market Report @ https://www.absolutereports.com/12688587 Smoking Cessation and Nicotine De-Addiction Products is a good substitute that is the reason that we believe there will be new enterprises and investors entering into this industry.", "score": 0.851474, "arguments": [{"text": "Charts", "location": [1230, 1236], "entities": [{"type": "Person", "text": "Charts"}]}, {"text": "Figures", "location": [1221, 1228], "entities": [{"type": "Person", "text": "Figures"}]}]}, {"type": "agentOf", "sentence": "Then it analysed the sectors predominant vicinity market situations, consisting of the production rate, income, capacity, production, delivery, demand, and marketplace boom price and forecast etc. Browse complete TOC, Tables, Figures, Charts and Companies stated in Global Smoking Cessation and Nicotine De-Addiction Products Market Report @ https://www.absolutereports.com/12688587 Smoking Cessation and Nicotine De-Addiction Products is a good substitute that is the reason that we believe there will be new enterprises and investors entering into this industry.", "score": 0.487706, "arguments": [{"text": "Figures", "location": [1221, 1228], "entities": [{"type": "Person", "text": "Figures"}]}, {"text": "stated", "location": [1251, 1257], "entities": [{"type": "EventCommunication", "text": "stated"}]}]}, {"type": "affectedBy", "sentence": "Then it analysed the sectors predominant vicinity market situations, consisting of the production rate, income, capacity, production, delivery, demand, and marketplace boom price and forecast etc. Browse complete TOC, Tables, Figures, Charts and Companies stated in Global Smoking Cessation and Nicotine De-Addiction Products Market Report @ https://www.absolutereports.com/12688587 Smoking Cessation and Nicotine De-Addiction Products is a good substitute that is the reason that we believe there will be new enterprises and investors entering into this industry.", "score": 0.493944, "arguments": [{"text": "Global Smoking Cessation", "location": [1261, 1285], "entities": [{"type": "Organization", "text": "Global Smoking Cessation", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "stated", "location": [1251, 1257], "entities": [{"type": "EventCommunication", "text": "stated"}]}]}, {"type": "hasAttribute", "sentence": "Then it analysed the sectors predominant vicinity market situations, consisting of the production rate, income, capacity, production, delivery, demand, and marketplace boom price and forecast etc. Browse complete TOC, Tables, Figures, Charts and Companies stated in Global Smoking Cessation and Nicotine De-Addiction Products Market Report @ https://www.absolutereports.com/12688587 Smoking Cessation and Nicotine De-Addiction Products is a good substitute that is the reason that we believe there will be new enterprises and investors entering into this industry.", "score": 0.398137, "arguments": [{"text": "Nicotine De-Addiction Products Market Report @", "location": [1290, 1336], "entities": [{"type": "Organization", "text": "Nicotine De-Addiction Products Market Report @", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "https://www.absolutereports.com/", "location": [1337, 1369], "entities": [{"type": "Web", "text": "https://www.absolutereports.com/"}]}]}, {"type": "partOf", "sentence": "Key Manufacturers Like Cipla Ltd., GlaxoSmithKline plc, Imperial Tobacco Company of India Limited., McNeil AB, NJOY, Inc., Novartis International AG, Pfizer, Inc., Revolymer PLC, Takeda Pharmaceutical Co., Ltd., .", "score": 0.433334, "arguments": [{"text": "Key Manufacturers", "location": [1727, 1744], "entities": [{"type": "Organization", "text": "Key Manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Cipla Ltd.", "location": [1750, 1760], "entities": [{"type": "Organization", "text": "Cipla Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Ask for Sample PDF @ https://www.absolutereports.com/enquiry/request-sample/12688587 Market Segments by Region: North America (United States, Canada, and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Smoking Cessation and Nicotine De-Addiction Products Market by Applications: Application1 Application2.. Smoking Cessation and Nicotine De-Addiction Products Market by Types: Nicotine Gums Nicotine Patches Nicotine Sprays Nicotine Inhalers Nicotine Lozenges Nicotine Sub lingual Tablets Bupropione (Zyban) Varenicline (Champix Chantix) E- CigarettesBy By .", "score": 0.615246, "arguments": [{"text": "Market", "location": [2026, 2032], "entities": [{"type": "Facility", "text": "Market"}]}, {"text": "Region", "location": [2045, 2051], "entities": [{"type": "GeopoliticalEntity", "text": "Region"}]}]}], "keywords": [{"text": "Smoking Cessation", "sentiment": {"score": -0.714512, "label": "negative"}, "relevance": 0.773615, "count": 3}, {"text": "Nicotine De-Addiction Products Market", "sentiment": {"score": -0.868022, "label": "negative"}, "relevance": 0.675429, "count": 3}, {"text": "global market", "sentiment": {"score": -0.628032, "label": "negative"}, "relevance": 0.643566, "count": 1}, {"text": "Cessation", "sentiment": {"score": -0.889235, "label": "negative"}, "relevance": 0.628876, "count": 11}, {"text": "Nicotine De-Addiction Products fundamentals", "sentiment": {"score": -0.76781, "label": "negative"}, "relevance": 0.622312, "count": 1}, {"text": "North America", "sentiment": {"score": -0.628032, "label": "negative"}, "relevance": 0.587332, "count": 2}, {"text": "report", "sentiment": {"score": -0.813489, "label": "negative"}, "relevance": 0.583066, "count": 4}, {"text": "Nicotine De-Addiction Products Market Growth", "sentiment": {"score": -0.628032, "label": "negative"}, "relevance": 0.581787, "count": 1}, {"text": "careful analysis of this market", "sentiment": {"score": 0.824829, "label": "positive"}, "relevance": 0.580413, "count": 1}, {"text": "Global Smoking Cessation", "sentiment": {"score": -0.842314, "label": "negative"}, "relevance": 0.580222, "count": 3}, {"text": "market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.579664, "count": 1}, {"text": "worldwide market", "sentiment": {"score": -0.680847, "label": "negative"}, "relevance": 0.56893, "count": 1}, {"text": "Nicotine De-Addiction Products", "sentiment": {"score": -0.879379, "label": "negative"}, "relevance": 0.566146, "count": 4}, {"text": "United States", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562241, "count": 1}, {"text": "South America", "sentiment": {"score": -0.628032, "label": "negative"}, "relevance": 0.552055, "count": 2}, {"text": "Major Topics", "sentiment": {"score": -0.966009, "label": "negative"}, "relevance": 0.550974, "count": 1}, {"text": "Imperial Tobacco Company of India Limited", "sentiment": {"score": 0.83521, "label": "positive"}, "relevance": 0.5497, "count": 1}, {"text": "production rate", "sentiment": {"score": -0.57576, "label": "negative"}, "relevance": 0.547552, "count": 1}, {"text": "investment feasibility", "sentiment": {"score": -0.966009, "label": "negative"}, "relevance": 0.543559, "count": 1}, {"text": "Middle East", "sentiment": {"score": -0.628032, "label": "negative"}, "relevance": 0.541969, "count": 2}, {"text": "Research Report", "sentiment": {"score": -0.966009, "label": "negative"}, "relevance": 0.541902, "count": 1}, {"text": "production procedures", "sentiment": {"score": -0.76781, "label": "negative"}, "relevance": 0.541546, "count": 1}, {"text": "Asia-Pacific", "sentiment": {"score": -0.628032, "label": "negative"}, "relevance": 0.540578, "count": 2}, {"text": "industry", "sentiment": {"score": 0.695636, "mixed": "1", "label": "positive"}, "relevance": 0.533553, "count": 2}, {"text": "Saudi Arabia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530343, "count": 1}, {"text": "predominant vicinity market situations", "sentiment": {"score": -0.57576, "label": "negative"}, "relevance": 0.529433, "count": 1}, {"text": "Southeast Asia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529161, "count": 1}, {"text": "Companies", "sentiment": {"score": -0.36214, "label": "negative"}, "relevance": 0.528342, "count": 1}, {"text": "GlaxoSmithKline plc", "sentiment": {"score": 0.83521, "label": "positive"}, "relevance": 0.527838, "count": 1}, {"text": "Nicotine", "sentiment": {"score": -0.992102, "label": "negative"}, "relevance": 0.527526, "count": 1}, {"text": "product specifications", "sentiment": {"score": -0.76781, "label": "negative"}, "relevance": 0.527191, "count": 1}, {"text": "new project investment feasibility analysis", "sentiment": {"score": -0.966009, "label": "negative"}, "relevance": 0.527081, "count": 1}, {"text": "India", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526969, "count": 1}, {"text": "Downstream industry analysis", "sentiment": {"score": -0.966009, "label": "negative"}, "relevance": 0.526115, "count": 1}, {"text": "Cipla Ltd", "sentiment": {"score": 0.83521, "label": "positive"}, "relevance": 0.526007, "count": 1}, {"text": "production", "sentiment": {"score": -0.57576, "label": "negative"}, "relevance": 0.525587, "count": 1}, {"text": "Europe", "sentiment": {"score": -0.628032, "label": "negative"}, "relevance": 0.525215, "count": 2}, {"text": "new enterprises", "sentiment": {"score": -0.36214, "label": "negative"}, "relevance": 0.523986, "count": 1}, {"text": "Nicotine De-Addiction Products Market Research", "sentiment": {"score": -0.628032, "label": "negative"}, "relevance": 0.523259, "count": 1}, {"text": "Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522276, "count": 1}, {"text": "Novartis International AG", "sentiment": {"score": 0.83521, "label": "positive"}, "relevance": 0.521113, "count": 1}, {"text": "sectors", "sentiment": {"score": -0.57576, "label": "negative"}, "relevance": 0.520389, "count": 1}, {"text": "complete TOC", "sentiment": {"score": -0.36214, "label": "negative"}, "relevance": 0.520315, "count": 1}, {"text": "demand", "sentiment": {"score": -0.57576, "label": "negative"}, "relevance": 0.520187, "count": 1}, {"text": "end", "sentiment": {"score": -0.966009, "label": "negative"}, "relevance": 0.517867, "count": 1}, {"text": "manufacturers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517554, "count": 1}, {"text": "regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517439, "count": 1}, {"text": "Region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517439, "count": 1}, {"text": "Canada", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517088, "count": 1}, {"text": "enterprises", "sentiment": {"score": 0.824829, "label": "positive"}, "relevance": 0.517071, "count": 1}]}, "extracted_metadata": {"sha1": "910c296d881dab4a718fce2911224cd5e73fd3e4", "filename": "1543222474915.zip-c4428bf266e9ab28c31d474b64411ef3.xml", "file_type": "json"}, "title": "Smoking Cessation and Nicotine De-Addiction Products Market Growth 2018-2023: Top Manufacturers Share, Mergers and Acquisitions, Expansion \u2013 iCrowdNewswire"}, {"id": "1jXMnIW5z3riVOlXaSW5gKkRqN5snYcq2fgSbSj09j_Qpl6EiAZIl74N7OirMsGm", "result_metadata": {"score": 33.901493}, "author": "PRESS RELEASE PR Newswire", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biologics Sector", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Visiongain Report", "keywords": [{"text": "Visiongain Report"}]}, "sentence": "Visiongain Report Looks at Opportunities Within the $250bn Biologics Sector", "object": {"text": "at Opportunities Within the $250bn Biologics Sector", "keywords": [{"text": "Biologics Sector"}, {"text": "Opportunities"}], "entities": [{"type": "Company", "text": "Biologics Sector"}]}, "action": {"verb": {"text": "Looks", "tense": "present"}, "text": "Looks", "normalized": "Looks"}}], "concepts": [], "categories": [{"score": 0.699842, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.65289, "label": "/business and industrial/manufacturing"}, {"score": 0.636141, "label": "/health and fitness"}], "relations": [], "keywords": [{"text": "Visiongain Report", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.998679, "count": 1}, {"text": "Opportunities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.844727, "count": 1}, {"text": "Biologics Sector", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.087056, "count": 1}]}, "crawl_date": "2018-11-26T10:28:06Z", "url": "https://markets.businessinsider.com/news/stocks/visiongain-report-looks-at-opportunities-within-the-250bn-biologics-sector-1027754149", "host": "markets.businessinsider.com", "text": "Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T05:00:00-06:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": -0.906031, "label": "negative"}, "text": "Fibrosis Foundation Therapeutics Inc", "relevance": 0.891518, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.440371, "label": "positive"}, "text": "Bamboo Therapeutics, Inc", "relevance": 0.881889, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Biologics Submarkets", "relevance": 0.832451, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.788515, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": -0.611089, "label": "negative"}, "text": "Portola Pharmaceuticals Inc", "relevance": 0.77251, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BrainStorm Cell Therapeutics", "relevance": 0.77099, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Proteon Therapeutics", "relevance": 0.766511, "type": "Company", "disambiguation": {"subtype": [], "name": "Proteon Therapeutics", "dbpedia_resource": "http://dbpedia.org/resource/Proteon_Therapeutics"}}, {"count": 2, "sentiment": {"score": 0.488663, "label": "positive"}, "text": "Amgen", "relevance": 0.761038, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca", "relevance": 0.755325, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 2, "sentiment": {"score": -0.367244, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.752801, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer", "relevance": 0.747598, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BioXpress Therapeutics", "relevance": 0.74479, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.740835, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer", "relevance": 0.740591, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CytomX Therapeutics", "relevance": 0.740064, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.739947, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Harpoon Therapeutics", "relevance": 0.733402, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tissue Engineered Products", "relevance": 0.73285, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Heptares Therapeutics", "relevance": 0.731697, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United Therapeutics", "relevance": 0.73053, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sara Peerun", "relevance": 0.72745, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "US", "relevance": 0.726829, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Moderna Therapeutics", "relevance": 0.723864, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma", "relevance": 0.723639, "type": "Company", "disambiguation": {"subtype": [], "name": "Astellas Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mirati Therapeutics", "relevance": 0.7213, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Apeiron Biologics", "relevance": 0.719141, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sangamo Therapeutics", "relevance": 0.717573, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Anthera Pharmaceuticals", "relevance": 0.717429, "type": "Company", "disambiguation": {"subtype": [], "name": "Anthera Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Anthera_Pharmaceuticals"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Toronto University", "relevance": 0.715426, "type": "Organization", "disambiguation": {"subtype": ["Location", "TouristAttraction", "CollegeUniversity", "University"], "name": "University of Toronto", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Toronto"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sigilon Therapeutics", "relevance": 0.709085, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.544801, "label": "positive"}, "text": "Spark Therapeutics", "relevance": 0.706137, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Emcure Pharmaceuticals", "relevance": 0.704418, "type": "Company", "disambiguation": {"subtype": [], "name": "Emcure Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Emcure_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Intas Pharmaceuticals", "relevance": 0.700771, "type": "Company", "disambiguation": {"subtype": [], "name": "Intas Biopharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Intas_Biopharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0.464702, "label": "positive"}, "text": "Voyager Therapeutics", "relevance": 0.700374, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.458561, "label": "positive"}, "text": "Merz Pharma", "relevance": 0.698556, "type": "Company", "disambiguation": {"subtype": [], "name": "Merz Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Merz_Pharma"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eliza Hall Institute", "relevance": 0.695425, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.690722, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.567864, "label": "negative"}, "text": "Regeneron Pharmaceuticals", "relevance": 0.689532, "type": "Company", "disambiguation": {"subtype": [], "name": "Regeneron", "dbpedia_resource": "http://dbpedia.org/resource/Regeneron"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Acceleron Pharma", "relevance": 0.682124, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.503849, "label": "negative"}, "text": "Afferent Pharmaceuticals", "relevance": 0.679176, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AurKa Pharma", "relevance": 0.676571, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Valeant Pharmaceuticals", "relevance": 0.675089, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Turnstone Biologics", "relevance": 0.673756, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.599843, "label": "negative"}, "text": "Vertex Pharmaceuticals", "relevance": 0.673387, "type": "Company", "disambiguation": {"subtype": [], "name": "Vertex Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Vertex_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.567864, "label": "negative"}, "text": "Anacor Pharmaceuticals", "relevance": 0.671698, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.752006, "label": "negative"}, "text": "University of Texas", "relevance": 0.669242, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.70983, "label": "negative"}, "text": "Benda Pharmaceuticals", "relevance": 0.668351, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of California", "relevance": 0.667944, "type": "Organization", "disambiguation": {"subtype": [], "name": "David Geffen School of Medicine at UCLA", "dbpedia_resource": "http://dbpedia.org/resource/David_Geffen_School_of_Medicine_at_UCLA"}}], "sentiment": {"document": {"score": 0.393209, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "The global biologics market", "keywords": [{"text": "global biologics market"}]}, "sentence": " The global biologics market is estimated to reach $250bn in 2023.", "object": {"text": "estimated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global biologics market", "keywords": [{"text": "global biologics market"}]}, "sentence": " The global biologics market is estimated to reach $250bn in 2023.", "object": {"text": "to reach $250bn in 2023"}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "The global biologics market", "keywords": [{"text": "global biologics market"}]}, "sentence": " The global biologics market is estimated to reach $250bn in 2023.", "object": {"text": "$250bn in 2023"}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is estimated to reach", "normalized": "be estimate to reach"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}]}, "sentence": " The market is expected to grow at a CAGR of 4.8% from 2018 to 2023.", "object": {"text": "at a CAGR of 4.8%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "4.8"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "the monoclonal antibodies submarket", "keywords": [{"text": "monoclonal antibodies submarket"}]}, "sentence": " In 2017, the monoclonal antibodies submarket held 36.3% share of the global biologics market.", "object": {"text": "36.3% share of the global biologics market", "keywords": [{"text": "global biologics market"}, {"text": "share"}], "entities": [{"type": "Quantity", "text": "36.3"}]}, "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "How this report", "keywords": [{"text": "report"}]}, "sentence": " How this report will benefit you", "object": {"text": "you"}, "action": {"verb": {"text": "benefit", "tense": "future"}, "text": "will benefit", "normalized": "will benefit"}}, {"subject": {"text": "you"}, "sentence": " Read on to discover how you can exploit the future business opportunities emerging in this sector.", "object": {"text": "the future business opportunities emerging in this sector", "keywords": [{"text": "future business opportunities"}, {"text": "sector"}]}, "action": {"verb": {"text": "exploit", "tense": "future"}, "text": "can exploit", "normalized": "can exploit"}}, {"subject": {"text": "the future business opportunities", "keywords": [{"text": "future business opportunities"}]}, "sentence": " Read on to discover how you can exploit the future business opportunities emerging in this sector.", "action": {"verb": {"text": "emerge", "tense": "present"}, "text": "emerging", "normalized": "emerge"}}, {"subject": {"text": "you"}, "sentence": " In this brand new 303-page report you will receive 166 charts - all unavailable elsewhere.", "object": {"text": "166 charts", "keywords": [{"text": "charts"}]}, "action": {"verb": {"text": "receive", "tense": "future"}, "text": "will receive", "normalized": "will receive"}}, {"subject": {"text": "the key drivers and challenges", "keywords": [{"text": "challenges"}, {"text": "key drivers"}]}, "sentence": " Discover the key drivers and challenges affecting the market.", "object": {"text": "the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "you"}, "sentence": " By ordering and reading our brand-new report today you stay better informed and ready to act.", "object": {"text": "our brand-new report", "keywords": [{"text": "brand-new report"}]}, "action": {"verb": {"text": "read", "tense": "present"}, "text": "reading", "normalized": "read"}}, {"subject": {"text": "\u2022 This report", "keywords": [{"text": "report"}]}, "sentence": " \u2022 This report provides individual revenue forecasts from 2018-2028 for these national markets :", "object": {"text": "individual revenue forecasts", "keywords": [{"text": "individual revenue forecasts"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "\u2022 Our study", "keywords": [{"text": "study"}]}, "sentence": " \u2022 Our study discusses the selected leading companies that are the major players in the biologics market:", "object": {"text": "the selected leading companies that are the major players in the biologics market", "keywords": [{"text": "biologics market"}, {"text": "major players"}, {"text": "companies"}]}, "action": {"verb": {"text": "discuss", "tense": "present"}, "text": "discusses", "normalized": "discuss"}}, {"subject": {"text": "\u2022 This report", "keywords": [{"text": "report"}]}, "sentence": " \u2022 This report discusses factors that drive and restrain this market.", "object": {"text": "factors that drive and restrain this market", "keywords": [{"text": "factors"}, {"text": "market"}]}, "action": {"verb": {"text": "discuss", "tense": "present"}, "text": "discusses", "normalized": "discuss"}}, {"subject": {"text": "factors", "keywords": [{"text": "factors"}]}, "sentence": " \u2022 This report discusses factors that drive and restrain this market.", "object": {"text": "this market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "restrain", "tense": "present"}, "text": "restrain", "normalized": "restrain"}}, {"subject": {"text": "\u2022 This report", "keywords": [{"text": "report"}]}, "sentence": " \u2022 This report discusses the SWOT and STEP Analysis of the biologics market.", "object": {"text": "the SWOT and STEP Analysis of the biologics market", "keywords": [{"text": "biologics market"}, {"text": "SWOT"}, {"text": "STEP Analysis"}]}, "action": {"verb": {"text": "discuss", "tense": "present"}, "text": "discusses", "normalized": "discuss"}}, {"subject": {"text": "Visiongain's study", "keywords": [{"text": "Visiongain"}], "entities": [{"type": "Person", "text": "Visiongain"}]}, "sentence": " Visiongain's study is intended for anyone requiring commercial analyses for the biologics market.", "object": {"text": "intended for anyone requiring commercial analyses for the biologics market", "keywords": [{"text": "biologics market"}, {"text": "commercial analyses"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "for anyone requiring commercial analyses for the biologics market", "keywords": [{"text": "biologics market"}, {"text": "commercial analyses"}]}, "sentence": " Visiongain's study is intended for anyone requiring commercial analyses for the biologics market.", "object": {"text": "Visiongain's study", "keywords": [{"text": "Visiongain"}], "entities": [{"type": "Person", "text": "Visiongain"}]}, "action": {"verb": {"text": "intend", "tense": "past"}, "text": "is intended", "normalized": "be intend"}}, {"subject": {"text": "You"}, "sentence": " You find data, trends and predictions.", "object": {"text": "data, trends and predictions", "keywords": [{"text": "predictions"}, {"text": "trends"}, {"text": "data"}]}, "action": {"verb": {"text": "find", "tense": "present"}, "text": "find", "normalized": "find"}}, {"subject": {"text": "you"}, "sentence": " Did you know that we also offer a report add-on service?", "object": {"text": "that we also offer a report add-on service", "keywords": [{"text": "report add-on service"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "know", "normalized": "know"}}, {"subject": {"text": "we"}, "sentence": " Did you know that we also offer a report add-on service?", "object": {"text": "a report add-on service", "keywords": [{"text": "report add-on service"}]}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offer", "normalized": "offer"}}, {"subject": {"text": "Email sara.peerun@visiongain.com", "keywords": [{"text": "Email sara.peerun"}], "entities": [{"type": "EmailAddress", "text": "sara.peerun@visiongain.com"}]}, "sentence": " Email sara.peerun@visiongain.com to discuss any customized research needs you may have.", "object": {"text": "any customized research needs", "keywords": [{"text": "customized research"}]}, "action": {"verb": {"text": "discuss", "tense": "future"}, "text": "to discuss", "normalized": "to discuss"}}, {"subject": {"text": "any customized research", "keywords": [{"text": "customized research"}]}, "sentence": " Email sara.peerun@visiongain.com to discuss any customized research needs you may have.", "object": {"text": "you"}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "needs", "normalized": "need"}}, {"subject": {"text": "Daiichi", "keywords": [{"text": "Daiichi"}], "entities": [{"type": "Company", "text": "Daiichi Sankyo Company"}]}, "sentence": " Daiichi Sankyo Company, Limited", "object": {"text": "Company", "keywords": [{"text": "Company"}]}, "action": {"verb": {"text": "Sankyo", "tense": "present"}, "text": "Sankyo", "normalized": "Sankyo"}}, {"subject": {"text": "Xiamen", "keywords": [{"text": "Xiamen"}], "entities": [{"type": "Company", "text": "Xiamen Amoytop Biotech"}]}, "sentence": " Xiamen Amoytop Biotech", "object": {"text": "Biotech", "keywords": [{"text": "Biotech"}]}, "action": {"verb": {"text": "Amoytop", "tense": "present"}, "text": "Amoytop", "normalized": "Amoytop"}}, {"subject": {"text": "Organizations", "keywords": [{"text": "Organizations"}]}, "sentence": " Organizations Mentioned in the Report", "action": {"verb": {"text": "Mentioned", "tense": "past"}, "text": "Mentioned", "normalized": "Mentioned"}}], "concepts": [{"text": "Medicine", "relevance": 0.973631, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmaceutical industry", "relevance": 0.876469, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Biotechnology", "relevance": 0.86608, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "Stem cell", "relevance": 0.840508, "dbpedia_resource": "http://dbpedia.org/resource/Stem_cell"}, {"text": "Pharmacology", "relevance": 0.798198, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Food and Drug Administration", "relevance": 0.698541, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.686026, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Pharmaceutical drug", "relevance": 0.685611, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Monoclonal antibodies", "relevance": 0.645469, "dbpedia_resource": "http://dbpedia.org/resource/Monoclonal_antibodies"}, {"text": "Pharmacy", "relevance": 0.584569, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Association of American Universities", "relevance": 0.57242, "dbpedia_resource": "http://dbpedia.org/resource/Association_of_American_Universities"}, {"text": "Biotechnology companies", "relevance": 0.50835, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Stem cell treatments", "relevance": 0.474166, "dbpedia_resource": "http://dbpedia.org/resource/Stem_cell_treatments"}, {"text": "Drug", "relevance": 0.439701, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Generic drug", "relevance": 0.424926, "dbpedia_resource": "http://dbpedia.org/resource/Generic_drug"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.417481, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Centocor", "relevance": 0.411351, "dbpedia_resource": "http://dbpedia.org/resource/Centocor"}, {"text": "Therapy", "relevance": 0.401588, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Novartis", "relevance": 0.400981, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Corticosteroid", "relevance": 0.391461, "dbpedia_resource": "http://dbpedia.org/resource/Corticosteroid"}, {"text": "Protein", "relevance": 0.389025, "dbpedia_resource": "http://dbpedia.org/resource/Protein"}, {"text": "Stem cells", "relevance": 0.382723, "dbpedia_resource": "http://dbpedia.org/resource/Stem_cells"}, {"text": "University of Toronto", "relevance": 0.382238, "dbpedia_resource": "http://dbpedia.org/resource/University_of_Toronto"}, {"text": "Ranbaxy Laboratories", "relevance": 0.378261, "dbpedia_resource": "http://dbpedia.org/resource/Ranbaxy_Laboratories"}, {"text": "GlaxoSmithKline", "relevance": 0.368785, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Etanercept", "relevance": 0.365183, "dbpedia_resource": "http://dbpedia.org/resource/Etanercept"}, {"text": "Cord blood", "relevance": 0.360839, "dbpedia_resource": "http://dbpedia.org/resource/Cord_blood"}, {"text": "Pharmacotherapy", "relevance": 0.352254, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacotherapy"}, {"text": "Pharmaceutical companies of Japan", "relevance": 0.350876, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_Japan"}, {"text": "Blood", "relevance": 0.344079, "dbpedia_resource": "http://dbpedia.org/resource/Blood"}, {"text": "Gene therapy", "relevance": 0.340571, "dbpedia_resource": "http://dbpedia.org/resource/Gene_therapy"}, {"text": "Cord blood bank", "relevance": 0.339345, "dbpedia_resource": "http://dbpedia.org/resource/Cord_blood_bank"}, {"text": "Sanofi-Aventis", "relevance": 0.338961, "dbpedia_resource": "http://dbpedia.org/resource/Sanofi-Aventis"}], "categories": [{"score": 0.905294, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.816146, "label": "/science/medicine/oncology"}, {"score": 0.789708, "label": "/science/medicine/medical research"}], "relations": [{"type": "partOf", "sentence": "LONDON , November 26, 2018 /PRNewswire/ -- Biologics Market Trends and Forecasts 2018-2028 Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg ) The global biologics market is estimated to reach $250bn in 2023.", "score": 0.526648, "arguments": [{"text": "Protein Therapeutics", "location": [91, 111], "entities": [{"type": "Organization", "text": "Protein Therapeutics", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Biologics Market Trends and Forecasts", "location": [43, 80], "entities": [{"type": "Organization", "text": "Biologics Market Trends and Forecasts"}]}]}, {"type": "agentOf", "sentence": "To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/biologics-market-trends-and-forecasts-2018-2028/ Did you know that we also offer a report add-on service?", "score": 0.582206, "arguments": [{"text": "Sara Peerun", "location": [3078, 3089], "entities": [{"type": "Person", "text": "Sara Peerun"}]}, {"text": "report", "location": [3056, 3062], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "managerOf", "sentence": "Limited Dako Dendreon Dezima Pharma B.V. DNAtrix Dong-A Pharmaceutical Dr. Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Emcure Pharmaceuticals EMS Epirus Europharm Evotec FDA FibroGen FierceBiotech Finox Biotech Flatiron Health Foundation Medicine, Inc. Fuji Pharma Galencia Gan & Lee GE Healthcare Genentech Gennova GenSci Genzyme Gilead Sciences GlaxoSmithKline (GSK) Hangzhou Jiuyuan Gene Engineering Co. Hanwha Chemical Harpoon Therapeutics Harrisvaccines Inc. Heptares Therapeutics Hexal Hindustan Antibiotic Histogenics Hospira, Inc. Human Genome Sciences Humana Inc. Hypermarcas IBM Watson Health ICU Medical Inc. Ignyta, Inc. Immatics Biotechnologies GmbH Immune Design Immunex Corporation Immunocore Limited Incyte Corporation Innovare R&D Intas Pharmaceuticals IOmet Pharma Ipsen Isis Pharmaceuticals, Inc. Janssen JingYuan Bio Johnson & Johnson Kite Pharma Kyowa Hakko Kirin Laboratorios Delta LG Life Sciences LifeSouth Community Blood Centers Lonza Luye Pharma Group, Ltd. M2Gen MacroGenics,", "score": 0.234394, "arguments": [{"text": "Reddy", "location": [4613, 4618], "entities": [{"type": "Person", "text": "Reddy"}]}, {"text": "Laboratories\nDynavax Technologies Corporation\nEisai Co., Ltd.\nEli Lilly and Company\nEmcure Pharmaceuticals\nEMS\nEpirus\nEuropharm\nEvotec\nFDA\nFibroGen\nFierceBiotech\nFinox Biotech\nFlatiron Health\nFoundation Medicine, Inc.\nFuji Pharma\nGalencia\nGan & Lee\nGE Healthcare\nGenentech\nGennova\nGenSci\nGenzyme\nGilead Sciences\nGlaxoSmithKline", "location": [4621, 4948], "entities": [{"type": "Organization", "text": "Laboratories\nDynavax Technologies Corporation\nEisai Co., Ltd.\nEli Lilly and Company\nEmcure Pharmaceuticals\nEMS\nEpirus\nEuropharm\nEvotec\nFDA\nFibroGen\nFierceBiotech\nFinox Biotech\nFlatiron Health\nFoundation Medicine, Inc.\nFuji Pharma\nGalencia\nGan & Lee\nGE Healthcare\nGenentech\nGennova\nGenSci\nGenzyme\nGilead Sciences\nGlaxoSmithKline"}]}]}, {"type": "employedBy", "sentence": "Limited Dako Dendreon Dezima Pharma B.V. DNAtrix Dong-A Pharmaceutical Dr. Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Emcure Pharmaceuticals EMS Epirus Europharm Evotec FDA FibroGen FierceBiotech Finox Biotech Flatiron Health Foundation Medicine, Inc. Fuji Pharma Galencia Gan & Lee GE Healthcare Genentech Gennova GenSci Genzyme Gilead Sciences GlaxoSmithKline (GSK) Hangzhou Jiuyuan Gene Engineering Co. Hanwha Chemical Harpoon Therapeutics Harrisvaccines Inc. Heptares Therapeutics Hexal Hindustan Antibiotic Histogenics Hospira, Inc. Human Genome Sciences Humana Inc. Hypermarcas IBM Watson Health ICU Medical Inc. Ignyta, Inc. Immatics Biotechnologies GmbH Immune Design Immunex Corporation Immunocore Limited Incyte Corporation Innovare R&D Intas Pharmaceuticals IOmet Pharma Ipsen Isis Pharmaceuticals, Inc. Janssen JingYuan Bio Johnson & Johnson Kite Pharma Kyowa Hakko Kirin Laboratorios Delta LG Life Sciences LifeSouth Community Blood Centers Lonza Luye Pharma Group, Ltd. M2Gen MacroGenics,", "score": 0.598955, "arguments": [{"text": "Gene", "location": [4972, 4976], "entities": [{"type": "Person", "text": "Gene Therapies"}]}, {"text": "Hangzhou Jiuyuan", "location": [4955, 4971], "entities": [{"type": "Organization", "text": "Hangzhou Jiuyuan", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "Limited Dako Dendreon Dezima Pharma B.V. DNAtrix Dong-A Pharmaceutical Dr. Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Emcure Pharmaceuticals EMS Epirus Europharm Evotec FDA FibroGen FierceBiotech Finox Biotech Flatiron Health Foundation Medicine, Inc. Fuji Pharma Galencia Gan & Lee GE Healthcare Genentech Gennova GenSci Genzyme Gilead Sciences GlaxoSmithKline (GSK) Hangzhou Jiuyuan Gene Engineering Co. Hanwha Chemical Harpoon Therapeutics Harrisvaccines Inc. Heptares Therapeutics Hexal Hindustan Antibiotic Histogenics Hospira, Inc. Human Genome Sciences Humana Inc. Hypermarcas IBM Watson Health ICU Medical Inc. Ignyta, Inc. Immatics Biotechnologies GmbH Immune Design Immunex Corporation Immunocore Limited Incyte Corporation Innovare R&D Intas Pharmaceuticals IOmet Pharma Ipsen Isis Pharmaceuticals, Inc. Janssen JingYuan Bio Johnson & Johnson Kite Pharma Kyowa Hakko Kirin Laboratorios Delta LG Life Sciences LifeSouth Community Blood Centers Lonza Luye Pharma Group, Ltd. M2Gen MacroGenics,", "score": 0.49862, "arguments": [{"text": "Janssen\nJingYuan Bio\nJohnson", "location": [5402, 5430], "entities": [{"type": "Person", "text": "Janssen\nJingYuan Bio\nJohnson"}]}, {"text": "& Johnson\nKite Pharma\nKyowa Hakko Kirin\nLaboratorios Delta\nLG Life Sciences\nLifeSouth Community Blood Centers\nLonza\nLuye Pharma Group", "location": [5431, 5564], "entities": [{"type": "Organization", "text": "& Johnson\nKite Pharma\nKyowa Hakko Kirin\nLaboratorios Delta\nLG Life Sciences\nLifeSouth Community Blood Centers\nLonza\nLuye Pharma Group"}]}]}, {"type": "employedBy", "sentence": "Limited Dako Dendreon Dezima Pharma B.V. DNAtrix Dong-A Pharmaceutical Dr. Reddy's Laboratories Dynavax Technologies Corporation Eisai Co., Ltd. Eli Lilly and Company Emcure Pharmaceuticals EMS Epirus Europharm Evotec FDA FibroGen FierceBiotech Finox Biotech Flatiron Health Foundation Medicine, Inc. Fuji Pharma Galencia Gan & Lee GE Healthcare Genentech Gennova GenSci Genzyme Gilead Sciences GlaxoSmithKline (GSK) Hangzhou Jiuyuan Gene Engineering Co. Hanwha Chemical Harpoon Therapeutics Harrisvaccines Inc. Heptares Therapeutics Hexal Hindustan Antibiotic Histogenics Hospira, Inc. Human Genome Sciences Humana Inc. Hypermarcas IBM Watson Health ICU Medical Inc. Ignyta, Inc. Immatics Biotechnologies GmbH Immune Design Immunex Corporation Immunocore Limited Incyte Corporation Innovare R&D Intas Pharmaceuticals IOmet Pharma Ipsen Isis Pharmaceuticals, Inc. Janssen JingYuan Bio Johnson & Johnson Kite Pharma Kyowa Hakko Kirin Laboratorios Delta LG Life Sciences LifeSouth Community Blood Centers Lonza Luye Pharma Group, Ltd. M2Gen MacroGenics,", "score": 0.836084, "arguments": [{"text": "M2Gen\nMacroGenics", "location": [5571, 5588], "entities": [{"type": "Person", "text": "M2Gen\nMacroGenics"}]}, {"text": "Ltd.", "location": [5566, 5570], "entities": [{"type": "Organization", "text": "Ltd."}]}]}, {"type": "employedBy", "sentence": "Inc. Massachusetts General Hospital Medice MEDICE Arzneimittel P\u00fctter MedImmune MEDIPOST Medivation, Inc. Medtronic Merck & Co., Inc. Merck KGaA Merz Pharma Mirati Therapeutics, Inc. Mitsubishi Tanabe Mochida Pharmaceutical Moderna Therapeutics Mylan NanoString Technologies, Inc. NGM Biopharmaceuticals, Inc. Nippion Kayaku Northwestern University Novartis Novo Nordisk NuVasive Oanda Organogenes OrLife Bio Orthofix Orygen Peregrine Pharmaceuticals, Inc. Pfizer Pharmacyclics Pharmicell Pharmstandard Plexxikon Inc. Porbiomed Portola Pharmaceuticals Inc. Premier Inc. Principia Probiomed Protein Sciences Proteon Therapeutics Qilu Pharmaceutical Ranbaxy Ratiopharm Redvax GmbH Regeneron Pharmaceuticals, Inc. Regenerys Reliance Life Sciences Rentschler Biotechnologie.", "score": 0.73097, "arguments": [{"text": "Merz Pharma\nMirati Therapeutics", "location": [5735, 5766], "entities": [{"type": "Person", "text": "Merz Pharma\nMirati Therapeutics"}]}, {"text": "Inc.\nMassachusetts General Hospital\nMedice\nMEDICE Arzneimittel P\u00fctter\nMedImmune\nMEDIPOST\nMedivation, Inc.\nMedtronic\nMerck & Co., Inc.\nMerck KGaA", "location": [5590, 5734], "entities": [{"type": "Organization", "text": "Inc.\nMassachusetts General Hospital\nMedice\nMEDICE Arzneimittel P\u00fctter\nMedImmune\nMEDIPOST\nMedivation, Inc.\nMedtronic\nMerck & Co., Inc.\nMerck KGaA", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.643062, "arguments": [{"text": "Bioepis\nSandoz\nSangamo Therapeutics", "location": [6384, 6419], "entities": [{"type": "Person", "text": "Bioepis\nSandoz\nSangamo Therapeutics"}]}, {"text": "Roche\nSamsung", "location": [6370, 6383], "entities": [{"type": "Organization", "text": "Roche\nSamsung", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.976693, "arguments": [{"text": "XO1 Limited\nZenotech\nZS Pharma\nZuventus\nZydus Biovation\nZydus Cadila\nOrganizations", "location": [7152, 7234], "entities": [{"type": "Organization", "text": "XO1 Limited\nZenotech\nZS Pharma\nZuventus\nZydus Biovation\nZydus Cadila\nOrganizations"}]}, {"text": "Inc.\nSanofi\nSchering-Plough\nSciGen\nShandong Kexing Pharma\nShanghai CP Guojian Pharmaceutical\nShanghai Fosun\nShanghai Sunway Biotech\nShantha Biotechnics\nShenzhen SiBiono GeneTech\nShire\nSicor Biotech\nSigilon Therapeutics\nSimcere Pharmaceutical Group\nSmith and Nephew\nSpark Therapeutics\nStada\nStemcentrx\nStragen Pharma\nStratatech Corporation\nSwiss Re\nTakeda Pharmaceutical Company Limited\nTESARO, Inc.\nTetraLogic Pharmaceuticals Corporation\nTeva\nTianjin Hualida Biotechnology\nTiGenix\nTonghua Dongbao\nTrophos\nTurnstone Biologics\nUCB\nUni\u00e3o Qu\u00edmica\nUniQure\nValeant Pharmaceuticals\nVertex Pharmaceuticals\nViralytics Limited\nVital Therapies Inc.\nVoyager Therapeutics\nWockhardt\nWyeth-Ayerst Laboratories\nXencor, Inc.\nXiamen Amoytop Biotech", "location": [6421, 7151], "entities": [{"type": "Organization", "text": "Inc.\nSanofi\nSchering-Plough\nSciGen\nShandong Kexing Pharma\nShanghai CP Guojian Pharmaceutical\nShanghai Fosun\nShanghai Sunway Biotech\nShantha Biotechnics\nShenzhen SiBiono GeneTech\nShire\nSicor Biotech\nSigilon Therapeutics\nSimcere Pharmaceutical Group\nSmith and Nephew\nSpark Therapeutics\nStada\nStemcentrx\nStragen Pharma\nStratatech Corporation\nSwiss Re\nTakeda Pharmaceutical Company Limited\nTESARO, Inc.\nTetraLogic Pharmaceuticals Corporation\nTeva\nTianjin Hualida Biotechnology\nTiGenix\nTonghua Dongbao\nTrophos\nTurnstone Biologics\nUCB\nUni\u00e3o Qu\u00edmica\nUniQure\nValeant Pharmaceuticals\nVertex Pharmaceuticals\nViralytics Limited\nVital Therapies Inc.\nVoyager Therapeutics\nWockhardt\nWyeth-Ayerst Laboratories\nXencor, Inc.\nXiamen Amoytop Biotech"}]}]}, {"type": "agentOf", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.912608, "arguments": [{"text": "XO1 Limited\nZenotech\nZS Pharma\nZuventus\nZydus Biovation\nZydus Cadila\nOrganizations", "location": [7152, 7234], "entities": [{"type": "Organization", "text": "XO1 Limited\nZenotech\nZS Pharma\nZuventus\nZydus Biovation\nZydus Cadila\nOrganizations"}]}, {"text": "Mentioned", "location": [7235, 7244], "entities": [{"type": "EventCommunication", "text": "Mentioned"}]}]}, {"type": "basedIn", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.709779, "arguments": [{"text": "Children's Hospital\nCenter for Disease Prevention and Control", "location": [7360, 7421], "entities": [{"type": "Organization", "text": "Children's Hospital\nCenter for Disease Prevention and Control"}]}, {"text": "Boston", "location": [7353, 7359], "entities": [{"type": "GeopoliticalEntity", "text": "Boston"}]}]}, {"type": "employedBy", "sentence": "LONDON , November 26, 2018 /PRNewswire/ -- Biologics Market Trends and Forecasts 2018-2028 Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg ) The global biologics market is estimated to reach $250bn in 2023.", "score": 0.645773, "arguments": [{"text": "Gene Therapies", "location": [338, 352], "entities": [{"type": "Person", "text": "Gene Therapies"}]}, {"text": "Logo", "location": [354, 358], "entities": [{"type": "Organization", "text": "Logo", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Rigontec Roche Samsung Bioepis Sandoz Sangamo Therapeutics, Inc. Sanofi Schering-Plough SciGen Shandong Kexing Pharma Shanghai CP Guojian Pharmaceutical Shanghai Fosun Shanghai Sunway Biotech Shantha Biotechnics Shenzhen SiBiono GeneTech Shire Sicor Biotech Sigilon Therapeutics Simcere Pharmaceutical Group Smith and Nephew Spark Therapeutics Stada Stemcentrx Stragen Pharma Stratatech Corporation Swiss Re Takeda Pharmaceutical Company Limited TESARO, Inc. TetraLogic Pharmaceuticals Corporation Teva Tianjin Hualida Biotechnology TiGenix Tonghua Dongbao Trophos Turnstone Biologics UCB Uni\u00e3o Qu\u00edmica UniQure Valeant Pharmaceuticals Vertex Pharmaceuticals Viralytics Limited Vital Therapies Inc. Voyager Therapeutics Wockhardt Wyeth-Ayerst Laboratories Xencor, Inc. Xiamen Amoytop Biotech XO1 Limited Zenotech ZS Pharma Zuventus Zydus Biovation Zydus Cadila Organizations Mentioned in the Report Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Australia's Walter and Eliza Hall Institute Boston Children's Hospital Center for Disease Prevention and Control (CDC)", "score": 0.655543, "arguments": [{"text": "CDC", "location": [7423, 7426], "entities": [{"type": "Organization", "text": "CDC", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Children's Hospital\nCenter for Disease Prevention and Control", "location": [7360, 7421], "entities": [{"type": "Organization", "text": "Children's Hospital\nCenter for Disease Prevention and Control"}]}]}, {"type": "partOf", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.83705, "arguments": [{"text": "School of Medicine", "location": [7523, 7541], "entities": [{"type": "Organization", "text": "School of Medicine", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "Central Drugs Standard Control Organisation\nChina Food and Drug Administration\nDuke University", "location": [7428, 7522], "entities": [{"type": "Organization", "text": "Central Drugs Standard Control Organisation\nChina Food and Drug Administration\nDuke University"}]}]}, {"type": "employedBy", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.51565, "arguments": [{"text": "EMA", "location": [7542, 7545], "entities": [{"type": "Person", "text": "EMA"}]}, {"text": "School of Medicine", "location": [7523, 7541], "entities": [{"type": "Organization", "text": "School of Medicine", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "employedBy", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.556076, "arguments": [{"text": "EMA", "location": [7542, 7545], "entities": [{"type": "Person", "text": "EMA"}]}, {"text": "European Medicines Agency", "location": [7547, 7572], "entities": [{"type": "Organization", "text": "European Medicines Agency", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.732437, "arguments": [{"text": "European Commission", "location": [7574, 7593], "entities": [{"type": "Organization", "text": "European Commission", "disambiguation": {"subtype": ["Multigov"]}}]}, {"text": "EC", "location": [7595, 7597], "entities": [{"type": "Ticker", "text": "EC"}]}]}, {"type": "employedBy", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.827155, "arguments": [{"text": "President", "location": [8093, 8102], "entities": [{"type": "Person", "text": "President"}]}, {"text": "U.S.", "location": [8088, 8092], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.398118, "arguments": [{"text": "President", "location": [8093, 8102], "entities": [{"type": "Person", "text": "President"}]}, {"text": "Emergency Plan for AIDS Relief", "location": [8105, 8135], "entities": [{"type": "Organization", "text": "Emergency Plan for AIDS Relief", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Central Drugs Standard Control Organisation China Food and Drug Administration Duke University School of Medicine EMA (European Medicines Agency) European Commission (EC) European Federation of Pharmaceutical Industries and Associations Harvard University Human Stem Cells Institute International Myeloma Foundation Johns Hopkins Musculoskeletal Transplant Foundation (MTF) National Cancer Institute New York Blood Center NHS NICE Rice University Saudi Food and Drug Authority SSN Cardinal Glennon Children's Medical Center Stanford University The European Generic medicines Association (EGA) The European Group for Blood and Marrow Transplantation (EBMT) The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) The University of Manchester The University of Texas The University of Texas MD Anderson Cancer Center Toronto University Toronto University UCSF ( University of California, San Francisco ) United Therapeutics University of California,", "score": 0.968039, "arguments": [{"text": "UCSF", "location": [8286, 8290], "entities": [{"type": "Organization", "text": "UCSF"}]}, {"text": "University of Manchester\nThe University of Texas\nThe University of Texas MD Anderson Cancer Center\nToronto University\nToronto University", "location": [8149, 8285], "entities": [{"type": "Organization", "text": "University of Manchester\nThe University of Texas\nThe University of Texas MD Anderson Cancer Center\nToronto University\nToronto University"}]}]}, {"type": "basedIn", "sentence": "Berkeley University of Colorado Cord Blood Bank University of Tokyo US Center for Disease Prevention and Control (CDC) US Food and Drug Administration Walter and Eliza Hall Institute World Bank World Health Organization (WHO) Yonsei University To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com SOURCE Visiongain", "score": 0.69082, "arguments": [{"text": "Center for Disease Prevention and Control", "location": [8452, 8493], "entities": [{"type": "Organization", "text": "Children's Hospital\nCenter for Disease Prevention and Control"}]}, {"text": "US", "location": [8449, 8451], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Berkeley University of Colorado Cord Blood Bank University of Tokyo US Center for Disease Prevention and Control (CDC) US Food and Drug Administration Walter and Eliza Hall Institute World Bank World Health Organization (WHO) Yonsei University To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com SOURCE Visiongain", "score": 0.985668, "arguments": [{"text": "Food and Drug Administration", "location": [8503, 8531], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "US", "location": [8500, 8502], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "LONDON , November 26, 2018 /PRNewswire/ -- Biologics Market Trends and Forecasts 2018-2028 Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies (Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg ) The global biologics market is estimated to reach $250bn in 2023.", "score": 0.431647, "arguments": [{"text": "Logo", "location": [354, 358], "entities": [{"type": "Organization", "text": "Logo", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg", "location": [360, 419], "entities": [{"type": "Web", "text": "https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg"}]}]}, {"type": "employedBy", "sentence": "Berkeley University of Colorado Cord Blood Bank University of Tokyo US Center for Disease Prevention and Control (CDC) US Food and Drug Administration Walter and Eliza Hall Institute World Bank World Health Organization (WHO) Yonsei University To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com SOURCE Visiongain", "score": 0.689392, "arguments": [{"text": "Walter", "location": [8532, 8538], "entities": [{"type": "Person", "text": "Walter"}]}, {"text": "Food and Drug Administration", "location": [8503, 8531], "entities": [{"type": "Organization", "text": "Food and Drug Administration", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "partOf", "sentence": "Berkeley University of Colorado Cord Blood Bank University of Tokyo US Center for Disease Prevention and Control (CDC) US Food and Drug Administration Walter and Eliza Hall Institute World Bank World Health Organization (WHO) Yonsei University To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com SOURCE Visiongain", "score": 0.849354, "arguments": [{"text": "Bank\nWorld Health Organization", "location": [8570, 8600], "entities": [{"type": "Organization", "text": "Bank\nWorld Health Organization", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "World", "location": [8564, 8569], "entities": [{"type": "Organization", "text": "World", "disambiguation": {"subtype": ["Multigov"]}}]}]}, {"type": "timeOf", "sentence": "By ordering and reading our brand-new report today you stay better informed and ready to act.", "score": 0.790505, "arguments": [{"text": "today", "location": [1066, 1071], "entities": [{"type": "Date", "text": "today"}]}, {"text": "ordering", "location": [1024, 1032], "entities": [{"type": "EventLegal", "text": "ordering"}]}]}, {"type": "employedBy", "sentence": "Report Scope \u00b7 Global Biologics Market outlook from 2018-2028 \u00b7 Global Biologics Submarkets analysis and forecast from 2018-2028 : \u00b7 Protein therapeutics , with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents \u00b7 Monoclonal antibodies (mAbs) \u00b7 Fusion proteins \u00b7 Regenerative medicine , with sub-forecasting for stem cell treatment, tissue engineering and gene therapy \u00b7 Vaccines \u00b7 Analysis and forecast from 2018-2028 for selected leading biologics in the market: \u00b7 Lantus \u00b7 NovoLog/NovoRapid \u00b7 Humalog \u00b7 Avonex \u00b7 Rebif \u00b7 Humira \u00b7 Remicade \u00b7 Tysabri \u00b7 Herceptin \u00b7 Kadcyla \u00b7 Perjeta \u00b7 Enbrel \u00b7 Eylea \u00b7 OsteoCel Plus \u00b7 Trinity Evolution and Trinity Elite \u00b7 Apligraf \u00b7 Dermagraft \u00b7 IMLYGIC \u00b7 This report provides individual revenue forecasts from 2018-2028 for these national markets : \u00b7 The US \u00b7", "score": 0.560083, "arguments": [{"text": "Scope", "location": [1122, 1127], "entities": [{"type": "Person", "text": "Scope"}]}, {"text": "Global Biologics Market", "location": [1130, 1153], "entities": [{"type": "Organization", "text": "Global Biologics Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Report Scope \u00b7 Global Biologics Market outlook from 2018-2028 \u00b7 Global Biologics Submarkets analysis and forecast from 2018-2028 : \u00b7 Protein therapeutics , with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents \u00b7 Monoclonal antibodies (mAbs) \u00b7 Fusion proteins \u00b7 Regenerative medicine , with sub-forecasting for stem cell treatment, tissue engineering and gene therapy \u00b7 Vaccines \u00b7 Analysis and forecast from 2018-2028 for selected leading biologics in the market: \u00b7 Lantus \u00b7 NovoLog/NovoRapid \u00b7 Humalog \u00b7 Avonex \u00b7 Rebif \u00b7 Humira \u00b7 Remicade \u00b7 Tysabri \u00b7 Herceptin \u00b7 Kadcyla \u00b7 Perjeta \u00b7 Enbrel \u00b7 Eylea \u00b7 OsteoCel Plus \u00b7 Trinity Evolution and Trinity Elite \u00b7 Apligraf \u00b7 Dermagraft \u00b7 IMLYGIC \u00b7 This report provides individual revenue forecasts from 2018-2028 for these national markets : \u00b7 The US \u00b7", "score": 0.977459, "arguments": [{"text": "Lantus\n\u2022 NovoLog/NovoRapid\n\u2022 Humalog\n\u2022 Avonex\n\u2022 Rebif\n\u2022 Humira\n\u2022 Remicade\n\u2022 Tysabri\n\u2022 Herceptin\n\u2022 Kadcyla\n\u2022 Perjeta\n\u2022 Enbrel\n\u2022 Eylea\n\u2022 OsteoCel Plus\n\u2022 Trinity Evolution and Trinity Elite\n\u2022 Apligraf\n\u2022 Dermagraft\n\u2022 IMLYGIC\n\u2022 This", "location": [1681, 1908], "entities": [{"type": "Organization", "text": "Lantus\n\u2022 NovoLog/NovoRapid\n\u2022 Humalog\n\u2022 Avonex\n\u2022 Rebif\n\u2022 Humira\n\u2022 Remicade\n\u2022 Tysabri\n\u2022 Herceptin\n\u2022 Kadcyla\n\u2022 Perjeta\n\u2022 Enbrel\n\u2022 Eylea\n\u2022 OsteoCel Plus\n\u2022 Trinity Evolution and Trinity Elite\n\u2022 Apligraf\n\u2022 Dermagraft\n\u2022 IMLYGIC\n\u2022 This"}]}, {"text": "report", "location": [1909, 1915], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "Japan \u00b7 Germany \u00b7 France \u00b7 UK \u00b7 Italy \u00b7 Spain \u00b7 China \u00b7 India \u00b7 Russia \u00b7 Brazil \u00b7 Our study discusses the selected leading companies that are the major players in the biologics market: \u00b7 AbbVie \u00b7 Amgen \u00b7 AstraZeneca \u00b7 Bayer \u00b7 Eli Lilly \u00b7 GlaxoSmithKline (GSK) \u00b7 Johnson & Johnson \u00b7 Merck & Co., Inc. \u00b7 Novartis \u00b7 Pfizer \u00b7 Roche \u00b7 Sanofi S.A. \u00b7 This report discusses factors that drive and restrain this market.", "score": 0.963415, "arguments": [{"text": "Johnson & Johnson\n\u2022 Merck & Co., Inc.\n\u2022 Novartis\n\u2022 Pfizer\n\u2022 Roche\n\u2022 Sanofi S.A.\n\u2022 This", "location": [2271, 2357], "entities": [{"type": "Organization", "text": "Johnson & Johnson\n\u2022 Merck & Co., Inc.\n\u2022 Novartis\n\u2022 Pfizer\n\u2022 Roche\n\u2022 Sanofi S.A.\n\u2022 This", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "report", "location": [2358, 2364], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "Buy our report today Biologics Market Trends and Forecasts 2018-2028 : Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.", "score": 0.928663, "arguments": [{"text": "our", "location": [2689, 2692], "entities": [{"type": "Person", "text": "our"}]}, {"text": "report", "location": [2693, 2699], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "timeOf", "sentence": "Buy our report today Biologics Market Trends and Forecasts 2018-2028 : Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.", "score": 0.795984, "arguments": [{"text": "today", "location": [2700, 2705], "entities": [{"type": "Date", "text": "today"}]}, {"text": "report", "location": [2693, 2699], "entities": [{"type": "EventCommunication", "text": "report"}]}]}], "keywords": [{"text": "new 303-page report", "sentiment": {"score": -0.596518, "label": "negative"}, "relevance": 0.597582, "count": 1}, {"text": "Monoclonal Antibodies", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.590984, "count": 2}, {"text": "report", "sentiment": {"score": 0.414771, "mixed": "1", "label": "positive"}, "relevance": 0.584517, "count": 5}, {"text": "Protein Therapeutics", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.584409, "count": 2}, {"text": "Trinity Evolution", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.570201, "count": 1}, {"text": "ordering", "sentiment": {"score": 0.77585, "label": "positive"}, "relevance": 0.564494, "count": 1}, {"text": "University of Manchester", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561991, "count": 1}, {"text": "European Medicines Agency", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.561987, "count": 1}, {"text": "Biologics Market Trends", "sentiment": {"score": -0.322495, "label": "negative"}, "relevance": 0.552863, "count": 1}, {"text": "brand-new report today", "sentiment": {"score": 0.77585, "label": "positive"}, "relevance": 0.552287, "count": 1}, {"text": "303-page report", "sentiment": {"score": 0.663354, "label": "positive"}, "relevance": 0.542748, "count": 1}, {"text": "brand", "sentiment": {"score": -0.596518, "label": "negative"}, "relevance": 0.539477, "count": 1}, {"text": "Recombinant Hormones", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.539443, "count": 2}, {"text": "Fusion Proteins", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.535379, "count": 2}, {"text": "Visiongain's study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534344, "count": 1}, {"text": "European Commission", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.532096, "count": 1}, {"text": "monoclonal antibodies submarket", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53177, "count": 1}, {"text": "Monoclonal antibodies", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.530631, "count": 1}, {"text": "Regenerative Medicines", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.529112, "count": 2}, {"text": "Recombinant Coagulating Factors", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.52832, "count": 2}, {"text": "U.S. President's Emergency Plan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528022, "count": 1}, {"text": "global biologics market", "sentiment": {"score": 0.401432, "mixed": "1", "label": "positive"}, "relevance": 0.527589, "count": 2}, {"text": "Forecasts", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.52699, "count": 2}, {"text": "University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526804, "count": 1}, {"text": "University of Texas", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52533, "count": 1}, {"text": "report overview of this report", "sentiment": {"score": -0.421302, "label": "negative"}, "relevance": 0.524804, "count": 1}, {"text": "Protein therapeutics", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.5242, "count": 1}, {"text": "Regenerative medicine", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.523787, "count": 1}, {"text": "Yonsei University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521594, "count": 1}, {"text": "Trinity Elite", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.521478, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.521206, "count": 2}, {"text": "European Group", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.519539, "count": 1}, {"text": "study", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.517895, "count": 1}, {"text": "Disease Prevention", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.517253, "count": 2}, {"text": "Stem Cell Therapies", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.516755, "count": 2}, {"text": "Report Scope", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.516336, "count": 1}, {"text": "trends", "sentiment": {"score": -0.557524, "label": "negative"}, "relevance": 0.515666, "count": 2}, {"text": "market", "sentiment": {"score": 0.310662, "mixed": "1", "label": "positive"}, "relevance": 0.515461, "count": 5}, {"text": "individual revenue forecasts", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.514631, "count": 1}, {"text": "insulin", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.514631, "count": 1}, {"text": "Insulin", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.514631, "count": 2}, {"text": "Plasma", "sentiment": {"score": 0.508374, "mixed": "1", "label": "positive"}, "relevance": 0.514071, "count": 2}, {"text": "plasma", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.514071, "count": 1}, {"text": "major players", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.513875, "count": 1}, {"text": "Email sara.peerun@visiongain.com", "sentiment": {"score": 0.467502, "label": "positive"}, "relevance": 0.513314, "count": 1}, {"text": "Marrow Transplantation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512973, "count": 1}, {"text": "tissue engineering", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.512064, "count": 1}, {"text": "US", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.511679, "count": 1}, {"text": "Australia's Walter", "sentiment": {"score": -0.756352, "label": "negative"}, "relevance": 0.511275, "count": 1}, {"text": "Analysis", "sentiment": {"score": 0.468132, "label": "positive"}, "relevance": 0.511164, "count": 1}]}, "extracted_metadata": {"sha1": "32d8f00540e5124e74a452c7fda2cc53ccc1721b", "filename": "1543228086761.zip-28ac1a7f2e205a7a4b3862c00daefeed.xml", "file_type": "json"}, "external_links": ["https://www.visiongain.com/report/biologics-market-trends-and-forecasts-2018-2028/"], "title": "Visiongain Report Looks at Opportunities Within the $250bn Biologics Sector", "forum_title": "Stock Market News | Financial &amp; Business News | Markets Insider"}, {"id": "4-Wyg3IaASvXdvFeWUyL1_JLl4GfWCM8V4V2wpLolAMo-uaDfghIWY2TEIU3UKrQ", "result_metadata": {"score": 33.761623}, "author": "tanuj", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Immune system", "relevance": 0.85695, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}], "categories": [{"score": 0.976665, "label": "/health and fitness"}, {"score": 0.826576, "label": "/health and fitness/disease/heart disease"}], "relations": [], "keywords": [{"text": "Cardiovascular Drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.990015, "count": 1}, {"text": "Impressive Growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.009985, "count": 1}]}, "crawl_date": "2018-11-26T11:01:07Z", "url": "https://www.findmarketresearch.org/2018/11/cardiovascular-drugs-market-to-exhibit-impressive-growth-during-2015-2021/", "host": "findmarketresearch.org", "text": "Some of the major cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T04:05:00+05:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": -0.867064, "label": "negative"}, "text": "hypertensive heart disease", "relevance": 0.886997, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}, {"count": 2, "sentiment": {"score": -0.911619, "label": "negative"}, "text": "inflammatory heart disease", "relevance": 0.727153, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}, {"count": 3, "sentiment": {"score": -0.75901, "label": "negative"}, "text": "Cerebrovascular disease", "relevance": 0.53919, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Cerebrovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cerebrovascular_disease"}}, {"count": 3, "sentiment": {"score": -0.787412, "label": "negative"}, "text": "rheumatic fever", "relevance": 0.440721, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"count": 7, "sentiment": {"score": -0.411977, "label": "negative"}, "text": "Japan", "relevance": 0.431737, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.832513, "label": "negative"}, "text": "kawasaki disease", "relevance": 0.312599, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}, {"count": 3, "sentiment": {"score": -0.0693386, "label": "negative"}, "text": "Asia", "relevance": 0.297048, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 2, "sentiment": {"score": -0.767521, "label": "negative"}, "text": "group A streptococcal infection", "relevance": 0.284181, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}, {"count": 1, "sentiment": {"score": -0.306977, "label": "negative"}, "text": "subarachnoid hemorrhage", "relevance": 0.243583, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Subarachnoid hemorrhage", "dbpedia_resource": "http://dbpedia.org/resource/Subarachnoid_hemorrhage"}}, {"count": 1, "sentiment": {"score": -0.336336, "label": "negative"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.212051, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tredaptive", "relevance": 0.204314, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eliquis", "relevance": 0.20324, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.20124, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.199377, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.197411, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.194599, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca PLC", "relevance": 0.19359, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": -0.292396, "label": "negative"}, "text": "Solvay SA", "relevance": 0.193074, "type": "Company", "disambiguation": {"subtype": [], "name": "Solvay (company)", "dbpedia_resource": "http://dbpedia.org/resource/Solvay_(company)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.191963, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": -0.224413, "label": "negative"}, "text": "Bayer AG", "relevance": 0.190719, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Forest Laboratories Inc.", "relevance": 0.18417, "type": "Company", "disambiguation": {"subtype": [], "name": "Forest Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Forest_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.177181, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiichi Sankyo Co. Ltd.", "relevance": 0.176915, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.292396, "label": "negative"}, "text": "Pfizer Inc.", "relevance": 0.176796, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.174034, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories Inc.", "relevance": 0.170217, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.168316, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Spain", "relevance": 0.166315, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.165756, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.165317, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.K.", "relevance": 0.16183, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.160281, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd.", "relevance": 0.157733, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Italy", "relevance": 0.148169, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": -0.703326, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Cardiovascular diseases,", "keywords": [{"text": "Cardiovascular diseases"}]}, "sentence": "Cardiovascular diseases, also known as heart diseases, are diseases of heart and circulatory system.", "object": {"text": "as heart diseases", "keywords": [{"text": "heart diseases"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "also known", "normalized": "also know"}}, {"subject": {"text": "Cardiovascular diseases, also known as heart diseases,", "keywords": [{"text": "Cardiovascular diseases"}, {"text": "heart diseases"}]}, "sentence": "Cardiovascular diseases, also known as heart diseases, are diseases of heart and circulatory system.", "object": {"text": "diseases of heart and circulatory system", "keywords": [{"text": "diseases"}, {"text": "heart"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Some of the most common cardiovascular diseases", "keywords": [{"text": "common cardiovascular diseases"}]}, "sentence": " Some of the most common cardiovascular diseases are hypertensive heart disease, rheumatic heart disease, cerebrovascular heart disease, ischemic heart disease and inflammatory heart disease.", "object": {"text": "hypertensive heart disease", "keywords": [{"text": "hypertensive heart disease"}], "entities": [{"type": "HealthCondition", "text": "hypertensive heart disease", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Major problems", "keywords": [{"text": "Major problems"}]}, "sentence": " Major problems associated with hypertensive heart disease include heart failure, hypertrophy, coronary heart disease and angina.", "object": {"text": "with hypertensive heart disease", "keywords": [{"text": "hypertensive heart disease"}], "entities": [{"type": "HealthCondition", "text": "hypertensive heart disease", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "heart failure, hypertrophy, coronary heart disease and angina", "keywords": [{"text": "coronary heart disease"}, {"text": "heart failure"}, {"text": "hypertrophy"}, {"text": "angina"}]}, "sentence": " Major problems associated with hypertensive heart disease include heart failure, hypertrophy, coronary heart disease and angina.", "object": {"text": "Major problems associated with hypertensive heart disease", "keywords": [{"text": "hypertensive heart disease"}, {"text": "Major problems"}], "entities": [{"type": "HealthCondition", "text": "hypertensive heart disease", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Rheumatic heart disease", "keywords": [{"text": "Rheumatic heart disease"}]}, "sentence": " Rheumatic heart disease is caused by rheumatic fever.", "object": {"text": "by rheumatic fever", "keywords": [{"text": "rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is caused", "normalized": "be cause"}}, {"subject": {"text": "by rheumatic fever", "keywords": [{"text": "rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "sentence": " Rheumatic heart disease is caused by rheumatic fever.", "object": {"text": "Rheumatic heart disease", "keywords": [{"text": "Rheumatic heart disease"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "is caused", "normalized": "be cause"}}, {"subject": {"text": "by preceding group A streptococcal infection", "keywords": [{"text": "streptococcal infection"}, {"text": "group"}], "entities": [{"type": "HealthCondition", "text": "group A streptococcal infection", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}]}, "sentence": " Rheumatic fever occurs by preceding group A streptococcal infection.", "object": {"text": "Rheumatic fever", "keywords": [{"text": "Rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "action": {"verb": {"text": "occur", "tense": "present"}, "text": "occurs", "normalized": "occur"}}, {"subject": {"text": "It"}, "sentence": " It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "object": {"text": "one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries", "keywords": [{"text": "heart diseases"}, {"text": "countries"}, {"text": "children"}, {"text": "world"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Cerebrovascular disease", "keywords": [{"text": "Cerebrovascular disease"}], "entities": [{"type": "HealthCondition", "text": "Cerebrovascular disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Cerebrovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cerebrovascular_disease"}}]}, "sentence": " Cerebrovascular disease affects blood vessels of the brain.", "object": {"text": "blood vessels of the brain", "keywords": [{"text": "blood vessels"}, {"text": "brain"}], "entities": []}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "Most common types of cerebrovascular disease", "keywords": [{"text": "cerebrovascular disease"}, {"text": "common types"}], "entities": [{"type": "HealthCondition", "text": "Cerebrovascular disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Cerebrovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cerebrovascular_disease"}}]}, "sentence": " Most common types of cerebrovascular disease are vascular dementia, stroke, subarachnoid hemorrhage and transient ischemic attack (TIA).", "object": {"text": "vascular dementia", "keywords": [{"text": "vascular dementia"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Ischemic heart disease", "keywords": [{"text": "Ischemic heart disease"}]}, "sentence": " Ischemic heart disease is characterized by reduced blood supply to the heart.", "object": {"text": "by reduced blood supply to the heart", "keywords": [{"text": "blood supply"}, {"text": "heart"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is characterized", "normalized": "be characterize"}}, {"subject": {"text": "by reduced blood supply to the heart", "keywords": [{"text": "blood supply"}, {"text": "heart"}]}, "sentence": " Ischemic heart disease is characterized by reduced blood supply to the heart.", "object": {"text": "Ischemic heart disease", "keywords": [{"text": "Ischemic heart disease"}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "is characterized", "normalized": "be characterize"}}, {"subject": {"text": "It"}, "sentence": " It is one of the most common causes of death in western parts of the world.", "object": {"text": "one of the most common causes of death in western parts of the world", "keywords": [{"text": "common causes"}, {"text": "western parts"}, {"text": "death"}, {"text": "world"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Inflammatory heart disease", "keywords": [{"text": "Inflammatory heart disease"}], "entities": [{"type": "HealthCondition", "text": "inflammatory heart disease", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}]}, "sentence": " Inflammatory heart disease occurs due to the infection of bacteria and virus.", "object": {"text": "due to the infection of bacteria and virus", "keywords": [{"text": "bacteria"}, {"text": "infection"}, {"text": "virus"}], "entities": [{"type": "HealthCondition", "text": "group A streptococcal infection", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}]}, "action": {"verb": {"text": "occur", "tense": "present"}, "text": "occurs", "normalized": "occur"}}, {"subject": {"text": "This type of inflammation", "keywords": [{"text": "inflammation"}, {"text": "type"}]}, "sentence": " This type of inflammation is often associated with episodes of rheumatic fever and kawasaki disease.", "object": {"text": "often associated with episodes of rheumatic fever and kawasaki disease", "keywords": [{"text": "rheumatic fever"}, {"text": "kawasaki disease"}, {"text": "episodes"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"type": "HealthCondition", "text": "kawasaki disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This type of inflammation", "keywords": [{"text": "inflammation"}, {"text": "type"}]}, "sentence": " This type of inflammation is often associated with episodes of rheumatic fever and kawasaki disease.", "object": {"text": "with episodes of rheumatic fever and kawasaki disease", "keywords": [{"text": "rheumatic fever"}, {"text": "kawasaki disease"}, {"text": "episodes"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"type": "HealthCondition", "text": "kawasaki disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The global cardiovascular drugs market is categorized based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs.", "object": {"text": "based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs", "keywords": [{"text": "various anti-hypertensive drugs"}, {"text": "anti-dyslipidemics drugs"}, {"text": "anti-thrombotics drugs"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "The global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The global cardiovascular drugs market is categorized based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs.", "object": {"text": "on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs", "keywords": [{"text": "various anti-hypertensive drugs"}, {"text": "anti-dyslipidemics drugs"}, {"text": "anti-thrombotics drugs"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}, {"subject": {"text": "Anti-hypertensive drug segment", "keywords": [{"text": "Anti-hypertensive drug segment"}]}, "sentence": " Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "object": {"text": "further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL", "keywords": [{"text": "Benicar/Benicar HCT"}, {"text": "Micardis/Micardis HCT"}, {"text": "Exforge/Exforge HCT"}, {"text": "Norvasc"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Lipitor, Crestor, Niaspan, TriCor/Trilipix, Zetia/Vytorin and Tredaptive", "keywords": [{"text": "Niaspan"}, {"text": "Crestor"}, {"text": "Lipitor"}, {"text": "TriCor/Trilipix"}], "entities": [{"type": "Location", "text": "Tredaptive", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Anti-dyslipidemics drug segment includes Lipitor, Crestor, Niaspan, TriCor/Trilipix, Zetia/Vytorin and Tredaptive.", "object": {"text": "Anti-dyslipidemics drug segment", "keywords": [{"text": "Anti-dyslipidemics drug segment"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Anti-thrombotics drug segment", "keywords": [{"text": "Anti-thrombotics drug segment"}]}, "sentence": " Anti-thrombotics drug segment is further sub-segmented into Plavix, Lovenox, Pradaxa, Xarelto, Brilique/Brilinta and Eliquis.", "object": {"text": "further sub-segmented into Plavix, Lovenox, Pradaxa, Xarelto, Brilique/Brilinta and Eliquis", "keywords": [{"text": "Plavix"}, {"text": "Lovenox"}, {"text": "Pradaxa"}, {"text": "Xarelto"}], "entities": [{"type": "Location", "text": "Eliquis", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The U.S.", "keywords": [{"text": "U.S"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America.", "object": {"text": "the largest market for cardiovascular drugs followed by Canada in North America", "keywords": [{"text": "cardiovascular drugs"}, {"text": "largest market"}, {"text": "North America"}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "by Canada in North America", "keywords": [{"text": "North America"}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America.", "object": {"text": "cardiovascular drugs", "keywords": [{"text": "cardiovascular drugs"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "the U.K., Spain, Italy and France", "keywords": [{"text": "U.K."}, {"text": "Spain"}, {"text": "Italy"}, {"text": "France"}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Location", "text": "Spain", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"type": "Location", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "France", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}]}, "sentence": " In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market.", "object": {"text": "major share of cardiovascular drugs market", "keywords": [{"text": "cardiovascular drugs"}, {"text": "major share"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "Asia", "keywords": [{"text": "Asia"}], "entities": [{"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " However, Asia is expected global cardiovascular drugs market.", "object": {"text": "expected global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "many companies", "keywords": [{"text": "companies"}]}, "sentence": " This is due to many companies constructing their R&D facilities in the region.", "object": {"text": "their R&D facilities in the region", "keywords": [{"text": "R&D facilities"}, {"text": "region"}]}, "action": {"verb": {"text": "construct", "tense": "present"}, "text": "constructing", "normalized": "construct"}}, {"subject": {"text": "Less stringent wages and availability of skilled labor", "keywords": [{"text": "stringent wages"}, {"text": "skilled labor"}, {"text": "availability"}]}, "sentence": " Less stringent wages and availability of skilled labor attracts manufacturing companies to invest in Asia.", "object": {"text": "manufacturing companies", "keywords": [{"text": "manufacturing companies"}]}, "action": {"verb": {"text": "attract", "tense": "present"}, "text": "attracts", "normalized": "attract"}}, {"subject": {"text": "increasing awareness about heart related problems", "keywords": [{"text": "awareness"}, {"text": "heart"}, {"text": "problems"}]}, "sentence": " In addition, increasing awareness about heart related problems is also supporting in the growth of cardiovascular drugs market in the region.", "action": {"verb": {"text": "support", "tense": "present"}, "text": "is also supporting", "normalized": "be also support"}}, {"subject": {"text": "Japan, China and India", "keywords": [{"text": "Japan"}, {"text": "China"}, {"text": "India"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "sentence": " Japan, China and India are expected to be the fastest growing cardiovascular drugs markets in Asia.", "object": {"text": "the fastest growing cardiovascular drugs markets in Asia", "keywords": [{"text": "cardiovascular drugs"}, {"text": "markets"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "increasing prevalence of heart diseases and extensive pipeline drugs", "keywords": [{"text": "extensive pipeline drugs"}, {"text": "prevalence"}, {"text": "heart diseases"}]}, "sentence": " In recent time, increasing prevalence of heart diseases and extensive pipeline drugs are some of the major drivers of global cardiovascular drugs market.", "object": {"text": "some of the major drivers of global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "major drivers"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Rising number of diabetic patients", "keywords": [{"text": "diabetic patients"}, {"text": "number"}]}, "sentence": " Rising number of diabetic patients holds immense potential to the growth of global cardiovascular drugs market.", "object": {"text": "immense potential to the growth of global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "immense potential"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "stringent regulations and side-effects of cardiovascular drugs", "keywords": [{"text": "cardiovascular drugs"}, {"text": "stringent regulations"}, {"text": "side-effects"}]}, "sentence": " However, stringent regulations and side-effects of cardiovascular drugs hamper the growth of global cardiovascular drugs market.", "object": {"text": "the growth of global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hamper", "normalized": "hamper"}}, {"subject": {"text": "patent expiry of various blockbuster drugs", "keywords": [{"text": "various blockbuster drugs"}, {"text": "patent expiry"}]}, "sentence": " Moreover, patent expiry of various blockbuster drugs also obstructs the growth of the global cardiovascular drugs market.", "object": {"text": "the growth of the global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "obstruct", "tense": "present"}, "text": "obstructs", "normalized": "obstruct"}}, {"subject": {"text": "Some of the major cardiovascular drugs market", "keywords": [{"text": "major cardiovascular drugs"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Some of the major cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "object": {"text": "Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Forest Laboratories Inc."}, {"text": "F. Hoffmann-La Roche"}, {"text": "AstraZeneca PLC"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "Abbott Laboratories Inc."}, {"type": "Company", "text": "AstraZeneca PLC", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd."}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Forest Laboratories Inc.", "disambiguation": {"subtype": [], "name": "Forest Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Forest_Laboratories"}}, {"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Roche Ltd."}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Daiichi Sankyo Co. Ltd."}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Solvay SA", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Solvay (company)", "dbpedia_resource": "http://dbpedia.org/resource/Solvay_(company)"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Hypertension", "relevance": 0.987314, "dbpedia_resource": "http://dbpedia.org/resource/Hypertension"}, {"text": "Heart", "relevance": 0.821375, "dbpedia_resource": "http://dbpedia.org/resource/Heart"}, {"text": "Cardiology", "relevance": 0.791095, "dbpedia_resource": "http://dbpedia.org/resource/Cardiology"}, {"text": "Heart disease", "relevance": 0.783051, "dbpedia_resource": "http://dbpedia.org/resource/Heart_disease"}, {"text": "Blood", "relevance": 0.682853, "dbpedia_resource": "http://dbpedia.org/resource/Blood"}, {"text": "Circulatory system", "relevance": 0.646171, "dbpedia_resource": "http://dbpedia.org/resource/Circulatory_system"}, {"text": "Blood vessel", "relevance": 0.62852, "dbpedia_resource": "http://dbpedia.org/resource/Blood_vessel"}, {"text": "Bristol-Myers Squibb", "relevance": 0.601912, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Myocardial infarction", "relevance": 0.593416, "dbpedia_resource": "http://dbpedia.org/resource/Myocardial_infarction"}, {"text": "Cardiovascular system", "relevance": 0.564336, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_system"}, {"text": "Genetic disorder", "relevance": 0.559087, "dbpedia_resource": "http://dbpedia.org/resource/Genetic_disorder"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.55256, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Ischaemic heart disease", "relevance": 0.546517, "dbpedia_resource": "http://dbpedia.org/resource/Ischaemic_heart_disease"}, {"text": "Ischemia", "relevance": 0.531597, "dbpedia_resource": "http://dbpedia.org/resource/Ischemia"}, {"text": "Aspirin", "relevance": 0.523246, "dbpedia_resource": "http://dbpedia.org/resource/Aspirin"}, {"text": "Cardiovascular diseases", "relevance": 0.517136, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_diseases"}, {"text": "Pfizer", "relevance": 0.511121, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Stroke", "relevance": 0.50627, "dbpedia_resource": "http://dbpedia.org/resource/Stroke"}, {"text": "Diseases and disorders", "relevance": 0.479267, "dbpedia_resource": "http://dbpedia.org/resource/Diseases_and_disorders"}, {"text": "Circulatory System", "relevance": 0.456211, "dbpedia_resource": "http://dbpedia.org/resource/Circulatory_System"}, {"text": "Streptococcus", "relevance": 0.432986, "dbpedia_resource": "http://dbpedia.org/resource/Streptococcus"}, {"text": "Rheumatic fever", "relevance": 0.429637, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}, {"text": "Heart failure", "relevance": 0.428867, "dbpedia_resource": "http://dbpedia.org/resource/Heart_failure"}, {"text": "Clopidogrel", "relevance": 0.417607, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Pharmaceutical industry", "relevance": 0.401752, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Infection", "relevance": 0.387735, "dbpedia_resource": "http://dbpedia.org/resource/Infection"}, {"text": "Atherosclerosis", "relevance": 0.383162, "dbpedia_resource": "http://dbpedia.org/resource/Atherosclerosis"}, {"text": "Coronary artery disease", "relevance": 0.383093, "dbpedia_resource": "http://dbpedia.org/resource/Coronary_artery_disease"}, {"text": "Multinational companies", "relevance": 0.368288, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Blood pressure", "relevance": 0.35763, "dbpedia_resource": "http://dbpedia.org/resource/Blood_pressure"}, {"text": "Pulmonary vein", "relevance": 0.350162, "dbpedia_resource": "http://dbpedia.org/resource/Pulmonary_vein"}, {"text": "Inflammation", "relevance": 0.348039, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Rheumatism", "relevance": 0.337354, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatism"}, {"text": "Medicine", "relevance": 0.335438, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Amlodipine", "relevance": 0.332797, "dbpedia_resource": "http://dbpedia.org/resource/Amlodipine"}, {"text": "Immune system", "relevance": 0.330387, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Disease", "relevance": 0.324526, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Infectious disease", "relevance": 0.320896, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_disease"}, {"text": "Genentech", "relevance": 0.320454, "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}, {"text": "Arthralgia", "relevance": 0.313346, "dbpedia_resource": "http://dbpedia.org/resource/Arthralgia"}, {"text": "Hypercholesterolemia", "relevance": 0.311611, "dbpedia_resource": "http://dbpedia.org/resource/Hypercholesterolemia"}, {"text": "Streptococcus pyogenes", "relevance": 0.308582, "dbpedia_resource": "http://dbpedia.org/resource/Streptococcus_pyogenes"}, {"text": "Irbesartan", "relevance": 0.308154, "dbpedia_resource": "http://dbpedia.org/resource/Irbesartan"}, {"text": "AstraZeneca", "relevance": 0.304443, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Cerebral hemorrhage", "relevance": 0.304223, "dbpedia_resource": "http://dbpedia.org/resource/Cerebral_hemorrhage"}, {"text": "Pharmaceutical drug", "relevance": 0.300022, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Transient ischemic attack", "relevance": 0.299259, "dbpedia_resource": "http://dbpedia.org/resource/Transient_ischemic_attack"}, {"text": "Artery", "relevance": 0.294795, "dbpedia_resource": "http://dbpedia.org/resource/Artery"}, {"text": "Cardiovascular disease", "relevance": 0.288986, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}, {"text": "Cardiac muscle", "relevance": 0.2887, "dbpedia_resource": "http://dbpedia.org/resource/Cardiac_muscle"}], "categories": [{"score": 0.999946, "label": "/health and fitness/disease/heart disease"}], "relations": [{"type": "affectedBy", "sentence": "Rheumatic fever occurs by preceding group A streptococcal infection.", "score": 0.668725, "arguments": [{"text": "group", "location": [573, 578], "entities": [{"type": "Person", "text": "group"}]}, {"text": "preceding", "location": [563, 572], "entities": [{"type": "EventCommunication", "text": "preceding"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.676207, "arguments": [{"text": "Benicar HCT", "location": [1515, 1526], "entities": [{"type": "GeopoliticalEntity", "text": "Benicar HCT"}]}, {"text": "Micardis", "location": [1528, 1536], "entities": [{"type": "GeopoliticalEntity", "text": "Micardis HCT"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.676207, "arguments": [{"text": "Micardis HCT", "location": [1537, 1549], "entities": [{"type": "GeopoliticalEntity", "text": "Micardis HCT"}]}, {"text": "Aprovel", "location": [1551, 1558], "entities": [{"type": "GeopoliticalEntity", "text": "CoAprovel"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.623328, "arguments": [{"text": "CoAprovel", "location": [1559, 1568], "entities": [{"type": "GeopoliticalEntity", "text": "CoAprovel"}]}, {"text": "Tekturna", "location": [1570, 1578], "entities": [{"type": "GeopoliticalEntity", "text": "Tekturna"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.829898, "arguments": [{"text": "Rasilez", "location": [1579, 1586], "entities": [{"type": "GeopoliticalEntity", "text": "Rasilez"}]}, {"text": "Edarbi", "location": [1588, 1594], "entities": [{"type": "GeopoliticalEntity", "text": "Edarbi"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.529909, "arguments": [{"text": "Edarbi", "location": [1588, 1594], "entities": [{"type": "GeopoliticalEntity", "text": "Edarbi"}]}, {"text": "Cozaar", "location": [1596, 1602], "entities": [{"type": "GeopoliticalEntity", "text": "Cozaar"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.92593, "arguments": [{"text": "Hyzaar", "location": [1603, 1609], "entities": [{"type": "GeopoliticalEntity", "text": "Hyzaar"}]}, {"text": "Norvasc", "location": [1611, 1618], "entities": [{"type": "GeopoliticalEntity", "text": "Norvasc"}]}]}, {"type": "locatedAt", "sentence": "The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America.", "score": 0.840381, "arguments": [{"text": "drugs", "location": [2105, 2110], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "Canada", "location": [2123, 2129], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America.", "score": 0.637932, "arguments": [{"text": "drugs", "location": [2105, 2110], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "North America", "location": [2133, 2146], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market.", "score": 0.954556, "arguments": [{"text": "Europe", "location": [2151, 2157], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}, {"text": "Germany", "location": [2159, 2166], "entities": [{"type": "GeopoliticalEntity", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market.", "score": 0.704525, "arguments": [{"text": "U.K.", "location": [2172, 2176], "entities": [{"type": "GeopoliticalEntity", "text": "U.K."}]}, {"text": "Spain", "location": [2178, 2183], "entities": [{"type": "GeopoliticalEntity", "text": "Spain", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Rheumatic fever occurs by preceding group A streptococcal infection.", "score": 0.881228, "arguments": [{"text": "group", "location": [573, 578], "entities": [{"type": "Person", "text": "group"}]}, {"text": "infection", "location": [595, 604], "entities": [{"type": "HealthCondition", "text": "cerebrovascular disease"}]}]}, {"type": "ownerOf", "sentence": "This is due to many companies constructing their R&D facilities in the region.", "score": 0.268793, "arguments": [{"text": "companies", "location": [2334, 2343], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "facilities", "location": [2367, 2377], "entities": [{"type": "Facility", "text": "facilities"}]}]}, {"type": "locatedAt", "sentence": "This is due to many companies constructing their R&D facilities in the region.", "score": 0.950849, "arguments": [{"text": "facilities", "location": [2367, 2377], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "region", "location": [2385, 2391], "entities": [{"type": "GeopoliticalEntity", "text": "Tredaptive"}]}]}, {"type": "locatedAt", "sentence": "Less stringent wages and availability of skilled labor attracts manufacturing companies to invest in Asia.", "score": 0.397101, "arguments": [{"text": "companies", "location": [2471, 2480], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Asia", "location": [2494, 2498], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Japan, China and India are expected to be the fastest growing cardiovascular drugs markets in Asia.", "score": 0.602137, "arguments": [{"text": "drugs", "location": [2719, 2724], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "Asia", "location": [2736, 2740], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "In recent time, increasing prevalence of heart diseases and extensive pipeline drugs are some of the major drivers of global cardiovascular drugs market.", "score": 0.744416, "arguments": [{"text": "drivers", "location": [2849, 2856], "entities": [{"type": "Person", "text": "drivers"}]}, {"text": "cardiovascular", "location": [2867, 2881], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "hasAttribute", "sentence": "Increasing aging population and rising number of life-style diseases are also contributing in the growth of global cardiovascular drugs market.", "score": 0.743664, "arguments": [{"text": "population", "location": [2913, 2923], "entities": [{"type": "Person", "text": "population"}]}, {"text": "diseases", "location": [2956, 2964], "entities": [{"type": "HealthCondition", "text": "heart diseases"}]}]}, {"type": "hasAttribute", "sentence": "Rising number of diabetic patients holds immense potential to the growth of global cardiovascular drugs market.", "score": 0.909393, "arguments": [{"text": "patients", "location": [3066, 3074], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "diabetic", "location": [3057, 3065], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "locatedAt", "sentence": "Moreover, patent expiry of various blockbuster drugs also obstructs the growth of the global cardiovascular drugs market.", "score": 0.499794, "arguments": [{"text": "drugs", "location": [3328, 3333], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "blockbuster", "location": [3316, 3327], "entities": [{"type": "Facility", "text": "blockbuster"}]}]}, {"type": "affectedBy", "sentence": "Increasing mergers and acquisitions between drug manufacturing companies and rapid product launches are key trends of the global cardiovascular drugs market.", "score": 0.48594, "arguments": [{"text": "companies", "location": [3466, 3475], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisitions", "location": [3426, 3438], "entities": [{"type": "EventBusiness", "text": "acquisitions"}]}]}, {"type": "hasAttribute", "sentence": "It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "score": 0.927547, "arguments": [{"text": "children", "location": [662, 670], "entities": [{"type": "Person", "text": "children"}]}, {"text": "heart diseases", "location": [644, 658], "entities": [{"type": "HealthCondition", "text": "heart diseases"}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "score": 0.463019, "arguments": [{"text": "children", "location": [662, 670], "entities": [{"type": "Person", "text": "children"}]}, {"text": "countries", "location": [679, 688], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "score": 0.466845, "arguments": [{"text": "countries", "location": [679, 688], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "world", "location": [696, 701], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "Most common types of cerebrovascular disease are vascular dementia, stroke, subarachnoid hemorrhage and transient ischemic attack (TIA).", "score": 0.50584, "arguments": [{"text": "TIA", "location": [930, 933], "entities": [{"type": "Person", "text": "TIA"}]}, {"text": "attack", "location": [922, 928], "entities": [{"type": "EventViolence", "text": "attack"}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common causes of death in western parts of the world.", "score": 0.506713, "arguments": [{"text": "western", "location": [1062, 1069], "entities": [{"type": "Location", "text": "western"}]}, {"text": "parts", "location": [1070, 1075], "entities": [{"type": "Location", "text": "parts"}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common causes of death in western parts of the world.", "score": 0.780669, "arguments": [{"text": "parts", "location": [1070, 1075], "entities": [{"type": "Location", "text": "parts"}]}, {"text": "world", "location": [1083, 1088], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.68216, "arguments": [{"text": "Co-Diovan", "location": [1486, 1495], "entities": [{"type": "GeopoliticalEntity", "text": "Co-Diovan"}]}, {"text": "Blopress", "location": [1497, 1505], "entities": [{"type": "GeopoliticalEntity", "text": "Blopress"}]}]}], "keywords": [{"text": "Cardiovascular diseases", "sentiment": {"score": -0.960538, "label": "negative"}, "relevance": 0.772061, "count": 1}, {"text": "global cardiovascular drugs market", "sentiment": {"score": -0.631734, "label": "negative"}, "relevance": 0.714518, "count": 2}, {"text": "heart diseases", "sentiment": {"score": -0.906384, "label": "negative"}, "relevance": 0.70983, "count": 2}, {"text": "recent time", "sentiment": {"score": -0.908696, "label": "negative"}, "relevance": 0.664165, "count": 1}, {"text": "various anti-hypertensive drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.642259, "count": 1}, {"text": "hypertensive heart disease", "sentiment": {"score": -0.889217, "label": "negative"}, "relevance": 0.627032, "count": 2}, {"text": "common cardiovascular diseases", "sentiment": {"score": -0.957113, "label": "negative"}, "relevance": 0.614952, "count": 1}, {"text": "diseases of heart", "sentiment": {"score": -0.960538, "label": "negative"}, "relevance": 0.602533, "count": 1}, {"text": "rheumatic heart disease", "sentiment": {"score": -0.957113, "label": "negative"}, "relevance": 0.596146, "count": 1}, {"text": "Anti-hypertensive drug segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.588508, "count": 1}, {"text": "Major problems", "sentiment": {"score": -0.809269, "label": "negative"}, "relevance": 0.57866, "count": 1}, {"text": "anti-dyslipidemics drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571991, "count": 1}, {"text": "stringent wages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571829, "count": 1}, {"text": "ischemic heart disease", "sentiment": {"score": -0.957113, "label": "negative"}, "relevance": 0.566068, "count": 1}, {"text": "common types of cerebrovascular disease", "sentiment": {"score": -0.820147, "label": "negative"}, "relevance": 0.559733, "count": 1}, {"text": "Hypertensive heart disease", "sentiment": {"score": -0.935836, "label": "negative"}, "relevance": 0.559592, "count": 1}, {"text": "Takeda Pharmaceutical Co. Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559395, "count": 1}, {"text": "Abbott Laboratories Inc.", "sentiment": {"score": -0.455662, "label": "negative"}, "relevance": 0.556093, "count": 1}, {"text": "addition", "sentiment": {"score": -0.515029, "label": "negative"}, "relevance": 0.544057, "count": 1}, {"text": "Rheumatic heart disease", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542843, "count": 1}, {"text": "cerebrovascular heart disease", "sentiment": {"score": -0.957113, "label": "negative"}, "relevance": 0.541012, "count": 1}, {"text": "anti-thrombotics drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539732, "count": 1}, {"text": "vascular dementia", "sentiment": {"score": -0.820147, "label": "negative"}, "relevance": 0.539485, "count": 1}, {"text": "Anti-dyslipidemics drug segment", "sentiment": {"score": -0.804171, "label": "negative"}, "relevance": 0.537518, "count": 1}, {"text": "Benicar HCT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536685, "count": 1}, {"text": "Europe", "sentiment": {"score": -0.252491, "label": "negative"}, "relevance": 0.536135, "count": 1}, {"text": "F. Hoffmann-La Roche Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535676, "count": 1}, {"text": "coronary heart disease", "sentiment": {"score": -0.809269, "label": "negative"}, "relevance": 0.534723, "count": 1}, {"text": "companies", "sentiment": {"score": -0.515029, "label": "negative"}, "relevance": 0.534271, "count": 2}, {"text": "rheumatic fever", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533785, "count": 1}, {"text": "heart failure", "sentiment": {"score": -0.809269, "label": "negative"}, "relevance": 0.532223, "count": 1}, {"text": "largest market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531269, "count": 1}, {"text": "subarachnoid hemorrhage", "sentiment": {"score": -0.820147, "label": "negative"}, "relevance": 0.531008, "count": 1}, {"text": "Novartis AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53096, "count": 1}, {"text": "Japan", "sentiment": {"score": 0.321593, "label": "positive"}, "relevance": 0.528202, "count": 1}, {"text": "Ischemic heart disease", "sentiment": {"score": -0.608359, "label": "negative"}, "relevance": 0.526797, "count": 1}, {"text": "Co-Diovan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52639, "count": 1}, {"text": "high blood pressure", "sentiment": {"score": -0.876595, "label": "negative"}, "relevance": 0.524714, "count": 1}, {"text": "AstraZeneca PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524149, "count": 1}, {"text": "Germany", "sentiment": {"score": -0.252491, "label": "negative"}, "relevance": 0.520984, "count": 1}, {"text": "Rheumatic fever", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520801, "count": 1}, {"text": "problems", "sentiment": {"score": -0.515029, "label": "negative"}, "relevance": 0.520658, "count": 1}, {"text": "cardiovascular drugs market", "sentiment": {"score": -0.608737, "label": "negative"}, "relevance": 0.52046, "count": 1}, {"text": "awareness", "sentiment": {"score": -0.564468, "label": "negative"}, "relevance": 0.520192, "count": 2}, {"text": "population", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519887, "count": 1}, {"text": "stringent regulations", "sentiment": {"score": -0.867135, "label": "negative"}, "relevance": 0.519522, "count": 1}, {"text": "patent expiry of various blockbuster drugs", "sentiment": {"score": -0.592423, "label": "negative"}, "relevance": 0.518447, "count": 1}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": -0.455662, "label": "negative"}, "relevance": 0.518108, "count": 1}, {"text": "Anti-thrombotics drug segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517322, "count": 1}, {"text": "Forest Laboratories Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516318, "count": 1}]}, "extracted_metadata": {"sha1": "9e1a6aba16b16f180d641d4fb64adb11697a2fd3", "filename": "1543230067796.zip-61992269e4b9f8d1f1d85ffd14af8a5f.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/samples/3776", "https://www.persistencemarketresearch.com/market-research/cardiovascular-drugs-market.asp"], "title": "Cardiovascular Drugs to Exhibit Impressive Growth During 2015-2021", "forum_title": "Research Insights | Find Market Research - Part 41"}]}